

RECOM MANAGED SYSTEMS INC DE/
Form SB-2
January 02, 2004

As filed with the Securities and Exchange Commission on December 31, 2003

Commission File No. 333- _____

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

Form SB-2
Registration Statement Under The Securities Act Of 1933

Recom Managed Systems, Inc.

(Name of small business issuer in its charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

87-0441351

(I.R.S. Employer Identification
No.)

Marvin H. Fink
Chief Executive Officer
4705 Laurel Canyon Boulevard, Suite 203
Studio City, California 91607
(818) 432-4560

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

(Name, address, including zip code, and telephone number, including area code, of agent for service of process)

Copies to
John M. Woodbury, Jr., Esq.
Of Counsel
Richardson & Patel LLP
10900 Wilshire Boulevard, Suite 500
Los Angeles, California 90024
Telephone (310) 208-1182

Approximate date of proposed sale to public: As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box:

If this Form is a post effective amendment filed pursuant to Rule 462(c) under the Securities Act of 1933, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering:

If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act of 1933, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering:

If delivery of this prospectus is expected to be made pursuant to Rule 434, please check the following box:

Calculation of Registration Fee

Title of Each Class of Securities to be Registered	Amount to be Registered	Proposed Offering Price Per Share	Proposed Aggregate Offering Price	Amount of Registration Fee
Common stock underlying series 'A' convertible preferred stock	1,792,921	\$ 3.15 (2)	\$ 5,647,701	\$ 456.90
Common stock underlying class 'C' warrants	896,460	\$ 3.15 (2)	\$ 2,823,849	\$ 228.45
Common stock underlying placement agent's warrants	268,938	\$ 3.15 (2)	\$ 847,155	\$ 68.53

(1) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) of Regulation C as of the close of the market on December 26 , 2003 based upon the average of the high and low prices for that date.

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

PRELIMINARY PROSPECTUS SUBJECT TO COMPLETION DATED DECEMBER 31, 2003

The information in this prospectus is not complete and may be changed. We have filed a registration statement containing this prospectus with the Securities and Exchange Commission. The common stock offered for sale under this prospectus may not be offered for sale or sold until that registration statement is declared effective by the Securities and Exchange Commission. This prospectus is not an offer to sell the common shares-and doesn't solicit an offer to purchase the common shares-in any jurisdiction where this offer or sale is not otherwise permitted.

Prospectus

2,958,319 Common Shares

This prospectus relates to the offer and sale by some of our shareholders during the period in which the registration statement containing this prospectus is effective of up to 2,958,319 common shares which they may acquire upon their conversion of series 'A' convertible preferred shares or exercise of class 'C' common share purchase warrants. This offering is not being underwritten.

The common shares offered under this prospectus may be sold by the selling shareholders on the public market, in negotiated transactions with a broker-dealer or market maker as principal or agent, or in privately negotiated transactions not involving a broker or dealer. We will not receive any of the proceeds from those sales. Should the selling shareholders in their discretion exercise the class 'C' common share purchase warrants underlying the common shares offered under this prospectus, we would, however, receive the exercise price for those warrants.

Our common shares trade on the Over-The-Counter Bulletin Board, also called the OTCBB, under the trading symbol "RECM". The last reported closing price for our common shares as reported on the OTCBB as of the close of the market on December 26, 2003 was \$3.15 per share. As of December 26, 2003, there were issued and outstanding 32,993,912 common shares and 1,792,921 series 'A' convertible preferred shares.

An investment in the common shares offered for sale under this prospectus involves a high degree of risk.
See "Risk Factors" beginning on page 3 of this prospectus.

Neither the United States Securities and Exchange Commission nor any state securities commission has approved or disapproved of the common shares offered for sale under this prospectus or the merits of that offering, or has determined that this prospectus is truthful or complete.
It's illegal for anyone to tell you otherwise.

The date of this prospectus is o , 2003

4705 Laurel Canyon Boulevard, Suite 203, Studio City, California 91607
(818) 432-4560

TABLE OF CONTENTS

PROSPECTUS SUMMARY

The Company And Business

Offering

RISK FACTORS

Risks Relating To Our Business

Risks relating to an investment in our securities

USE OF PROCEEDS

BUSINESS

Overview

Corporate History

Our Products And Services

Description Of Heart Monitors And ECGs

Product Advantages

Market For Heart Monitor Products

Marketing And Distribution Strategy

Product Evolution Strategy

Manufacturing Capacity

Regulatory Overview

Patents And Licenses

Competition

Costs And Effects Of Compliance With Environmental Laws

Employees

PROPERTY

PLAN OF OPERATION

LEGAL PROCEEDINGS

MANAGEMENT

Identity

Business Experience

Board Of Directors

Board Compensation

Employment And Consulting Agreements With Management

Summary Compensation Table

Stock Options And Stock Appreciation Rights

PRINCIPAL SHAREHOLDERS

TRANSACTIONS AND BUSINESS RELATIONSHIPS WITH MANAGEMENT AND PRINCIPAL

SHAREHOLDERS

DESCRIPTION OF CAPITAL STOCK

General

Common Shares

Preferred Shares

Series 'A' Preferred Shares

EQUITY COMPENSATION PLANS

Summary Equity Compensation Plan Data

Description of Equity Compensation Plans Not Approved By Shareholders

Description of Equity Compensation Plans Approved By Shareholders

MARKET FOR SECURITIES

Description Of Market

Dividend Policy

SELLING SHAREHOLDERS

REGISTRATION RIGHTS

PLAN OF DISTRIBUTION

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

TRANSFER AGENT

LEGAL MATTERS

EXPERTS

INDEMNIFICATION OF DIRECTORS AND OFFICERS

WHERE YOU CAN FIND MORE INFORMATION

NOTE RELATING TO STOCK SPLIT

On April 11, 2003, we effected a split in our common shares on a 3:1 forward basis through the mechanism of a stock dividend. Whenever we make any reference in this prospectus to the grant or issuance of common shares or options or warrants to purchase common shares, such reference shall, for comparison purposes, be made in reference to post-split numbers and, in the case of options and warrants, exercise prices, unless we state otherwise.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

In this prospectus we make a number of statements, referred to as *forward-looking statements*, which are intended to convey our expectations or predictions regarding the occurrence of possible future events or the existence of trends and factors that may impact our future plans and operating results. These forward-looking statements are derived, in part, from various assumptions and analyses we have made in the context of our current business plan and information currently available to us and in light of our experience and perceptions of historical trends, current conditions and expected future developments and other factors we believe to be appropriate in the circumstances. You can generally identify forward-looking statements through words and phrases such as *seek*, *anticipate*, *believe*, *estimate*, *expect*, *intend*, *plan*, *budget*, *will be*, *will continue*, *will likely result*, and similar expressions. When reading any forward looking statement you should remain mindful that actual results or developments may vary substantially from those expected as expressed in or implied by that statement for a number of reasons or factors, such as those relating to:

- the success of our research and development activities, the development of a viable commercial production model, and the speed with which regulatory authorizations and product launches may be achieved;
- whether or not a market for our products develops and, if a market develops, the pace at which it develops;
- our ability to successfully sell our products if a market develops;
- our ability to attract the qualified personnel to implement our growth strategies,
- our ability to develop sales, marketing and distribution capabilities;
- our ability to obtain reimbursement from third party payers for the products that we sell;
- the accuracy of our estimates and projections;
- our ability to fund our short-term and long-term financing needs;
- changes in our business plan and corporate strategies; and
- other risks and uncertainties discussed in greater detail in the sections of this prospectus, including those captioned " Risk Factors " and " Plan of Operation ".

Each forward-looking statement should be read in context with, and with an understanding of, the various other disclosures concerning our company and our business made elsewhere in this prospectus. You should not place undue reliance on any forward-looking statement as a prediction of actual results or developments. We are not obligated to update or revise any forward-looking statement contained in this prospectus to reflect new events or circumstances unless and to the extent required by applicable law.

PROSPECTUS SUMMARY

This summary highlights important information about our company and business. Because it is a summary, it may not contain all of the information that is important to you. To understand this offering fully, you should read this entire prospectus and the financial statements and related notes included in this prospectus carefully. Unless the context requires otherwise, *Recom*, *we*, *us*, *our* and similar terms refer to Recom Managed Systems, Inc.

The Company And Business

Recom is a development stage medical device company focused on researching, developing and marketing heart (cardiac) monitors and other diagnostic medical devices which monitor and measure the body's physiological signals in order to detect and prevent medical complications and diseases that impact an individual's health. Our products will operate using a proprietary patented amplification technology which enables them to more accurately discriminate physiological signals from ambient electromagnetic background noise than existing amplification technologies.

We are currently developing our first product, a non-invasive ambulatory heart monitor, and have submitted the "front-end" or hardware portion of this device, which collects, processes and records data, to the U.S. Food and Drug Administration for marketing approval. We hope to receive this approval during the first quarter of 2004. We are currently developing the "back-end" or software portion of the device, which allows the management and interpretation of the data, and for which FDA approval is not generally required. We anticipate that we will complete a production model of our heart monitor, including both back-end and front-end functions, within two years, and will have also commenced commercial marketing efforts by the end of that period.

Our corporate offices are located at 4705 Laurel Canyon Boulevard, Suite 203, Studio City, California 91607. Our telephone number is (818) 432-4560.

Offering

This prospectus relates to the offer and sale by some of our shareholders during the period in which the registration statement containing this prospectus is effective of up to 2,958,319 common shares, consisting of:

- 1,792,921 common shares underlying series 'A' convertible preferred shares issued on October 2, 2003 to a number of investors pursuant to a private placement effected through Maxim Group, LLC, as placement agent,
- 896,460 common shares underlying class 'C' common share purchase warrants issued to those investors under that private placement;
- 179,292 common shares underlying series 'A' convertible preferred shares issuable under placement agent's unit purchase warrants granted to Maxim Group as agent's compensation under that private placement; and
- 89,646 common shares underlying class 'C' common share purchase warrants also issuable under those placement agent's warrants.

The common shares offered under this prospectus may be sold by the selling shareholders on the public market, in negotiated transactions with a broker-dealer or market maker as principal or agent, or in privately negotiated transactions not involving a broker or dealer. Information regarding the selling shareholders, the common shares they are offering to sell under this prospectus, and the times and manner in which they may offer and sell those shares is provided in the sections of this prospectus captioned *Selling Shareholders*, *Registration Rights* and *Plan of Distribution*. We will not receive any of the proceeds from those sales. Should the selling shareholders in their discretion exercise the class C common share purchase warrants underlying the common shares offered under this prospectus, we would, however, receive the exercise price for those warrants. The registration of common shares pursuant to this prospectus does not necessarily mean that any of those shares will ultimately be offered or sold by the selling shareholders.

RISK FACTORS

An investment in our common shares involves a high degree of risk and is subject to many uncertainties. These risks and uncertainties may adversely affect our business, operating results and financial condition. In such an event, the trading price for our common shares could decline substantially, and you could lose all or part of your investment. In order to attain an appreciation for these risks and uncertainties, you should read this prospectus in its entirety and consider all of the information and advisements contained in this prospectus, including the following risk factors and uncertainties.

Risks Relating To Our Business

As a recently formed company with a limited operating history, we are subject to all the risks and issues inherent in the establishment and expansion of a new business enterprise. Our failure to address these risks and issues will adversely affect our business and the value of your investment

We have a limited operating history and have not to date finalized development of or introduced our heart monitoring products commercially to the markets or entered into any binding contracts to do so. We are, as a consequence, subject to all the risks and issues inherent in the establishment and expansion of a new business enterprise. Our failure to successfully address these risks would adversely affect our ability to introduce our products onto the market and to compete, with consequential delays in our ability to generate revenues and profits, and raise additional working capital. Our activities through the date of this prospectus have been limited to developing our business plan; establishing administrative offices; engaging administrative and research and development personnel; developing the front-end or hardware portion of our heart monitor device and submitting it to the FDA for marketing approval, and continuing development on the "back-end" or software portion of our device. Risks and issues inherent in the establishment and expansion of a new business enterprise which we face include, among others, problems of entering new markets, marketing new technologies, hiring and training personnel, acquiring reliable facilities and equipment, and implementing operational controls. In general, development stage companies are subject to risks and or levels of risk that are often greater than those encountered by companies with established operations and relationships. Development stage companies often require significant capital from sources other than operations. The management and employees of startup business shoulder the burdens of the business operations and a workload associated with company growth and capitalization that is disproportionately greater than that for an established business. Our limited operating history makes it difficult, if not impossible, to predict future operating results. We cannot give you any assurance that we will successfully address these risks.

We have accumulated losses since our inception. Our continued inability to generate revenues and profits will adversely affect our business and the value of your investment

We are a developmental stage company since we have not commenced commercial sales of our products to date and have no revenues. Our failure to generate revenues and ultimately profits would, in the shorter-term, adversely affect our ability to introduce our heart monitor products onto the market and to compete, with consequential delays in our ability to generate revenues and profits; and raise additional working capital; and in the longer-term, force us to suspend our operations, and possibly even liquidate our assets and wind-up and dissolve our company. We do not anticipate that we will generate revenues for at least two years at the earliest. We have, as a result of our lack of revenues, incurred operating losses in the amount of \$3,727,712 from our inception through September 30, 2003, and we anticipate that we will continue to incur substantial operating losses for the foreseeable future, despite any revenues we may receive in the short-term, due to the significant costs associated with the development and marketing of our products and services. We cannot give you any assurance that we will generate revenues or profits in the near future or at all.

We currently expect a working capital deficit in approximately two years. Our inability to raise additional working capital funds to cover this deficit until such time as we have sufficient revenues will adversely affect our business and the value of your investment

Based upon our current projections, we have sufficient working capital to fund our projected operating costs for approximately two years, although this coverage could be less than two years as the result of changes in our business plans, anticipated level of operations and higher than expected costs. We do not expect to receive revenues for at least two years, meaning that we will need to raise additional capital to cover any shortfall. We have no current arrangements for obtaining this additional capital, and will seek to raise it in one or more increments through contract advances, public or private sales of debt or equity securities, debt financing or short-term loans, or a combination of the foregoing. We cannot give you any assurance that we will be able to secure the additional capital we require to continue our operations at all, or on terms which will not be objectionable to our company or our shareholders, including substantial dilution or the sale or licensing of our technologies. Our inability to raise sufficient additional working capital to carry us beyond that two year period pending receipt of meaningful revenues would likely force us to suspend our operations, and possibly even liquidate our assets and wind-up and dissolve our company.

Our heart monitor products and technologies might not successfully compete with established products and technologies which have already achieved market acceptance on the market. Our inability to successfully compete will adversely affect our business and the value of your investment

The market for heart monitoring devices is intensely competitive and characterized by rapidly changing technology, evolving industry standards, price competition and frequent new product introductions. There are no substantial barriers to entry, and we expect that competition will continue to intensify. Most of our existing competitors have greater financial, technical, product development, marketing, and other resources than we do. These organizations may be better known and are likely to have more customers, money, products and systems than we have now or will have in the near future. These competitors may also be able to respond more quickly to new or emerging technologies and changes in customer requirements or devote greater resources to the development, promotion and sales of their products than we are presently able to. Our ability to compete will ultimately will be a function of many variables, including the efficacy, performance and attributes of our products; the ability to obtain necessary regulatory approvals to commercially market our products; the effectiveness of our marketing, sales and distribution efforts, including educating potential customers as to the distinctive characteristics and benefits of our products; our ability to meet manufacturing and delivery schedules; and our ability to price our products competitively. We cannot give you any assurance that we will be able to compete successfully in our markets, or that competitive factors we face will not have a material adverse effect on our business, operating results and financial condition. The failure of our heart monitor products to achieve and then sustain market acceptance would likely force us to suspend our operations, liquidate our assets, and wind-up and dissolve our company.

Our products are regulated by the FDA and, in the worldwide market, government agencies like the FDA. We may be unsuccessful in obtaining regulatory approvals for our products, even though we may invest a significant amount of time and money into seeking such approvals. Our failure to receive the regulatory approvals we need to sell our products will adversely affect our business and the value of your investment

The manufacture, sale, promotion and marketing of our heart monitor products and other products we intend to develop are subject to regulation by the FDA and similar government regulatory bodies in other countries. As we develop or obtain new products we will be required to determine what regulatory requirements, if any, we must comply with in order to market and sell our products in the United States and worldwide. The process of obtaining regulatory approval could take years and be very costly, if approval can be obtained at all. If we fail to comply with these requirements, we could be subjected to enforcement actions such as an injunction to stop us from marketing the product at issue or a possible seizure of our assets. We intend to work diligently to assure compliance with all applicable regulations that impact our business. We cannot assure you, however, that we will be able to obtain regulatory approval for all of our products or that, in the future, additional regulations will not be enacted which might adversely impact our operations. In either case, our revenues and operating results could be adversely effected and the value of your investment may decline.

Since we will focus on only one product line to date, heart monitors, we will not have the ability to rely upon other product lines in the event of our inability to successfully compete in the heart monitor market. Our inability to reduce our risk by diversifying into other product lines or businesses will adversely affect our business and the value of your investment

The only business opportunities we are presently pursuing are the heart monitor (ECG) market and, later, the neurological brain scan (EEG) markets. We do not presently intend to engage in other businesses, although we may eventually branch out by either acquisition or development into markets for other medical devices once we have successfully introduced our initial heart monitor products to market. According, our success will depend entirely upon the success of our single anticipated product line. We will not have the benefit of reducing risk by diversifying our business and funds among a portfolio of businesses, properties, investments or other income producing assets.

Our customers may not be able to receive third party reimbursement for our future products. If our customers are not reimbursed by third party payors, such as private health insurers, it is not likely that they will use our products. The inability of our customers to receive third party reimbursements for our products may adversely affect our business and the value of your investment

We intend to sell our heart monitoring device to individual patients and doctors who will seek reimbursement from various third party payers, including government health programs, private health insurance plans, managed care organizations and other similar programs. We cannot assure you that reimbursement will be available from third party payers or, if available, that the reimbursement policies of the third party payers will not adversely affect our ability to sell our product profitably. If our customers are not reimbursed by third party payers or if the reimbursement by third party payers is too low, our business may be adversely affected and the value of your investment will decline.

We currently have no internal sales, marketing and distribution capabilities. Our inability to develop our sales, marketing and distribution capabilities either internally or through licensees, strategic partners or third party marketing and distribution companies will adversely affect our business and the value of your investment

We currently have no internal sales, marketing and distribution capabilities, and will likely be forced to rely extensively on third-party licensees, strategic partners or third party marketing and distribution companies. Our failure to generate substantial sales through any third-party arrangements we procure or to otherwise develop our own internal sales, marketing and distribution capabilities would, in the shorter-term, adversely affect our ability to introduce our products onto the market and to compete, with consequential delays in our ability to generate revenues and profits; and raise additional working capital; and in the longer-term, force us to suspend our operations, and possibly even liquidate our assets and wind-up and dissolve our company.

As a consequence of our prospective reliance upon third-party licensees, strategic partners or third party marketing and distribution partners, our ability to effectively market and distribute our products will be dependent in large part on the strength and financial condition of others, the expertise and relationships of those third-parties with customers, and the interest of those parties in selling and marketing our products. Prospective third-party licensees, strategic partners and marketing and distribution parties may also market and distribute the products of other companies. If our relationships with any third-party licensees, strategic partners or marketing and distribution partners were to terminate, we would need to either develop alternative relationships or develop our own internal sales and marketing forces to continue to sell our products. Even if we are able to develop our internal sales, marketing and distribution capabilities, these efforts would require significant cash and other resources that would be diverted from other uses, if available at all, and could cause delays or interruptions in our product supply to customers, which could result in the loss of significant sales or customers. We can give you no assurance that we will be successful in our efforts to engage licensees, strategic partners or third party marketing and distribution companies to meet our sales, marketing and distribution requirements.

We currently have no internal manufacturing capability. The failure of our licensees, strategic partners or third party suppliers to satisfy our manufacturing requirements will adversely affect our ability to introduce our products to the market, which will adversely affect our business and the value of your investment

We currently have no internal manufacturing capability, and will likely be forced to rely extensively on licensees, strategic partners or third party contract manufacturers or suppliers. A delay or interruption in the supply of components or finished products would, in the shorter-term, adversely affect our ability to introduce our products onto the market and to compete, with consequential delays in our ability to generate revenues and profits; and raise additional working capital; and in the longer-term, force us to suspend our operations, and possibly even liquidate our assets and wind-up and dissolve our company. Should we be forced to manufacture our products, we cannot give you any assurance that we will be able to develop an internal manufacturing capability or procure third party suppliers. Moreover, we cannot give you any assurance that any contract manufacturers or suppliers we procure will be able to supply our product in a timely or cost effective manner or in accordance with applicable regulatory requirements or our specifications.

We are dependent for our success on a few officers. Our inability to retain those officers will adversely affect our business and the value of your investment

Our success depends to a significant extent on the continued efforts of services of our Chief Executive Officer, Mr. Marvin H. Fink, and our Vice President and Chief Technology Officer, Dr. Budimir S. Drakulic. The loss of any of these personnel could, in the shorter-term, adversely affect our ability to introduce our products onto the market and to compete, with consequential delays in our ability to generate revenues and profits; and raise additional working capital; and in the longer-term, if not satisfactorily replaced, force us to suspend our operations, and possibly even liquidate our assets and wind-up and dissolve our company. Although Mr. Fink has signed an employment agreement and Dr. Drakulic is employed as a consultant under a loan-out agreement, we cannot give you any assurance that one or more of these employees will not leave our company. We maintain key man life insurance policies in the amount of \$1 million with respect to Mr. Fink and \$3 million with respect to Dr. Drakulic.

Our inability to attract the qualified personnel engineering, managerial, sales and marketing and administrative personnel required to implement our growth strategies will adversely affect our business and the value of your investment

Our ability to implement our growth strategies will be dependent upon our continuing ability to attract and retain highly qualified engineering, managerial, sales and marketing and administrative personnel. Our inability to attract and retain the necessary personnel would impede our growth. Competition for the type of personnel we require is intense and we cannot give you any assurance that we will be able to retain our key managerial and technical employees, or that we will be able to attract and retain additional highly qualified managerial and technical personnel in the future.

Our inability to effectively manage our growth will adversely affect our business and the value of your investment

Our success will depend upon the rapid expansion of our business. Our inability to effectively manage our growth, or the failure of our new personnel to achieve anticipated performance levels, would adversely affect our ability to introduce our products onto the market and to compete, with consequential delays in our ability to generate revenues and profits; and raise additional working capital. Expansion will place a significant strain on our financial, management and other resources, and will require us, among other things, to change, expand and improve our operating, managerial and financial systems and controls; improve the coordination between our various corporate functions; and hire additional engineering, sales and marketing, customer service and managerial personnel. We cannot give you any assurance that our efforts to hiring or retain these personnel will be successful, or that we will be able to manage the expansion of our business effectively.

Our inability to protect our patents and proprietary rights will adversely affect our business and the value of your investment

Our ability to compete effectively will be materially dependent upon the proprietary nature of our designs, processes, technologies and materials. The invalidation or circumvention of key patents or proprietary rights which we own or license would likely force us to suspend our operations, liquidate our assets, and wind-up and dissolve our company.

Although we protect our proprietary property, technologies and processes through a combination of patent law, trade secrets and non-disclosure agreements, we cannot give you any assurance that these measures will prove to be effective. For example, in the case of patents, we cannot give you any assurance that our existing patents will not be invalidated, that any patents that we currently or prospectively apply for will be granted, or that any of these patents will ultimately provide significant commercial benefits. Moreover, it is possible that competing companies may circumvent any patents that we may hold by developing products which closely emulate but do not infringe our patents, and accordingly market products that compete with our products without obtaining a license from us. In addition to patented or potentially patentable designs, technologies, processes and materials, we also rely on proprietary designs, technologies, processes and know-how not eligible for patent protection. We cannot give you any assurance that our competitors will not independently develop the same or superior designs, technologies, processes and know-how as we possess.

We believe that the international market for our products and technologies is as important as the domestic market, and we will therefore seek patent protection for our products and technologies or those of our licensors in selected foreign countries. Because of the differences in foreign patent and other laws concerning proprietary rights, our products and technologies may not receive the same degree of protection in a number of foreign countries as they would in the United States.

We cannot give you any assurance that we will be able to successfully defend our patents and proprietary rights. We also cannot give you any assurance that we will not be required to defend against litigation involving the patents or proprietary rights of others, or that we will be able to obtain licenses for these rights. Legal and accounting costs relating to prosecuting or defending patent infringement litigation may be substantial.

Risks relating to an investment in our securities

Our common shares are thinly traded, so you may be unable to sell at or near ask prices or at all if you need to sell your shares to raise money or otherwise desire to liquidate your shares

Our common shares are thinly-traded on the OTCBB, meaning that the number of persons interested in purchasing our common shares at or near ask prices at any given time may be relatively small or non-existent. This situation is attributable to a number of factors, including the fact that we are a small company which is relatively unknown to stock analysts, stock brokers, institutional investors and others in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons, they tend to be risk-averse and would be reluctant to follow an unproven development stage company such as ours or purchase or recommend the purchase of our shares until such time as we became more seasoned and viable. As a consequence, there may be periods of several days or more when trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer which has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price. We cannot give you any assurance that a broader or more active public trading market for our common shares will develop or be sustained, or that current trading levels will be sustained. Due to these conditions, we can give you no assurance that you will be able to sell your shares at or near ask prices or at all if you need money or otherwise desire to liquidate your shares.

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

The market price for our common shares is extremely volatile, which could result in your suffering a substantial or total loss in your investment

The market for our common shares is characterized by significant price volatility when compared to seasoned issuers, and we expect that our share price will continue to be volatile for the indefinite future. The volatility in our share price is attributable to a number of factors.

First, as noted above, our common shares are thinly traded. In addition, we have relatively few common shares outstanding in the public float since most of our shares are held by a small number of shareholders. As a consequence, the trading of relatively small quantities of shares by our shareholders may disproportionately influence the price of those shares in either direction. The price for our shares could, for example, decline precipitously in the event that a large number of our common shares are sold on the market without commensurate demand, as compared to a seasoned issuer which could better absorb those sales without adverse impact on its share price.

The volatility of our share price is further affected due to our status as a development stage company. Since we have a limited operating history and no revenues or profits to date, the market price for the common shares is more volatile than that of a seasoned issuer both because we do not have a history of sales or earnings traditionally used to determine stock prices and our viability is more in doubt.

Finally, we will remain subject to variety of internal and external factors which generally affect the stock price of all companies. Examples of internal factors, which can generally be described as factors that are directly related to our operating performance or financial condition, would include release of reports by securities analysts and announcements we may make from time-to-time relative to our ability to enter into contracts or other arrangement, our operating performance, advances in our technology or other business developments specific to our company. Examples of external factors, which can generally be described as factors that are unrelated to the operating performance or financial condition of any particular company, include changes in interest rates and worldwide economic and market conditions and trends, as well as changes in industry conditions, such as changes in the cost of components and energy, regulatory and environment rules, announcements of technology innovations or new products by other companies, and quarterly fluctuation in our or in our competitors' operating results. In this regard we note that changes in the market price of our common shares may have no connection with our operating results, financial condition or prospects. Further, declines in our stock price may be exacerbated in periods where the general market is rapidly declining due to, among other things, our lack of liquidity as discussed above. We cannot make any predictions or projections as to what the prevailing market price for our common shares will be at any time, or as to what effect, if any, that the sale of shares or the availability of common shares for sale at any time will have on the prevailing market price.

We have issued a large number of common share purchase options and warrants. The sale of common shares on the public market to finance their exercise or pay associated income taxes could substantially depress the prevailing market prices for our shares

There are currently outstanding common share purchase options and warrants entitling the holders to purchase 172,292 series "A" preferred shares and 4,014,090 common shares, including a number granted to directors, officers, employees and consultants that are subject to vesting conditions. It is likely that a number of the holders of these options and warrants will sell common shares in tandem with their exercise of these securities to finance that exercise. Further, it is likely that a number of the holders of these options and warrants who have received these securities as compensation and will therefore be subject to taxation on their exercise of those securities will also sell common shares in tandem with that exercise in order to cover that income tax liability. Sales of substantial amounts of common shares on the public market to finance these exercises or to pay income taxes, or the perception that substantial sales could occur as these options and warrants become vested and exercisable, could substantially depress the prevailing market prices for our shares.

Our common shares are thinly-traded on the OTCBB, meaning that the number of persons interested in purchasing

We are subject to the penny stock rules and these rules may adversely effect trading in our common shares

Our common shares are considered a low-priced security under rules promulgated under the Securities Exchange Act of 1934. In accordance with these rules, broker-dealers participating in transactions in low-priced securities must first deliver a risk disclosure document which describes the risks associated with such stocks, the broker-dealer's duties in selling the stock, the customer's rights and remedies and certain market and other information. Furthermore, the broker-dealer must make a suitability determination approving the customer for low-priced stock transactions based on the customer's financial situation, investment experience and objectives. Broker-dealers must also disclose these restrictions in writing to the customer, obtain specific written consent from the customer, and provide monthly account statements to the customer. The effect of these restrictions will likely be a decrease in the willingness of broker-dealers to make a market in our common shares, decreased liquidity of our common shares and increased transaction costs for sales and purchases of our common shares as compared to other securities.

Our right to issue additional capital stock at any time could have an adverse effect on your proportionate ownership and voting rights

We are entitled under our Certificate of Incorporation to issue up to 100,000,000 common shares and 10,000,000 blank check preferred shares having such rights, preferences, privileges and restrictions as may be designated from time-to-time by our board. Our board may generally issue those common and preferred shares, or options or warrants to purchase those shares, without further approval by our shareholders based upon such factors as our board of directors may deem relevant at that time. It is likely that we will be required to issue a large amount of additional securities to raise capital to further our development and marketing plans. It is also likely that we will be required to issue a large amount of additional securities to directors, officers, employees and consultants as compensatory grants in connection with their services, both in the form of stand-alone grants or under our various stock plans. If you are a common shareholder, your proportionate ownership and voting rights could be adversely effected by the issuance of additional common or preferred shares, or options or warrants to purchase those shares, including a substantial dilution in your proportionate ownership and voting rights. We cannot give you any assurance that we will not issue additional common or preferred shares, or options or warrants to purchase those shares, under circumstances we may deem appropriate at the time. The issuance of preferred shares may also have the effect of delaying, deferring or preventing a change in control of the company.

A single shareholder currently beneficially owns the majority of our outstanding common shares. This means that that shareholder will be able to control our company by electing a majority of the members of our board of directors

Ms. Tracey Hampton beneficially owns, through ARC Finance Group, LLC, approximately 70% of our outstanding common shares. As a consequence, Ms. Hampton will retain the ability to elect a majority of our board of directors, and thereby control our management. Ms. Hampton also has the ability to control the outcome of corporate actions requiring shareholder approval, including mergers and other changes of corporate control, going private transactions, and other extraordinary transactions. This concentration of ownership may have the effect of delaying or preventing a change of control, even if a change of control would benefit our other shareholders.

USE OF PROCEEDS

The proceeds from the sale of the shares to be sold under this prospectus will be retained by the selling shareholders, and will not be paid or remitted or otherwise made available to our company.

BUSINESS

Overview

Recom is a development stage medical device company focused on researching, developing and marketing heart (cardiac) monitors and other diagnostic medical devices which monitor and measure the body's physiological signals in order to detect and prevent medical complications and diseases that impact an individual's health. Our products will operate using a proprietary patented amplification technology which enables them to more accurately discriminate physiological signals from ambient electromagnetic background noise than existing amplification technologies.

We are currently developing our first product, a non-invasive ambulatory heart monitor, and have submitted the "front-end" or hardware portion of this device, which collects, processes and records data, to the U.S. Food and Drug Administration for marketing approval. We hope to receive this approval during the first quarter of 2004. We are currently developing the "back-end" or software portion of the device, which allows the management and interpretation of the data, and for which FDA approval is not generally required. We anticipate that we will complete a production model of our heart monitor, including both back-end and front-end functions, within two years, and will have also commenced commercial marketing efforts by the end of that period.

Corporate History

We were originally incorporated in Delaware on January 19, 1987. We had no specific business purpose on the date of incorporation and were inactive until October 30, 1998. On that date, we completed a reverse acquisition with J2 Technologies LLC and changed our name to Recom Managed Systems, Inc. Subsequent to the reverse acquisition, we engaged in the business of developing, servicing and managing commercial computer networks both on-site and remotely.

On June 26, 2000, we filed a voluntary petition for reorganization under Chapter 11 of the Federal Bankruptcy Code. Our plan of reorganization was confirmed by the Bankruptcy Court and the confirmation order became final on November 7, 2000. Subsequent to declaring bankruptcy, we ceased our business operations. The plan of reorganization provided for a total discharge of the company and our officers and directors from all pre-petition debts, expenses and legal causes of action which may have existed on or before the filing of the bankruptcy. The plan further provided for the consolidation of all previously issued common shares, and the issuance of additional common shares to various creditors of the company. As of December 31, 2000, following full implementation of the plan, there were 4,139,784 common shares (1,379,928 shares pre-split) issued and outstanding.

On September 19, 2002, we acquired certain know how, trade secrets and other proprietary intellectual property rights relating to the development of a human biomedical signal amplification equipment and technology, referred to in this prospectus as the "*Signal Technologies*", from ARC Finance Group, LLC in exchange for 23,400,000 common shares (7,800,000 shares pre-split). The shares represented approximately 85% of our issued and outstanding common shares. We valued the Signal Technologies at \$150,000,780,23 for financial accounting purposes. The principal component of the Signal Technologies is a patented "amplification" technology which was originally invented by Dr. Budimir S. Drakulic. The underlying patent covers methods of discriminating different biomedical signals from a background of ambient noise. Also included in the Signal Technologies was an assignment of a license agreement dated December 9, 1993 between Dr. Drakulic and Teledyne Electronic Technologies pursuant to which Dr. Drakulic granted a limited license to use an early version of the amplification technology to analyze signals produced by the brain (EEG) in an effort to understand a patient's sleep patterns. Additional components of the Signal Technologies include methods to automatically and remotely provide and evaluate the signals over the telephone, the Internet, or other wireless transmissions systems. Concurrent with our acquisition of the Signal Technologies, we obtained Dr. Drakulic's services as our Vice President and Chief Technology Officer to lead our product development efforts.

On April 15, 2003, we completed a three for one forward stock split, resulting in a total of 31,510,848 common shares being outstanding as of that date.

Our Products And Services

We have recently completed development of the front-end or hardware portion of our initial product, a non-invasive heart monitor for ambulatory (freely-moving) patients which we anticipate will enable physicians to accurately monitor, in real-time, changes in the patient's physiological signals and assist in the detection of heart disease through the conduct of electrocardiogram tests, commonly known as ECGs or EKGs. This portion of our product principally consists of the data collection, processing and recording functions of the heart monitor utilizing, in part, our amplification technology. Our front-end hardware as presently designed will record up to 48 hours of data from each of its twelve leads. We submitted this portion of our heart monitor product to the U.S. Food and Drug Administration for approval on September 12, 2003, and hope to receive FDA clearance to market it within the United States during the first quarter of 2004.

We continue to develop the "back-end" or software portion of our heart monitor, which can be best described as the data management and interpretation functions of the heart monitor device which will allow the physician to analyze the data collected and processed by the "front-end" hardware. Much of the software used for the back-end functions can be readily acquired off the shelf and then modified to meet our needs. As of this date, we do not anticipate that we will need to submit any of the back-end software to the FDA for approval. Once we have completed these steps, we must design and engineer a "production" model for mass manufacturing which will be durable, reliable and maintenance-free, and competitively priced. We anticipate that we will complete a production model of our heart monitor, including both back-end and front-end functions, within two years, and will have also commenced commercial marketing efforts by the end of that period.

We are also developing an enhanced version of our first heart monitor. Our long term goal is to transmit the signal electronically, in real time, to a specially designed website that we will host and that the patient's physician can access.

We are also developing algorithms for use with our heart monitor, to facilitate the electronic recognition and categorization of different physiological signals and their correlation to different heart diseases. The algorithms will compare the user's ECG to a known database of ECG anomalies and to the user's historical baseline ECG data in order to assist the physician with his or her diagnosis.

Our amplification technology is also extremely effective when used for other biomedical signals such as electroencephalogram or EEG tests used to measure neurological (brain) responses. Indeed, as discussed below, the technology was originally developed for this purpose. We intend in the future to devote a portion of our development activities to EEG-related applications of our technology, such as Alzheimer's and other neurological diseases.

Description Of Heart Monitors And ECGs

A heart monitor is a device used to collect and record data when conducting ECG tests to detect and identify heart disease. An ECG gives the physician important information about the heart. For example, it can show the heart's rate and rhythm. It can also detect decreased blood flow (cardiac ischemia), enlargement (hypertrophy) of the heart and the presence of either current or past heart attacks. When an ECG test is conducted, the physiological signals from the patient's heart are collected through ten electrodes (12 leads) attached to the patient's arms, chest and legs. These signals are then amplified and recorded in the form of a series of wavy lines that can be either displayed on a screen or printed on paper for review by the physician or a medical technician. Any irregularity in the heart rhythm or damage or stress to the heart muscle will show up as a deviation from the normal waveform. Most ECGs today are given either under emergency circumstances when an individual complains of symptoms typically associated with heart disease (i.e. chest pains, shortness of breath, heart palpitations), or every year or so for older patients as part of their annual physicals.

While most ECG tests are conducted at the physician's office or a hospital, physicians are aware that some types of heart disease may only become apparent when the patient is subject to the stresses of normal day-to-day activities, and are further aware that other conditions such as episodic heart-beat irregularities only become apparent as the result of longer term monitoring which is otherwise impractical or unduly expensive to conduct on a clinical basis. For this reason the medical device industry has created a number of ambulatory or holter monitors which allow the patient's heart to be continuously monitored over a period of hours or days, while the patient carries out his or her daily activities away from the physician's office or hospital. Unfortunately, as discussed below, these ambulatory devices have limited effectiveness due to the susceptibility of the device to artifact or noise.

Product Advantages

As previously noted, ECGs monitor electronic activity generated by the heart, and physiological irregularities are more likely to be detected while the patient is in an ambulatory environment. Detection and isolation of ambulatory ECG signals are difficult due to the significant interference from other electromagnetic fields found in the environment, including those generated by the body itself as well as those generated by appliances and machines. This interference results in artifact or noise that interfere with the ability of current ECG monitoring devices to accurately isolate a high quality signal in an ambulatory environment. Cardiologists attempt to address the issue of noise by having the patient remain as still as possible while a reading is taken (that is why 12-lead ECGs are normally taken in the hospital or in physician offices) or by reducing the sensitivity of the monitoring. Reducing the sensitivity of the signal, however, results in a loss of both signal quality and the ability to read certain signal intricacies. The noise problem is compounded when a patient uses an ambulatory ECG monitor due to the physician's inability to control the patient's movement and enhanced unshielded electromagnetic interference from the surrounding environment.

Our patented amplification technology was originally developed by Dr. Drakulic to address the noise issue in response to the requirements of the United States Air Force. In an effort to explore ways to accurately and objectively monitor pilot performance, the Air Force wanted to record a pilot's neurological (brain) responses, consisting of tiny electrical impulses, to different tasks and stresses occurring in-flight using an electroencephalogram or EEG test. However, the Air Force found that the neurological signal monitoring equipment then available were not able to accurately monitor EEG in an electromagnetically charged environment such as the cockpit of a fighter jet or a B-52 bomber. In 1992 the United States Air Force selected Dr. Drakulic to lead the effort to develop a device to solve the monitoring problem. This effort ultimately resulted in the creation by Dr. Drakulic in 1994 of his first-generation amplifier, and its use by the Air Force to monitor pilot EEG signals. This model is currently used by the National Institute of Health as well as companies such as Titan Systems and Teledyne, Inc. for purposes of monitoring different neurological biomedical signals.

Dr. Drakulic has since enhanced signal processing technology and adopted it for heart monitors. These enhancements have resulted in Recom filing three additional patents covering different aspects of 24/7, 12-lead ECG monitoring technology.

The amplification technology also affords several other valuable product advantages relating to the quality of its signals. First, ambulatory heart monitors currently on the market only have three leads with limited bandwidth. Due to the ability of our amplification technology to eliminate noise and increase signal quality, we can increase the bandwidth on our ambulatory device to be comparable with the signal derived from stationary clinical devices without material interference.

Further, due to the clarity and consistency of the physiological signal, as well as the design of the amplification technology, we are able to develop algorithms for use with our heart monitor which will enable us to process the signal and correlate it to signals associated with different cardiac diseases or conditions, which we believe will prove to be a valuable tool for physicians. We do not know of any monitors currently on the market that have this latter ability.

Market For Heart Monitor Products

Cardiovascular disease is the leading cause of death in the industrialized world. Heart disease and stroke, the principal components of cardiovascular disease, claim more lives each year than the next five leading causes of death combined. In the United States alone, approximately 61,800,000 people suffer from one or more types of cardiovascular disease each year. These diseases claimed approximately 950,000 lives in the United States in 1999. Approximately one-sixth of all people in the United States killed by cardiovascular disease are under the age of 65. The American Heart Association estimated that in 2002 the direct and indirect healthcare cost of cardiovascular disease in the United States equaled \$351.8 billion. The Center for Disease Control has stated that, if all forms of major cardiovascular disease were eliminated, life expectancy would rise by almost 7 years while, in comparison, if all forms of cancer were eliminated, the gain in life expectancy would only be 3 years.

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

According to the American Heart Association, patients who have suffered heart attacks number 7.3 million, congestive heart failure 4.7 million, arrhythmia 2.0 million and angina 6.4 million. Patients with any of these health problems would probably benefit in some manner from improved heart monitoring.

Marketing And Distribution Strategy

Our current plans are to license our heart monitor technologies for stationary heart monitor applications to established medical-device manufacturers and distributors, who will most likely incorporate them into their own products. In the case of the market for ambulatory heart monitors, we anticipate that we will delegate most of our sales, marketing and distribution activities to third party medical-device marketing and distribution companies on a regional basis, while creating a small internal sales, marketing and distribution staff to monitor and manage those activities and to directly market and distribute our products to doctors, hospitals and distributors on a selected basis. We will also probably explore joint venture relationships.

Product Evolution Strategy

As previously discussed, the use of heart monitors today are usually given either under emergency circumstances when a physician suspects a heart attack, or every year or so for older patients as part of their physicals. In the latter case as also addressed above, episodic heart-beat irregularities and certain other heart diseases and conditions may not be identified by the ECGs under clinical conditions. With the product advantages afforded to our device, particularly in an ambulatory setting, we believe that our heart monitor can be used to create a more efficacious continuous preventive monitoring program. Specifically, we believe that individuals could periodically use the device to not only measure their heart functions, but to create a baseline of historical data relating to their individualized signals using the algorithmic programs we are developing. The physician can then not only compare these signals and baseline with our known database of ECG anomalies, but identify fluctuations from the individual's unique baseline. To support this theory, our scientists are currently undertaking focused research studies to categorize physiological baselines and their correlation to disease. If we can verify that deviations from a patient's baseline can serve as a marker of disease or life-threatening conditions, these events could be treated earlier, thereby resulting in decreased medical expenses, reduced hospitalization and fewer incidences of death and disability.

Manufacturing Capacity

We currently fabricate our heart monitors either in-house or through engineering consultants. Given the limitations in our internal manufacturing capability, we anticipate that we will rely upon third party contract manufacturers or joint-venture partners to satisfy future production requirements when we are able to introduce our products to market. Most of the components of our products are standard parts which will be available from multiple supply sources at competitive prices.

Regulatory Overview

The Medical Device Amendments of 1976 (the *Medical Device Act*), a section of the Federal Food, Drug & Cosmetic Act, establishes complex procedures for compliance based upon FDA regulations that designate devices as Class I (general controls, such as compliance with labeling and record-keeping requirements), Class II (performance standards in addition to general controls) or Class III (pre-market approval application before commercial marketing).

A medical device that is substantially equivalent to a directly related medical device previously in commerce may be eligible for the FDA's abbreviated pre-market notification 510(k) review process. FDA 510(k) clearance is a grandfather process. As such, FDA clearance does not imply that the safety, reliability and effectiveness of the medical device has been approved or validated by the FDA, but merely means that the medical device is substantially equivalent to a previously cleared commercially-related medical device. The review period and FDA determination as to substantial equivalence should be made within 90 days of submission of a 510(k) application, unless additional information or clarification or clinical studies are requested or required by the FDA. As a practical matter, the review process and FDA determination often take significantly longer than 90 days.

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

Our heart monitor is a Class II product. In September 2003, we submitted an application to the FDA on form 510(k). We cannot be certain that this product will receive approval from the FDA in the near future or at all. If we do not receive FDA approval for our product, we will not be able to market it.

Patents And Licenses

We hold patent number 5,678,559 issued by the United States Patent and Trademark Office for our core technology, our amplification device. This patent, which was assigned to us by ARC Finance Group as part of our acquisition of the Signal Technologies, expires on October 21, 2014. We also hold three patent applications filed with that office, number 10/293,105, 10/611,696 and 10/664,711 filed on November 13, 2002 on July 1, 2003, September 17, 2003, respectively. Each of these patent applications cover technologies that will enhance our heart monitor. Dr. Drakulic is the inventor named in our core patent and each of the patent applications.

Also included in the Signal Technologies was an assignment of a license agreement dated December 9, 1993 between Dr. Drakulic and Teledyne Electronic Technologies, pursuant to which Dr. Drakulic granted a limited license to use an early version of the amplification technology to analyze signals produced by the brain (EEG) in an effort to understand a patient's sleep patterns. We do not expect to earn significant revenues from this license. This license will not prevent Recom from competing in the broader market for EEG amplification products.

Competition

Because we do not yet have a saleable product, we have no competitive presence in the medical monitoring device market. Even if our heart monitor is approved for sale, we do not expect to establish a competitive presence in this market for several years, if at all. There are numerous suppliers of heart monitoring products, all of which have established products and methods of distribution as well as more money than we do. We may never be able to compete successfully in this or any other medical device market.

Costs And Effects Of Compliance With Environmental Laws

There are no special or unusual environmental laws or regulations that will require us to make material expenditures or that can be expected to materially impact on the operation of our business.

Employees

We currently have six full-time employees, and engage the services of seven engineering, marketing and financial consultants on a part-time basis. None of our employees is represented by a labor union and we consider our relationships with our employees to be good.

PROPERTY

Our executive offices are located at 4705 Laurel Canyon Boulevard, Suite 203, Studio City, California. These facilities, consisting of approximately 3,300 square feet and encompassing three suites including our administrative offices and research and development/laboratory facilities, are leased through August 30, 2005. We pay \$7,682 per month in base rent for these facilities, which we believe reflected market value on the date the lease was executed, and are also required to pay our share of any increase in operating expenses after August 2002. Operating expenses include expenses for maintenance of common areas, heating, air conditioning, plumbing, trash disposal, janitorial and security services and other like expenses. In August 2003 we were notified that our rent would increase in the amount of \$225 per month as a result of increased operating expenses. The leased premises are in good condition and we believe they will be suitable for our purposes for at least twelve months.

PLAN OF OPERATION

Our plan of operation over the next two years is to complete the development of our first product, a non-invasive ambulatory heart monitor. As previously noted, we have submitted the front-end or hardware portion of this device, which collects, processes and records data, to the U.S. Food and Drug Administration for marketing approval. We hope to receive this approval during the first quarter of 2004. We are currently developing the back-end or software portion of the device, which allows the management and interpretation of the data, and for which FDA approval is not generally required. We anticipate that we will complete a production model of our heart monitor, including both back-end and front-end functions, within two years, and will have also commenced commercial marketing efforts by the end of that period.

We have currently budgeted \$3,600,000 to complete this process, including \$2,300,000 to cover our projected general and administrative and marketing expenses, and \$1,300,000 to cover our projected research and development, and product testing and development costs. From October 1, 2003 to November 1, 2003 we raised \$5,378,750 through the sale of our securities in private placements. We currently have cash on hand of approximately \$4.1 million to fund the completion of our development activities over the next two years.

The steps we need to take to complete our research and development, product development and testing activities include the following:

- We need to finalize the remaining development work on the front-end portion of the device, which consists of designing the device to meet the FDA's EC 38 and other required standards. This work does not need to be approved by the FDA, but tests have to be completed before marketing. We anticipate that we will complete this work by the end of the second quarter of 2004. We have budgeted \$280,000 for this phase.
 - We also need to complete the back-end portion of the device. To do so, we anticipate spending \$250,000 to purchase off-the-shelf software which we can use with only minor modifications, and spending an additional \$200,000 to develop proprietary software and algorithms. We anticipate that we will complete this work by the end of the first quarter of 2005.
 - Once we have fully designed the front-end portion of our device, we intend to submit test protocols in the third quarter of 2005 to the Institutional Review Board (IRB) to review. We will coordinate the writing of a number of white papers relating to effectiveness of our device and published results in peer review journals. During this period, we also intend to make arrangements with four or more hospitals or clinics to test our device. We anticipate that we will complete this process by the third quarter of 2005. During the course of this period we should complete the back-end portion of the device, and we will then have the opportunity to use it during the clinical testing with the front-end portion. Our anticipated budget for these activities is \$300,000.
 - We need to design a vest which can be used on a 24/7 basis for extended periods of time, while being taken off by the patient intermittently for showers, etc. We must address two engineering issues in developing this vest. First, we need to develop an electrode which can be incorporated into the vest to monitor the patient's heart signal, thus replacing the use of leads and gels currently used in recording ECGs. Second, we need to design the vest in such a fashion that it not only holds the electrode against the body at the correct locations and in the proper manner, but it also can be adapted to fit patients with different heights, weights and physiques. We project that we will spend approximately \$230,000 to conduct these development activities, and expect to complete them by the last quarter of 2005.
 - We have also budgeted \$60,000 to purchase various items of equipment to test the operation of the device over different phases.
-

LEGAL PROCEEDINGS

As of the date of this prospectus, there are no material pending legal or governmental proceedings relating to our company or properties to which we are a party, or to our knowledge any proceeding of this nature which are being contemplated or threatened; and to our knowledge, no material proceedings to which any of our directors, executive officers or affiliates are a party adverse to us or which have a material interest adverse to us.

MANAGEMENT**Identity**

The following table identifies our current executive officers and directors, their respective offices and positions, and their respective dates of election or appointment:

There are no family relationships between any two or more of our directors or executive officers. There are no arrangements or understandings between any two or more of our directors or executive officers.

Name And Municipality Of Residence	Age	Office	Initial Election Or Appointment Date
Marvin H. Fink Los Angeles, California	67	Chief Executive Officer, President, Secretary, and Chairman of the Board	October 12, 2003
Budimir S. Drakulic, Ph.D. Los Angeles, California	53	Vice President and Chief Signal Technologies Officer	October 15, 2003
Charles Dargan Los Angeles, California	48	Interim Chief Financial Officer	December 18, 2003
Ellsworth Roston Los Angeles, California	81	Director	November 1, 2002
Robert Koblin, M.D. Los Angeles, California	72	Director	February 6, 2003
Lowell T. Harmison, Ph.D. Washington, D.C.	66	Director	June 6, 2003

Business Experience

Marvin H. Fink has served as our Chief Executive Officer, President and Chairman of the Board since October 2002, and our Secretary since November 2003. Prior to joining us, Mr. Fink was president of his own management consulting group from August 2001 until he joined Recom in October 2002. Mr. Fink has 45 years of experience in the management of high technology programs from development stage through production including projects for the Department of Defense, NASA, Teledyne Systems, Litton Industries and Hughes Aircraft. He served as President of Teledyne Electronic Technologies from 1993 until his retirement in August 2001. From 1986 until 1993, he served as President of Teledyne Microelectronics. Mr. Fink serves on the board of R. F. Industries and is a member of the California Bar Association. Mr. Fink holds a bachelors of science degree in electronic engineering from City College of New York, a Masters of Science degree in Electronic Engineering from the University of Southern California, and a Juris Doctor degree from the San Fernando Valley College of Law.

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

Dr. Budimir S. Drakulic has served as our Vice President and Chief Signal Technologies Officer since October 2002. Dr. Drakulic has more than 25 years of experience in the design, development and integration of hardware and software modules for biomedical microelectronics circuits and systems. From 1997 through February of 2002, Dr. Drakulic was involved directly and indirectly with Advanced Heart Technologies, Inc., a corporation controlled by Dr. Drakulic. Dr. Drakulic was the Consultant and Chief Scientist, Medical Device Business Unit for Teledyne Electronic Technologies from 1992 through 1997. Before that, he held numerous positions affiliated with the University of California at Los Angeles, including Visiting Assistant Professor with the Electrical Engineering Department and Director of the Microelectronics Development Lab at the Crump Institute for Medical Engineering. He holds a Bachelor of Science degree in electrical engineering from the University of Belgrade, Yugoslavia. He also holds a Masters degree and a Ph.D in Electronic and Biomedical Engineering from the same university. Dr. Drakulic was the recipient of the Ralph and Marjorie Crump Prize for Excellence in Medical Engineering from UCLA in 1985 and he was a Research Fellow with the Crump Institute for Medical Engineering at UCLA.

Mr. Charles Dargan is providing his services to us on a leased basis through an agency that specializes in providing financial management personnel to businesses on a temporary basis. We are actively recruiting a permanent full-time Chief Financial Officer. Mr. Dargan is also currently employed as the Chief Financial and Accounting Officer of Semotus Solutions, Inc. From April 2000 until his appointment as Chief Financial and Accounting Officer in January 2001, Mr. Dargan served as Semotus' Executive Vice President of Operations. Mr. Dargan was also a director of Semotus Solutions from March 1999 to July 2002. Prior to joining Semotus Solutions, Mr. Dargan served as a Managing Director of Corporate Finance for The Seidler Companies Incorporated, a private brokerage, investment banking and public finance firm. In addition, he was a partner and Chief Financial Officer of the investment banking firm of Ambient Capital; a Managing Director of Corporate Finance at L.H. Friend, Weinress, Frankson & Presson, Inc.; and a First Vice President at Drexel Burnham Lambert, Incorporated. His accounting and financial industry experience has made him an expert in public and private debt and equity finance, mergers and acquisitions and financial management of and planning for emerging growth companies. Mr. Dargan graduated from the University of Southern California with an MBA and an MS in Finance, and possesses an A.B. in Government and Economics from Dartmouth College. He also holds accounting and finance industry certifications of Chartered Financial Analyst (CFA) and Certified Public Accountant (CPA).

Mr. Ellsworth Roston has served as a director since October 2002. Mr. Roston has practiced patent law since 1943, and currently serves as Of Counsel to the patent firm of Fulwider Patton Lee & Utecht since 1997. Mr. Roston has a history of assisting technology companies during their development stages. He was one of three founders of Brooktree Corporation, and served on its board of directors for 15 years. Mr. Roston received his undergraduate degree and his law degree from Yale University.

Dr. Robert Koblin has served as a director since February 2003. Dr. Koblin, a cardiologist, has more than 30 years of medical experience beginning during the time he served in the United States Army as a medic and continuing most recently as a staff physician and instructor at the Cedars-Sinai Medical Center in Los Angeles. He also serves as the Managing Director of the Robertson Diagnostic Center in Beverly Hills, California, and is an assistant clinical professor of medicine at the University of California, Los Angeles (UCLA). Dr. Koblin received his undergraduate degree from New York University, his medical degree from Stanford University.

Dr. Lowell T. Harmison has served as a director since June 2003 and as a Senior Advisor since February of 2003. Dr. Harmison has a very distinguished 35 year career in the field of biomedicine. From 1990 through the present, Dr. Harmison has served as a Senior Advisor and Board Member to pharmaceutical and health companies. He is the holder of the first domestic and foreign patents on the fully implantable artificial heart; has served as CEO of USET, Inc.; and as the Director of a private foundation operating internationally and consisting of 21 operating companies. He has also served as the Principal Deputy Assistant Secretary for Health of the U.S. Public Health Service, Department of Health and Human Services. Dr. Harmison has a PhD from the University of Maryland and a B.S. and M.S. from West Virginia University. He was also given an honorary Doctor of Science degree from the West Virginia University .

Board Compensation

Our current compensation policy for our directors is to compensate them through stock grants under our 2002 Stock Plan pursuant to a director's compensation policy adopted on February 6, 2003. Upon joining our board of directors, each member is granted an option to purchase 50,000 common shares, exercisable at its then trading price. These options are fully vested upon grant, and lapse in five years if not exercised. Each director will thereafter be granted options on an annual basis entitling him to purchase an additional 28,000 common shares, which options will vest quarterly based upon the continued provision of services as a director, and lapse in five years if not exercised. The exercise price for these options will be fixed at current market price as of the date of grant.

Upon the adoption of the director's compensation policy on February 6, 2003, we granted directors' options under the 2003 Plan to each of Messrs. Fink and Roston and Dr. Koblin entitling each of them to purchase 150,000 common shares (50,000 shares pre-split) at \$0.88 per share. These options were fully vested upon grant, and will lapse on February 4, 2008. On June 5, 2003, we granted directors' options under the 2003 Plan to Dr. Harmison entitling him to purchase 50,000 common shares at \$4.20 per share. These options were fully vested upon grant, and will lapse on June 4, 2008. On November 3, 2003, shortly after the first anniversary of their respective start dates, we granted directors' options under the 2003 Plan to each of Messrs. Fink and Roston entitling each of them to purchase 28,000 common shares at \$4.40 per share. These options will vest quarterly commencing February 3, 2004 upon the continued provision of services as directors for a period of one year, and will lapse on November 2, 2008.

Employment And Consulting Agreements With Management

On October 11, 2002, Recom reached an agreement-in-principle with Mr. Marvin H. Fink to become our Chief Executive Officer and President and to issue him restricted common shares. Pursuant to that understanding, on October 12, 2002, we entered into a four-year employment agreement. The effective date for this transaction was October 11, 2002 with Mr. Fink. The essential terms of the employment agreement are as follows:

- Mr. Fink's will receive an initial base salary of \$1 per year. Following the one-year anniversary of the agreement, our board of directors may review and adjust the base salary in light of our company's performance.
 - Mr. Fink is entitled to a cash bonus for his second through fourth years of employment. The amount of the bonus is 10% of our after tax income exclusive of extraordinary expenses for the second year, and 15% of that amount for the third and fourth years.
 - Mr. Fink is granted 2,100,000 restricted common shares (700,000 shares pre-split), to be earned over three years of continuous employment. These shares, which are held in escrow by the company pursuant to the terms of a restricted stock agreement until they are earned, vest in tranches of 174,999 each at the end of the first eleven quarters of Mr. Fink's employment, with the balance vesting at the end of the twelfth quarter. Mr. Fink is entitled to all dividends which may be declared with respect to these shares, even if not vested.
 - The agreement contains a gross up provision obligating us to make a cash payment to Mr. Fink to cover any taxes he may incur by reason of receiving any payment or distribution that would constitute an excess golden parachute payment under the federal tax laws. The gross up provision also applies to the 2,100,000 restricted common shares described above, however, Mr. Fink exercised his section 83(b) election under the Internal Revenue Code subjecting him to immediate taxation upon the receipt of the shares notwithstanding their future forfeitability, so our liability, if any, for any taxes imposed under that grant should be nominal.
-

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

- Should our common shares be listed on any of the NYSE, AMEX or Nasdaq national stock exchanges or markets, Mr. Fink would be entitled, if then still employed by us, to an additional grant of 600,000 common shares (200,000 shares pre-split).
- In the event of a change in control (as that term is defined in the employment agreement), Mr. Fink would be entitled, if then still employed by us, to an additional grant of common shares having a market value of \$5,000,000, but not to exceed 600,000 common shares (200,000 shares pre-split) in total.
- Mr. Fink is entitled to a number of employee benefits under the agreement, including a \$1,200 per month automobile allowance, individual medical plan reimbursement of up to \$2,000 per month, and the right to participate in all benefit plans established for company employees or executives, including medical, hospitalization, dental, long-term care and life insurance programs.

The employment agreement provides for early termination in the case of Mr. Fink's death or disability, Mr. Fink's termination by Recom for cause as that term is defined in the agreement; Mr. Fink's termination of employment for good reason as that term is defined in the agreement, a change in ownership as that term is defined in the agreement, or sixty days prior notice by Mr. Fink. In the event of an early termination of the agreement for any reason, all compensation and benefits under the agreement will terminate and the unvested portion of the 2,100,000 restricted common share grant shall be deemed forfeit as of the effective termination date, with the following exceptions:

- if the agreement is terminated during years two through four due to Mr. Fink's disability, termination by Mr. Fink for good reason; Recom's termination of Mr. Fink without cause, or a change in ownership, Mr. Fink will nevertheless be entitled to a pro rata portion (based upon the actual number of days of employment) of the cash bonus based on our after-tax income that he would have otherwise received for the year of termination had he remained employed until the end of that year;
 - if the agreement is terminated due to Mr. Fink's death, disability, termination by Mr. Fink for good reason; Recom's termination of Mr. Fink without cause, or a change in ownership, the unvested portion of the 2,100,000 restricted common share grant to Mr. Fink will become fully vested and the shares released from escrow; and
 - ◆ Mr. Fink and his family will be entitled to an additional three years medical, hospitalization, dental, long-term care and life insurance coverage if the agreement is terminated by Mr. Fink for good reason or terminated by Recom's termination without cause, and an additional one years coverage if the agreement is terminated due to Mr. Fink's disability.
-

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

Concurrent with entering into the employment agreement, we entered into an indemnification agreement with Mr. Fink.

On October 11, 2002, Recom reached an agreement-in-principle with Dr. Budimir Drakulic to become our Vice President and Chief Technology Officer on a consulting basis through his consulting companies. Pursuant to that understanding, on October 15, 2002, we entered into a loan-out agreement with B World Technologies, Inc. and B Technologies, Inc. relative to the provision of Dr. Drakulic's services. Dr. Drakulic is the president and owner of these companies. The essential terms of the loan-out agreement are as follows:

- The agreement provides for a ten-year initial term. After the initial term, the agreement renews automatically for successive one year terms, unless either party delivers 90-days' written notice to the other of their intent not to renew.
- Dr. Drakulic's services are provided on a mutually-acceptable part-time basis.
- Recom is obligated to pay B Technologies a \$10,000 bonus upon execution, and a monthly service fee of \$15,000 thereafter.
- B World Technologies was granted 600,000 restricted common shares (200,000 shares pre-split), to be earned over five years of continuous provision of services by Dr. Drakulic. These shares, which will be held in escrow with the company pursuant to the terms of a restricted stock agreement until they are earned, vest at the rate of 30,000 shares per quarter with the first 30,000 shares vesting on January 15, 2003. B World Technologies is entitled to all dividends which may be declared with respect to these shares, even if not vested.

The loan-out agreement provides for early termination should B World and B Technologies fail, neglect or refuse to provide Dr. Drakulic's services. In such an event, all compensation under the agreement will terminate and the unvested portion of the 600,000 restricted common share grant shall be deemed forfeit as of the effective termination date.

Since March 1, 2003, Dr. Drakulic has worked for us on a full-time basis even though the loan-out agreement only provides for the provision of part-time services. We have agreed to characterize these additional services as being provided by Dr. Drakulic as an employee, and to pay him \$7,500 annually as compensation for their provision.

On March 10, 2003, as additional incentive for the performance of Dr. Drakulic, we granted to B World Technologies options entitling it to purchase 750,000 common shares at \$0.92 per share. These options vest quarterly over a four year term, and lapse, if not exercised, on March 9, 2008.

Concurrent with entering into the loan-out agreement, B World Technologies, B Technologies and Dr. Drakulic signed an employment, confidential information, invention assignment and arbitration agreement under which they agreed, among other things, to assign to us all of Dr. Drakulic's right, title and interest in and to any and all inventions, discoveries, etc. which he conceives or develops while engaged by Recom.

On October 11, 2003, Recom reached an agreement-in-principle with Mr. Ellsworth Roston to provide consulting advice to us relating to engineering, developing and refining our products and technologies; to become a director of the company, and to make an investment into the company. Pursuant to that understanding, on October 30, 2002 we sold Mr. Roston 71,250 common shares (23,750 shares pre-split) for \$190,000 in cash, and on November 1, 2002 we entered into a two year consulting agreement with Mr. Roston documenting the provision of his consulting services and his appointment to our board of directors. The agreement provides for us to grant to Mr. Roston 225,000 common shares (75,000 shares pre-split) and five-year warrants to purchase an additional 450,000 common shares (150,000 shares pre-split) at \$1.67 per share. We consider the grant of common shares to Mr. Roston to be compensation for the provision of his consulting services, and the grant of the common share purchase warrants to be additional consideration for his cash investment pursuant to our original understanding. Mr. Roston is a patent attorney who also handles our patent work. The agreement specifically provides that the consulting services provided by Mr. Roston will not include any legal work, for which we will compensate him separately.

Dr. Lowell T. Harmison, one of our directors, provides consulting services to Recom under a three-year agreement dated February 14, 2003. Under this agreement, Dr. Harmison provides advice to us in the areas of technological support and strategy, product development, medical and scientific advisory board development, and FDA regulation. The compensatory terms of the agreement are as follows:

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

- Recom is obligated to pay Dr. Harmison \$36,000 per year over the term of the agreement, payable quarter.
- Dr. Harmison was entitled to receive upon execution of the agreement an initial grant of options entitling him to purchase 108,000 common shares (36,000 shares pre-split) at \$0.36 per share, exercisable over five years.
- On the date of Dr Harmison s execution of the agreement, as well as the commencement of the first and second years of service under the agreement, Recom is obligated to grant Dr. Harmison options entitling him to purchase 36,000 common shares at \$0.36 per share, exercisable over five years; except that these options will vest quarterly based upon his provision of services over the first year of the agreement.
- Dr. Harmison is entitled to receive common shares grants in tranches of 20,000 common shares per milestone for assisting Recom in attaining various milestones determined by our board of directors, including the preparation and filing with the FDA of a 510(k) application for our product, approval of that application by the FDA, and market launch of that product.
- A grant of 20,000 common shares in the event of a change in control as that term is defined in the agreement.

In the event the agreement is terminated by Recom for any reason other than negligence, misconduct, breach of its material terms by Dr. Harmison or the failure of Dr. Harmison to render services in a reasonable fashion, all compensation prospectively payable under the agreement will become due and payable in 90 days.

Summary Compensation Table

The following table shows the compensation paid over the past three fiscal years with respect to Recom s named executive officers as that term is defined by the SEC.

Named Executive Officer and Principal Position	Year	Long Term Compensation							
		Annual Compensation			Awards		Payouts		
		Salary	Bonus	Other	Restricted Stock	Options & SARs	Long Term Incentive Plan	All Other Compensation	
Marvin H. Fink (2) Chief Executive Officer	2002	\$ 1	\$ -	\$ -	2,100,000 (7)	-	-	-	
	2001	-	-	-	-	-	-	-	
	2000	-	-	-	-	-	-	-	
Steve Sparks (3) Former Chief Executive Officer	2002	\$ -	\$ -	\$ -	-	-	-	-	
	2001	-	-	-	-	-	-	-	
	2000	-	-	-	-	-	-	-	
Sim Farar (4) Former Chief Executive Officer	2002	\$ -	\$ -	\$ -	-	-	-	-	
	2001	-	-	-	-	-	-	-	
	2000	-	-	-	-	-	-	-	
Dr. Budimir Drakulic Vice President and Chief Technology Officer	2002	\$45,000(4)	\$ -	\$ -	600,000 (7)	-	-	-	
	2001	-	-	-	-	-	-	-	
	2000	-	-	-	-	-	-	-	

- (1) Includes, among other things, perquisites and other personal benefits, securities or property which exceed in the aggregate the lesser of either \$50,000 or 10% of the total annual salary and bonus reported for that fiscal year.

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

- (2) Mr. Fink has served as our Chief Executive Officer since October 12, 2002.
 - (3) (1) Mr. Sparks served as our Chief Executive Officer from September 19, 2002 until October 12, 2002.
 - (4)) Farar served as our Chief Executive Officer through September 12, 2002.
 - (5) (1) These amounts were paid in consulting payments to B Technologies in connection with its provisions of the services of Dr. Drakulic.
 - (6) Mr. Fink was granted an award of 2,100,000 restricted common shares (700,000 shares pre-split) in conjunction with the execution of his employment agreement.
-

- (7) B. World Technologies was granted an award of 600,000 restricted common shares (200,000 shares pre-split) in conjunction in conjunction with the execution of a loan-out agreement by which it provided the services of Dr. Drakulic to Recom.

Stock Options And Stock Appreciation Rights

There were no grants to our named executive officers of options to purchase our capital stock or appreciation rights relating to our capital stock during the 2002 fiscal year. None of our named executive officers exercised any options to purchase our capital stock appreciation rights relating to our capital stock during the 2002 fiscal year

PRINCIPAL SHAREHOLDERS

The following table sets forth selected information, computed as of December 26, 2003, about the amount and nature of our securities beneficially owned by:

- each of our "executive officers" (defined as our President, Secretary, Chief Financial Officer or Treasurer, any vice-president in charge of a principal business function, such as sales, administration or finance, or any other person who performs similar policy making functions for our company);
- each of our directors;
- each person known to us to own beneficially more than 5% of any class of our securities with voting rights; and
- the group comprised of our current directors and executive officers.

This information was given to us by our shareholders and the numbers used are based on the definitions by the Securities and Exchange Commission (the *SEC*) found in Rules 13d-3 and 13d-5 under the Exchange Act. See footnote (2) to this table. Accordingly, the number of shares listed in the table represent beneficial ownership only for purposes of the reports required by the SEC. We believe that each individual or entity named has sole investment and voting power with respect to the securities indicated as beneficially owned by them, subject to community property laws, where applicable, except where otherwise noted.

Name (1)	Class Of Stock (2)			
	Common		Series 'A' Preferred (3)	
	Amount	%	Amount	%
Marvin H. Fink (4) (5) (6)	2,257,000 (7)	6.8%	0	-
Dr. Budimir S. Drakulic (5)	621,578 (8)	1.9%	0	-
Ellsworth Roston (4)	903,250 (9)	2.7%	0	-
Dr. Robert Koblin (4)	150,000 (10)	*	0	-
Dr. Lowell T. Harmison (4)	200,793 (11)	*	0	-
Tracey Hampton / ARC Finance Group, LLC (6)	22,950,000 (12)	69.6%	0	-
Directors and executive officers, as a group	4,132,621 (13)	12.1%	0	-

* Less than one percent.

- (1) The address of the shareholders named in this table are: Messrs. Fink, Drakulic, Roston, Koblin and Harmison-c/o Recom Managed Systems, Inc., 4705 Laurel Canyon Boulevard, Suite 203, Studio City, California 91607; Ms. Hampton and ARC Finance Group LLC - 23679 Calabasas Road, Suite 754, Calabasas, CA 91302; and Mr. Farar-c/o Vanguard West LLC, 914 Westwood Blvd., Suite 809, Los Angeles, CA 90024.

- (2) The determination and calculation of beneficial ownership for purposes of preparing this table is based upon the definition of beneficial ownership in Rules 13d-3 and 13d-5 of the United States Securities Exchange Act of 1934, pursuant to which a person is deemed to beneficially own any securities over which he or she has either investment or voting power. You should note that this method of calculation differs from that used to calculate beneficial ownership for other reports required under the Exchange Act, including section 16 of that act which calculates beneficial ownership based upon pecuniary interests. Pursuant to Rule 13d-3(d) of the Exchange Act, we have also included in each person's share count any shares under any options, warrants, rights or conversion privileges which are or may become exercisable by that person within 60 days of the date of calculation for purposes of this proxy statement. In computing each person's respective percentage ownership, the shares attributable to his or her exercisable securities under the 60-day inclusion rule are treated as being outstanding (i.e., are added to the total outstanding shares of that class for computational purposes), while exercisable securities attributable to the other executive officers, directors or 5% shareholders under the 60-day inclusion rule are disregarded. In computing the percentage ownership our company's officers and directors as a group, all shares attributable to exercisable securities held by the members of that group under the 60-day inclusion rule are treated as being outstanding (i.e., are added to the total outstanding shares of that class for computational purposes). The base number of outstanding shares of our common and series A preferred shares as of the applicable date are 32,993,912 and 1,792,153 shares, respectively.
- (3) Each series A preferred share is convertible into one common share.
- (4) Director.
- (5) Executive officer.
- (6) 5% shareholder.
- (7) Includes 2,100,000 common shares held by the Fink Family Trust, and 157,000 common shares issuable upon exercise of options granted to Mr. Fink in his capacity as a director.
- (8) Includes 600,000 common shares held by B World Technologies, Inc., 4,000 common shares held by B Technologies, Inc., and 93,750 common shares issuable upon exercise of options granted to B World Technologies in connection with services performed by Dr. Drakulic. Both B World Technologies and B Technologies are owned and controlled by Dr. Drakulic.
- (9) Includes 696,250 common shares held by Roston Enterprises, 450,000 common shares issuable upon exercise of warrants granted to Mr. Roston in his capacity as a consultant, and 157,000 common shares issuable upon exercise of options granted to Mr. Roston in his capacity as a director.
- (10) Includes 150,000 common shares issuable upon exercise of options granted to Dr. Koblin in his capacity as a director.
- (11) Includes 144,000 common shares issuable upon exercise of warrants granted to Dr. Harmison in his capacity as a consultant, and 50,000 common shares issuable upon exercise of options granted to Dr. Harmison in his capacity as a director.
- (12) Includes 22,950,000 common shares held by ARC Finance Group, Inc. ARC Finance Group is owned and controlled by Ms. Hampton.
- (13) Includes 1,125,578 common shares issuable upon exercise of common share purchase options and warrants.

TRANSACTIONS AND BUSINESS RELATIONSHIPS WITH

MANAGEMENT AND PRINCIPAL SHAREHOLDERS

Summarized below are certain transactions and business relationships between Recom and persons who are or were an executive officer, director or holder of more than five percent of any class of our securities since January 1, 2001:

- On September 19, 2002, as part of the agreements leading to and facilitating the acquisition of the Signal Technologies from ARC Finance Group, Mr. Sim Farar, our president and principal shareholder at that time, invested \$125,000 into the company as working capital in exchange for a warrant entitling him to purchase 600,000 common shares (200,000 shares pre-split) at approximately \$0.21 per share.
 - On October 12, 2002 we entered into a four-year employment agreement with Mr. Marvin H. Fink pursuant to which, among other things, we employed Mr. Fink as our Chief Executive Officer and Chairman of the Board, and granted to Mr. Fink 2,100,000 restricted common shares (700,000 shares pre-split) as compensation for those services. For a description of the full terms of that agreement see that section of this prospectus captioned Management Employment And Consulting Agreements With Management .
 - On October 15, 2002 we entered into a ten-year loan-out agreement with Dr. Budimir S. Drakulic and his two companies, B. World Technologies and B Technologies pursuant to which, among other things, we engaged the services of Dr. Drakulic as our Vice President and Chief Technology Officer, and granted B World Technologies 600,000 restricted common shares (200,000 shares pre-split) as compensation for those services. For a description of the full terms of that agreement see that section of this prospectus captioned Management Employment And Consulting Agreements With Management .
-

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

- On October 11, 2002, we reached an agreement-in-principle with Dr. Budimir Drakulic to become our Vice President and Chief Technology Officer on a consulting basis through his consulting companies. In conjunction with that understanding, we also reached an agreement-in-principle with Dr. Drakulic to offer to sell our common shares to certain individuals in order to protect our rights in the Signal Technologies. Pursuant to this understanding, on October 22, 2002, we sold 564,810 common shares (188,270 shares pre-split) to eleven of those individuals, and issued a five-year warrant to purchase 375,000 common shares (125,000 shares pre-split) for \$0.007 per share to one of those individuals, in consideration of their cash investment of \$17,786. We further agreed that should we raise more than \$2 million in certain offerings, to pay 4% of the proceeds of those offerings to those individuals up to the amount of \$480,350. We are currently in discussion with those investors relative to the payment of this obligation.
- On November 1, 2002, we entered into a two-year consulting agreement with Mr. Ellsworth Roston, who then became one of our directors pursuant to that agreement. Under the terms of that agreement, we granted to Mr. Roston, among other things, Roston 225,000 restricted common shares (75,000 shares pre-split) and five-year warrants to purchase an additional 450,000 common shares (150,000 shares pre-split) at \$1.67 per share. For a description of the full terms of that agreement see that section of this prospectus captioned Management Employment And Consulting Agreements With Management .
- In compensation for his consulting services, we granted to Mr. Roston 225,000 restricted common shares (75,000 shares pre-split) and five-year warrants to purchase an additional 450,000 common shares (150,000 shares pre-split) at \$1.67 per share
- On February 14, 2003, we entered into a three-year consulting agreement with Dr. Lowell T. Harmison, who later became one of our directors. Under the terms of that agreement, we granted to Dr. Harmison, among other things, (1) fully vested options entitling him to purchase 108,000 common shares (72,000 shares pre-split) at \$0.97 per share, and (2) options entitling him to purchase an additional 36,000 common shares at \$0.97 per share subject to vesting over one year. All of the aforesaid options are exercisable over five years. For a description of the full terms of that agreement see that section of this prospectus captioned Management Employment And Consulting Agreements With Management .

DESCRIPTION OF CAPITAL STOCK

General

Our authorized capital consists of 100,000,000 shares of common stock, par value \$.001 per share (these shares are referred to in this prospectus as *common shares*), and 10,000,000 shares of blank check preferred stock, par value \$.001 per share (these shares are referred to in this prospectus as *preferred shares*), having such rights, preferences, privileges and restrictions as may be designated from time-to-time by our board. On September 25, 2003, our board of directors designated 1,818,710 of the preferred shares as series A convertible preferred stock (these shares are referred to in this prospectus as *series A preferred shares*), with the rights, preferences, privileges and restrictions described below. As of December 29, 2003, there were issued and outstanding 32,993,912 common shares and 1,792,921 series A preferred shares.

Common Shares

Our common shareholders are entitled to one vote per share on all matters to be voted upon by those shareholders, and are also entitled to cumulative voting for the election of directors. Subject to the rights of our series A preferred shares, our common shareholders are entitled to receive ratably dividends as they may be declared by our board of directors out of funds legally available for that purpose. Subject to the rights of our series A preferred shares, upon the liquidation, dissolution, or winding up of Recom, our common shareholders will be entitled to share ratably in all of the assets which are legally available for distribution, after payment of all debts and other liabilities. Our common shareholders have no preemptive, subscription, redemption or conversion rights.

Preferred Shares

We may issue our preferred shares from time to time in one or more series as determined by our board of directors. The voting powers and preferences, the relative rights of each series, and the qualifications, limitations and restrictions thereof may be established by our board of directors without any further vote or action by our shareholders.

Series A Preferred Shares

Our series A preferred shares have the following rights, preferences, privileges and restrictions:

- Rank- Our series 'A' preferred shares rank senior to our common shares, and any other securities we may issue;
 - Dividends- Our series 'A' preferred shareholders are entitled to receive an annual cumulative dividend on each share equal to \$0.24 payable quarterly, on March 31, June 30, September 30 and December 31 of each year, either in cash from funds legally available for that purpose, or in kind, in the form of additional series 'A' preferred shares, at our discretion. Dividends for the period between the October 2, 2003 sale of the shares and December 31, 2003 are pro rated based upon the actual number of days elapsed, assuming a 360- day year. If the dividend is paid in the form of series 'A' preferred shares, each share which is paid will be valued at \$3 per share.
 - Conversion- Each series 'A' preferred share (along with accrued dividends payable in series 'A' preferred shares) is convertible, at the option of the holder, at any time into common shares on a one-for-one basis. The conversion price for the series 'A' preferred shares is subject to certain weighted average anti-dilution adjustments.
 - Forced Conversion- We can force conversion of the series 'A' preferred shares into common shares upon 45 days written notice to the holders of the shares in the event that:
 - ◆ our common shares are listed on a qualified national exchange (Nasdaq, AMEX or NYSE);
 - ◆ the closing bid price for our common shares as reported by the Nasdaq, AMEX or NYSE is at least \$7.50 for 30 consecutive trading days ending within three trading days prior to the date of the written notice of conversion;
 - ◆ the average trading volume during any such 30 consecutive trading day period equals or exceeds 30,000 shares per day; and
 - ◆ the common shares underlying the series 'A' preferred shares are covered by an effective registration statement filed with the SEC.
 - Liquidation Rights- In the event of any liquidation, dissolution or winding up of Recom, either voluntary or involuntary, our series 'A' preferred shareholders are entitled to receive an amount per share equal to the greater of \$3 for each outstanding share plus accrued and unpaid dividends (as adjusted for stock dividends, stock distributions, splits, combinations or recapitalizations), or the amount such shareholders would be entitled to receive had they converted their series 'A' preferred shares into common shares. These rights are prior and in preference to any distribution of any of our assets to our common shareholders or holders of any other series or class of preferred shares.
-

- Voting Rights- Our series 'A' preferred shareholders have the right to vote on an as-converted basis, with our common shareholders on all matters submitted to a vote of our shareholders. In addition, we cannot, without the prior approval of the holders of at least a majority of our then issued and series 'A' preferred shares voting as a separate class:

- ◆ issue or create any series or class of equity securities with rights superior to or on a parity with our series 'A' preferred shares or increase the rights or preferences of any series or class of equity securities having rights or preferences that are junior to our series 'A' preferred shares so as to make the rights or preferences of such series or class equal or senior to our series 'A' preferred shares;
- ◆ pay any cash dividends on shares of our capital stock; or
- ◆ effect any exchange or reclassification of any stock affecting our series 'A' preferred shares or a recapitalization involving Recom and our subsidiaries (if any) taken as a whole;

Further, we cannot, without the approval of each series 'A' preferred shareholder:

- ◆ effect any amendment of our Certificate of Incorporation or Bylaws which would materially and adversely affect his or her rights as a shareholder; or
- ◆ amend, alter, or repeal the preferences, special rights, or other powers of the series 'A' preferred shares so as to adversely effect the shareholder.

EQUITY COMPENSATION PLANS

Summary Equity Compensation Plan Data

The following table sets forth information compiled on an aggregate basis, with respect to equity compensation plans, including individual compensation arrangements as of December 31, 2002 under which we are granted or are authorized to issue equity securities to employees or non-employees in exchange for consideration in the form of goods or services:

Plan Category	Number Of Securities To Be Issued Upon Exercise Of Outstanding Options, Warrants Or Rights		Weighted- Average Exercise Price Of Outstanding Warrants And Rights		Number Of Securities Remaining Available For Future Issuance Under Equity Compensation Plans (Excluding Securities To Be Issued Upon Exercise Of Outstanding Options, Warrants And Rights)
	Options, Warrants Or Rights	Options, Warrants And Rights	Options, Warrants And Rights	Options, Warrants And Rights	
Equity compensation plans approved by shareholders		0		0	0(1)
Equity compensation plans not approved by shareholders	450,000		\$ 1.67		0(1)(2)
Total	450,000		\$ 1.67		0

(1) No formal stock plans under which securities were reserved for issuance had been adopted by Recom as of December 31, 2002.

(2) Warrants Issued to Mr. Ellworth Roston under the terms of his consulting agreement with Recom issued on a stand-alone basis.

Description of Equity Compensation Plans Not Approved By Shareholders

Recom has one formal stock plan considered to be an equity compensation plan or arrangement that has not been approved to date by our shareholders, the Recom Managed Systems, Inc. 2003 Nonqualified Stock Option And Stock Plan (the "2003 Stock Plan"). Recom adopted the 2003 Stock Plan, pursuant to which 1,500,000 common shares (500,000 shares pre-split) were originally reserved for issuance, on March 31, 2002. The 2003 Stock Plan was adopted by our board of directors as a vehicle to encourage and provide for the acquisition of an equity interest in Recom by our employees, officers, directors and consultants. Our board believes the plan will enable us to attract and retain the services of key employees, officers, directors and consultants upon whose judgment, interest and special effort the successful conduct of its operations is largely dependent, and to motivate those individuals by providing additional incentives and motivation toward superior performance.

The 2003 Stock Plan allows our board of directors to grant stock options or issue stock from time to time to our employees, officers, directors and consultants. Options granted under the 2003 Plan do not qualify under Section 422 of the Internal Revenue Code as an incentive stock options.

The 2003 Plan also provides that our board of directors, or a committee, may issue free-trading or restricted stock pursuant to stock right agreements containing such terms and conditions as our board of directors deems appropriate.

As of December 26, 2003, there were 312,727 common shares issued or reserved for issuance under the 2003 Stock Plan, and 1,187,273 common shares available for issuance.

On March 26, 2003, we filed with the SEC a registration statement on form S-8 for the purpose of registering the common shares issuable under our 2003 Stock Plan under the Securities Act of 1933. We have, to date, principally used the 2003 Stock Plan to grant registered common shares to selected consultants as compensation for services, while utilizing the 2002 Stock Plan for unregistered grants of stock and options to directors, officers, employees and other consultants.

The stand-alone grant to Mr. Marvin Fink of 2,100,000 restricted shares under his employment agreement pursuant to which he agreed to become our Chief Executive Officer, President and Chairman of the Board; the stand-alone grant to B Technologies of 600,000 restricted common shares under the terms of the loan-out agreement by which we procured the services of Mr. Budimir S. Drakulic as our Vice President and Chief Technology Officer, and the stand-alone grant to Mr. Ellsworth Roston of 225,000 restricted common shares and warrants entitling him to purchase an additional 450,000 common shares under the terms of his consulting agreement with our company, each constitute an equity compensation plan or arrangement that has not been approved to date by our shareholders. For further information relating to these transactions, see that section of this prospectus captioned *Management-Employment And Consulting Agreements With Management*.

Description of Equity Compensation Plans Approved By Shareholders

Recom has one equity compensation plan or arrangement that has been approved by our shareholders, the Recom Managed Systems, Inc. 2002 Stock Plan (the "2002 Stock Plan"). Recom adopted the 2002 Stock Plan, pursuant to which 6,000,000 common shares (2,000,000 shares pre-split) were originally reserved for issuance, on November 1, 2002. Shareholder approval was received on June 5, 2003.

The 2002 Stock Plan was adopted by our board of directors as a vehicle to encourage and provide for the acquisition of an equity interest in Recom by our employees, officers, directors and consultants. Our board believes the plan will enable us to attract and retain the services of key employees, officers, directors and consultants upon whose judgment, interest and special effort the successful conduct of its operations is largely dependent, and to motivate those individuals by providing additional incentives and motivation toward superior performance.

The 2002 Stock Plan allows our board of directors, or a committee established by our board, to award restricted stock and stock options from time to time to our employees, officers, directors and consultants. The board has the power to determine at the time an option is granted whether the option will be an incentive stock option (an option which qualifies under Section 422 of the Internal Revenue Code of 1986) or an option which is not an incentive stock option. Incentive stock options may only be granted to persons who are our employees. Vesting provisions are determined by our board at the time options are granted. Options may be exercisable by the payment of cash or by other means as authorized by the committee or our board of directors.

The 2003 Stock Plan also provides that our board of directors, or a committee established by our board, may issue restricted stock pursuant to restricted stock right agreements which will contain such terms and conditions as our board or committee determines.

As of December 26, 2003, there were 2,899,000 common shares issued or reserved for issuance under the 2002 Stock Plan, and 3,851,000 common shares available for issuance.

MARKET FOR SECURITIES

Description Of Market

Our common shares are currently quoted on the OTCBB under the symbol "RECM." The following table sets forth the quarterly high and low bid prices for our common shares on the OTCBB for the periods indicated. The prices set forth below represent inter-dealer quotations, without retail markup, markdown or commission and may not be reflective of actual transactions. The prices have been adjusted to reflect a 3 for 1 stock split that was effective on April 11, 2003.

Period	Volume	Bid Price	
		High	Low
2003:			
Fourth Quarter Through December 26, 2003	3,538,885	\$ 5.15	\$ 2.70
Third Quarter	3,683,800	5.55	3.24
Second Quarter	2,494,700	4.20	1.98
First Quarter	1,464,600	2.30	0.88
2002:			
Fourth Quarter	1,264,800	\$ 3.97	\$ 0.08
Third Quarter	0	0.08	0.07
Second Quarter	0	0.07	0.05
First Quarter	1,500	0.33	0.33
2001:			
Fourth Quarter	900	\$ 0.51	\$ 5.00
Third Quarter	0	1.50	5.00
Second Quarter	4,200	1.45	5.00
First Quarter	900	0.45	6.50

On December 26, 2003, the last reported closing price for our common shares as reported on the OTCBB was \$3.15 per share.

A shareholders' list provided by our transfer agent showed 316 registered shareholders and 32,993,912 common shares outstanding as of December 26, 2003. This number excludes any estimate by us of the number of beneficial owners of shares held in street name, the accuracy of which cannot be guaranteed.

Dividend Policy

We have never paid any cash dividends on our common shares, and we do not anticipate that we will pay any dividends with respect to those securities in the foreseeable future. Our current business plan is to retain any future earnings to finance the expansion development of our business. Any future determination to pay cash dividends will be at the discretion of our board of directors, and will be dependent upon our financial condition, results of operations, capital requirements and other factors as our board may deem relevant at that time.

SELLING SHAREHOLDERS

The following table identifies the selling shareholders and sets forth the total number of common shares they may sell under this prospectus, assuming they were to convert all of their series A preferred shares into common shares and exercise all of their class C warrants. Percentage ownership under this table is calculated as if there were 35,952,231 common shares outstanding, comprised of the 32,993,912 common shares currently outstanding and the 2,958,319 common shares which would be issued upon the conversion of the outstanding series A preferred shares and exercise of the outstanding class C warrants. Each series A preferred share is currently convertible into one common share, and each class C warrant currently entitles the holder to purchase one common share.

The maximum number of common shares offered for sale under this prospectus may vary from time to time based upon several factors, including (1) the total number of series A preferred shares the holders intend to convert, the amount of class C common share purchase warrants the holders intend to exercised, and the amount of placement agent's unit purchase warrants which it may exercise, (2) adjustments due to stock dividends, stock distributions, splits, combinations or recapitalizations, and (3) the triggering of certain anti-dilution provisions were we to sell securities at a price below the price at which we sold those shares. For a description of this mechanism, see *Description of Capital Stock-Series A Preferred Shares*.

Unless otherwise described below, to our knowledge no selling shareholder nor any of their affiliates has held any position or office with, been employed by or otherwise has had any material relationship with us or our affiliates during the three years prior to the date of this prospectus. Unless otherwise described below, the selling shareholders have confirmed to us that they are not broker-dealers or affiliates of a broker-dealer within the meaning of Rule 405 of the Securities Act of 1933.

The selling shareholders are under no obligation to sell all or any portion of the common shares offered for sale under this prospectus. Accordingly, no estimate can be given as to the amount or percentage of our common shares that will be held by the selling shareholders upon termination of sales pursuant to this prospectus. We will not receive any proceeds from the resale of the common shares by the selling shareholders.

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

Selling Shareholder	Common Shares Owned Before Sales		Common Shares Offered For Sale	Common Shares Owned After Sales(1)	
	Number	%		Number	%
Morgan Witt Alliance (2)	475,007	1.3%	475,007	0	0%
Axius Holdings, LLC (3)	25,000	*	25,000	0	0%
Richard Kent (3)	50,000	*	50,000	0	0%
Leonard Greenbaum (3)	25,000	*	25,000	0	0%
Sands Brothers Venture Capital III, LLC (5)	125,000	*	125,000	0	0%
Jeffrey Grodsko (6)	6,250	*	6,250	0	0%
Allen Grodsko (6)	6,250	*	6,250	0	0%
Prem C. Chatpar (3)	25,000	*	25,000	0	0%
Judith T. Huff Revocable Living Trust (6)	6,250	*	6,250	0	0%
John Viney (7)	150,000	*	150,000	0	0%
SB Mechanical Associates LLC (3)	25,000	*	25,000	0	0%
Sands Brothers Venture Capital IV LLC (4)	50,000	*	50,000	0	0%
Sands Brothers Venture Capital II LLC (3)	25,000	*	25,000	0	0%
Sands Brothers Venture Capital LLC (3)	25,000	*	25,000	0	0%
Jerold Weinger (4)	50,000	*	50,000	0	0%
Donald Asher (4)	50,000	*	50,000	0	0%
Robert Rosenberg (3)	25,000	*	25,000	0	0%
Ian McClure (8)	12,500	*	12,500	0	0%
Steven Berkowitz and Pamela Berkowitz (8)	12,500	*	12,500	0	0%
Charles Haddad (8)	12,500	*	12,500	0	0%
Derward G. Fountain (8)	12,500	*	12,500	0	0%
Wayne Saker (4)	50,000	*	50,000	0	0%
Alexei Doubovik and Tatyana Filek (3)	25,000	*	25,000	0	0%
Robert Kaufman (3)	25,000	*	25,000	0	0%
Shimon Wolkowicki (3)	25,000	*	25,000	0	0%
Earl James Ryan (3)	12,500	*	12,500	0	0%
Michael Harley (3)	25,000	*	25,000	0	0%
Vincent Vallarino (9)	17,000	*	17,000	0	0%
Landing Wholesale Group (10)	10,000	*	10,000	0	0%
W. R. Savey (4)	50,000	*	50,000	0	0%
Michael Chatwin (3)	25,000	*	25,000	0	0%
RL Capital Partners (4)	50,000	*	50,000	0	0%
Richard Wallace IRA (8)	12,500	*	12,500	0	0%
Geoffrey Coy (8)	12,500	*	12,500	0	0%
Arthur O'Silver, Trustee of the Arthur O'Silver Trust (3)	25,000	*	25,000	0	0%
Allen B. Guirguis (4)	50,000	*	50,000	0	0%
Najeeb Ghauri (8)	12,500	*	12,500	0	0%
Lee Pearlmutter (8)	12,500	*	12,500	0	0%
Larry Warner and Rebecca Warner (6)	6,250	*	6,250	0	0%
Michael Harley (3)	25,000	*	25,000	0	0%
Marcos Anszelowicz (3)	25,000	*	25,000	0	0%
James Halikas (3)	25,000	*	25,000	0	0%
Michael Stone (4)	50,000	*	50,000	0	0%
Hermann Binder (8)	12,500	*	12,500	0	0%
Roy G. Shaw, Sr. (3)	25,000	*	25,000	0	0%

SELLING SHAREHOLDERS

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

Richard C. Largarticha (3)	25,000	*	25,000	0	0%
John O'Neal Johnston Trust (6)	6,250	*	6,250	0	0%
Alfonse D'Amato (4)	50,000	*	50,000	0	0%
Susan Laden (8)	12,500	*	12,500	0	0%
Charles Haddad (8)	12,500	*	12,500	0	0%
Arthur and Deborah Fixel (8)	12,500	*	12,500	0	0%
Stephen Brazier (8)	12,500	*	12,500	0	0%
Joseph Marotta and Nancy Marotta (8)	12,500	*	12,500	0	0%
Arthur Garfinkle (3)	25,000	*	25,000	0	0%
Richard Wallace (6)	6,250	*	6,250	0	0%
David Kamins (6)	6,250	*	6,250	0	0%
Jonathan Young (3)	25,000	*	25,000	0	0%
Leslie Rosenberg and Sybil Rosenberg (8)	12,500	*	12,500	0	0%
Michael Ferrari (8)	6,250	*	6,250	0	0%
Joseph Richman (6)	6,250	*	6,250	0	0%
Catherine M. Richman (11)	3,750	*	3,750	0	0%
Ron Lazar IRA (3)	25,000	*	25,000	0	0%
Kevin Clarke (6)	6,250	*	6,250	0	0%
Richard Himpele (6)	6,250	*	6,250	0	0%
Christopher Kennan (3)	25,000	*	25,000	0	0%
Jonathan Rothschild (8)	12,500	*	12,500	0	0%
John Gross (8)	12,500	*	12,500	0	0%
Margrit Polack S Account (8)	12,500	*	12,500	0	0%
Fred Polak (8)	12,500	*	12,500	0	0%
Anthony Polak IRA (8)	12,500	*	12,500	0	0%
Anthony Polak S Account (8)	12,500	*	12,500	0	0%
Equity Interest Inc. (8)	12,500	*	12,500	0	0%
Damico Venture Capital (8)	12,500	*	12,500	0	0%
Jack Polak IRA (8)	12,500	*	12,500	0	0%
Mark Englebert (8)	12,500	*	12,500	0	0%
Jeffrey Robinson (8)	12,500	*	12,500	0	0%
Catherine Polak Trust (8)	12,500	*	12,500	0	0%
Peter Van Emon (12)	5,000	*	5,000	0	0%
William Peterson Living Trust (8)	12,500	*	12,500	0	0%
Randall Hight (8)	12,500	*	12,500	0	0%
Gary Stadmauer (8)	12,500	*	12,500	0	0%
Murray Stadmauer and Clare Stadmauer (8)	12,500	*	12,500	0	0%
Bart Halpern (3)	25,000	*	25,000	0	0%
Genevieve R. Goodge (13)	3,125	*	3,125	0	0%
Teddy Chasanoff (8)	12,500	*	12,500	0	0%
Bernd Allen (8)	12,500	*	12,500	0	0%
Kenneth Burdick and Denise Burdick (8)	12,500	*	12,500	0	0%
Peter J. Jegou (12)	5,000	*	5,000	0	0%
Michele Tarica (8)	12,500	*	12,500	0	0%
Bella Sander (8)	12,500	*	12,500	0	0%
Richard Wallace (8)	12,500	*	12,500	0	0%
Jamie Banks (6)	6,250	*	6,250	0	0%
Leonard Fryer and Michael Ann Fryer (14)	18,000	*	18,000	0	0%
Leo Long (15)	62,500	*	62,500	0	0%
Otape Investments LLC (5)	125,000	*	125,000	0	0%
Ronald Bergman (8)	12,500	*	12,500	0	0%

SELLING SHAREHOLDERS

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

Richard Kent (16)	15,000	*	15,000	0	0%
Dean Erickson Irrevocable Trust (3)	25,000	*	25,000	0	0%
Maxim Group, LLC (17)	268,938	*	268,938	0	0%

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

* Less than one percent

- (1) Assumes the sale of all common shares offered under this prospectus
- (2) Includes 316,671 common shares to be issued upon the conversion of series A preferred shares and 158,336 common shares to be issued upon the exercise of class C warrants.
- (3) Includes 16,667 common shares to be issued upon the conversion of series A preferred shares and 8,333 common shares to be issued upon the exercise of class C warrants.
- (4) (3) Includes 33,333 common shares to be issued upon the conversion of series A preferred shares and 16,667 common shares to be issued upon the exercise of class C warrants.
- (5) Includes 83,333 common shares to be issued upon the conversion of series A preferred shares and 41,667 common shares to be issued upon the exercise of class C warrants.
- (6) Includes 4,167 common shares to be issued upon the conversion of series A preferred shares and 2,083 common shares to be issued upon the exercise of class C warrants.
- (7) Includes 100,000 common shares to be issued upon the conversion of series A preferred shares and 50,000 common shares to be issued upon the exercise of class C warrants.
- (8) Includes 8,333 common shares to be issued upon the conversion of series A preferred shares and 4,167 common shares to be issued upon the exercise of class C warrants.
- (9) Includes 11,333 common shares to be issued upon the conversion of series A preferred shares and 5,667 common shares to be issued upon the exercise of class C warrants.
- (10) Includes 6,667 common shares to be issued upon the conversion of series A preferred shares and 3,333 common shares to be issued upon the exercise of class C warrants.
- (11) Includes 2,500 common shares to be issued upon the conversion of series A preferred shares and 1,250 common shares to be issued upon the exercise of class C warrants.
- (12) Includes 3,333 common shares to be issued upon the conversion of series A preferred shares and 1,667 common shares to be issued upon the exercise of class C warrants.
- (13) Includes 2,083 common shares to be issued upon the conversion of series A preferred shares and 1,042 common shares to be issued upon the exercise of class C warrants.
- (14) Includes 12,000 common shares to be issued upon the conversion of series A preferred shares and 6,000 common shares to be issued upon the exercise of class C warrants.
- (15) Includes 41,667 common shares to be issued upon the conversion of series A preferred shares and 20,833 common shares to be issued upon the exercise of class C warrants.
- (16) Includes 10,000 common shares to be issued upon the conversion of series A preferred shares and 5,000 common shares to be issued upon the exercise of class C warrants.
- (17) Includes 179,292 common shares to be issued upon the conversion of series A preferred shares and 89,646 common shares to be issued upon the exercise of class C warrants.

REGISTRATION RIGHTS

On October 1, 2003 through November 1, 2003, we sold to 100 investors in a private placement effected through Maxim Group, LLC, as placement agent:

- 1,792,921 series 'A' convertible preferred shares, with each share convertible into one common share; and
- 896,460 class 'C' warrants, each warrant entitling the holder to purchase one common share for \$3.75.

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

As part of that transaction, we entered into registration rights agreements with those investors under which we agreed to file the registration statement of which this prospectus is a part in order to register the common shares issuable upon the conversion of those series 'A' convertible preferred shares or the exercise of those class 'C' warrants. As compensation to Maxim Group for acting as placement agent, we concurrently issued to it placement agent's unit purchase warrants entitling it to purchase a total of 179,292 series 'A' convertible preferred shares and 89,646 class 'C' warrants, and also granted to it comparable registration rights. The registration right agreements require us to use our best efforts to file the registration statement as soon as reasonably practicable after the first closing for the offering (October 1, 2003), but in no event less than 90 days following the first closing. If we fail to do so, the exercise price for the class 'C' warrants will be reduced to \$3 from \$3.75. Our filing of the registration statement containing this prospectus is intended to satisfy that requirement.

PLAN OF DISTRIBUTION

The common shares offered by this prospectus may be sold by the selling shareholders in one or more transactions at market prices prevailing at the time of the sale, at negotiated prices, at fixed prices which may be changed, or at prices related to prevailing market prices, or at varying prices determined at the time of sale. These sales may be effected by the selling shareholders at various times in (1) transactions effected on any national securities exchange or United States inter-dealer system of a registered national securities association on which the common shares may be listed or quoted at the time of sale; (2) transactions effected on the over-the-counter market; or (3) in private transactions and transactions effected otherwise than on these exchanges or systems or in the over-the-counter market. We will receive no proceeds from any resales of the shares offered under this prospectus.

The selling shareholders and their successors, including their transferees, pledgees or donees or their successors, may sell the common shares directly to a purchaser or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions from the selling shareholder or the purchaser. These discounts, concessions or commissions as to any particular underwriter, broker-dealer or agent may be in excess of those customary in the types of transactions involved. These brokers or dealers and any other participating brokers or dealers may be deemed to be underwriters within the meaning of the Securities Act of 1933 in connection with these sales.

Brokers or dealers engaged by the selling shareholders may arrange for sales through (1) block trades in which the broker or dealer attempts to sell shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; (2) arrangements where the broker or dealer purchases the shares as principal and resells the shares for its account using this prospectus; (3) ordinary brokerage transactions in which the broker does not solicit purchasers and transactions in which the broker does solicit purchasers; or (4) transactions directly with market makers.

Our selling shareholders may also enter into hedging transactions, and persons with whom they effect such transactions, including broker-dealers, may engage in short sales of our common shares. Our selling shareholders may also engage in short sales and short sales against the box, and in options, swaps, derivatives and other transactions in our securities, and may sell and deliver the shares covered by this prospectus in connection with such transactions or in settlement of securities loans. These transactions may be entered into with broker-dealers or other financial institutions that may resell those shares.

A selling shareholder may also pledge the shares offered under this prospectus pursuant to the margin provisions of customer agreements or otherwise. Upon delivery of the shares or a default by a selling shareholder, the broker-dealer or financial institution may offer and sell the pledged shares from time to time.

To comply with the securities laws of some states, if applicable, the shares will be sold in those states only through brokers or dealers. In addition, in some states, the shares may not be sold in those states unless they have been registered or qualified for sale in those states or an exemption from registration or qualification is available and is complied with.

If necessary, the specific common shares to be sold, the names of the selling shareholders, the respective purchase prices and public offering prices, the names of any agent, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement of which this prospectus is a part.

Our selling shareholders may be deemed to be underwriters within the meaning of section 2(11) of the Securities Act in connection with the sales and distributions contemplated under this prospectus, and may have civil liability under Section 11 and 12 of the Securities Act for any omissions or misstatements in this prospectus and the registration statement of which it is a part. Additionally, any profits which our selling shareholders may receive might be deemed to be underwriting compensation under the Securities Act.

The rules and regulations in Regulation M under the Securities Exchange Act of 1934 provide that during the period that any person is engaged in the distribution (as that term is defined in Regulation M) of our common shares, that person generally may not purchase common shares. The selling shareholders are subject to applicable provisions of the Securities Act of 1933 and Securities Exchange Act of 1934 and the rules and regulations thereunder, including, without limitation, Regulation M, which provisions may limit the timing of purchases and sales of our common shares by the selling shareholders. The foregoing may affect the marketability of our common shares.

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

We have entered into registration rights agreements for the benefit of the selling shareholders to register the common shares under applicable federal and state securities laws. The registration rights agreements generally provide for cross-indemnification of those selling shareholders and us and each party's respective directors, officers and controlling persons against liability in connection with the offer and sale of our stock, including liabilities under the Securities Act of 1933, and to contribute to payments the parties may be required to make in respect thereof. We have agreed to indemnify those selling shareholders and hold them harmless from certain liabilities under the Securities Act of 1933. We will bear all expenses relating to the sale of our common shares under this prospectus, except that the selling shareholders will pay any applicable underwriting commissions and expenses, brokerage fees and transfer taxes, as well as the fees and disbursements of counsel to and experts for the selling shareholders.

Any common shares offered under this prospectus which qualify for sale pursuant to Rule 144 of the Securities Act may also be sold under Rule 144 rather than pursuant to this prospectus.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

On December 1, 2003, we dismissed our independent auditor, Burnett + Company, LLC, and on December 2, 2003, we engaged Stonefield Josephson, Inc. as our independent auditor for the fiscal year ending December 31, 2003. The decision to dismiss Burnett + Company was approved by our board of directors.

Burnett + Company's reports on our financial statements as of and for the years ended December 31, 2002 and December 31, 2001 did not contain an adverse opinion or a disclaimer of opinion, nor were they modified as to uncertainty, audit scope, or accounting principles. During the periods ended December 31, 2001 and December 31, 2002, and the interim period from January 1, 2003 through the date of Burnett + Company's dismissal, we did not have any disagreements with Burnett + Company on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to Burnett + Company's satisfaction, would have caused it to make a reference to the subject matter of the disagreements in connection with its reports.

Prior to engaging Stonefield Josephson, we did not consult with Stonefield Josephson regarding the application of accounting principles to a specified completed or contemplated transaction or the type of audit opinion that might be rendered on our financial statements.

TRANSFER AGENT

The transfer agent for our common shares is Atlas Stock Transfer Corporation, 5899 South State Street, Salt Lake City, Utah 84107. We act as our own transfer agent with regard to our series A preferred shares and our outstanding common share purchase options and warrants.

LEGAL MATTERS

The validity of the issuance of the common shares to be sold by the selling shareholders under this prospectus and the underlying series A preferred shares and class C common share purchase warrants was passed upon for our company by Richardson & Patel LLP.

EXPERTS

The financial statements included in this prospectus have been audited by Stonefield Josephson, Inc., independent certified public accountants to the extent and for the periods set forth in their report appearing elsewhere herein and are included in reliance upon such report given upon the authority of that firm as experts in auditing and accounting.

INDEMNIFICATION OF DIRECTORS AND OFFICERS

Our Certificate of Incorporation, as amended, provide shall that we shall, to the maximum extent and in the manner under Delaware corporate law, indemnify each of our directors and officers against expenses (including attorneys' fees), judgments, fines, settlements, and other amounts actually and reasonably incurred in connection with any proceeding, arising by reason of the fact that such person is or was an agent of the corporation. The effect of this provision of our Certificate of Incorporation is to eliminate our right and our shareholders (through shareholders' derivative suits on behalf of our company) to recover damages against a director or officer for breach of the fiduciary duty of care as a director or officer (including breaches resulting from negligent or grossly negligent behavior), except under certain situations defined by statute. We believe that the indemnification provisions contained in our Certificate of Incorporation are necessary to attract and retain qualified persons as directors and officers.

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. No pending material litigation or proceeding involving our directors, executive officers, employees or other agents as to which indemnification is being sought exists, and we are not aware of any pending or threatened material litigation that may result in claims for indemnification by any of our directors or executive officers.

WHERE YOU CAN FIND MORE INFORMATION

This prospectus is part of a registration statement on form SB-2 we have filed with the SEC. This prospectus does not contain all of the information set forth in that registration statement and the exhibits and schedules filed therewith because that information has been omitted from this prospectus in accordance with the SEC's rules and regulations. You should refer to that registration statement and those exhibits and schedules for further information regarding our company and the common shares to be offered and sold under this prospectus. Please also note that any statements or descriptions contained in this prospectus relating to the contents of any contract or other document are not necessarily complete, and those statements or descriptions are qualified in all respects to the underlying contract or document in each instance where it is filed as an exhibit to the registration statement.

You should rely only on the information or representations provided in this prospectus. We have authorized no one to provide you with different information. Neither the delivery of this prospectus nor any sale or distribution made under this prospectus shall, under any circumstances, create any implication that information contained in this prospectus is correct as of any time subsequent to the date of this prospectus.

We are also a reporting company under the Exchange Act and, as such, are obligated to file annual reports on form 10-KSB, quarterly reports on form 10-QSB, proxy statements and other reports, statements and information with the SEC in accordance with the Exchange Act. While we mail our annual proxy materials and annual reports on form 10-KSB to our shareholders prior to our annual meeting of shareholders, we do not mail any other periodic reports and other information to our shareholders other than in response to specific requests for these materials.

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

You may review and print-out the registration statement containing this prospectus as well as any other reports and statements we may file with the SEC through its website at <http://www.sec.gov>. You may also inspect and copy any document we file with the SEC at its public reference rooms in Washington, D.C., New York, New York and Chicago, Illinois. For obtain information about these references rooms you should call the SEC at 1-800-SEC-0330.

You may also request a copy of any document we file with the SEC, at no cost, by either writing us at our principal executive offices located at 4705 Laurel Canyon Boulevard, Suite 203, Studio City, California 91607; telephoning us at (818) 432-4560; or e-mailing your request to info@recom-systems.com. Selected documents we file with the SEC are also available for print-out in pdf format on our corporate website at www.recom-systems.com.

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
BALANCE SHEET
September 30, 2003
(Unaudited)
(As Restated)

September 30, 2003

ASSETS	
CURRENT ASSETS - cash	\$ 2,979
Equipment, net of accumulated depreciation	165,084
Intangible assets - patents	167,729
	170,713
TOTAL ASSETS	\$ 335,792
LIABILITIES & STOCKHOLDERS' EQUITY	
CURRENT LIABILITIES - accrued expenses	\$ 179,360
STOCKHOLDERS' EQUITY	
Common stock, \$.001 par value; 100,000,000 shares authorized; 32,153,740 shares issued and outstanding	32,153
Additional paid-in capital	4,297,484
Deferred compensation	(445,492)
Deficit accumulated during development stage	(3,727,713)
	(3,727,713)
TOTAL STOCKHOLDERS' EQUITY	156,432
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 335,792

The accompanying notes are an integral part of these financial statements.

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
STATEMENTS OF OPERATIONS
For The Nine Months Ended September 30, 2003 And 2002 And From Inception
Of Development Stage (November 7, 2000) To September 30, 2003
(Unaudited)

	For the Nine Months Ended September 30, (As Restated)		From Inception of Development Stage (November 7, 2000) to September 30, 2003
	2003	2002	(As Restated)
Revenue	\$ -	\$ -	\$ -
Research and development	166,910	-	234,410
General and administrative expenses	3,262,175	49,341	3,493,303
Loss before income tax provision	(3,429,086)	(49,341)	(3,727,713)
Provision for income taxes	-	-	-
Net loss	\$ (3,429,086)	\$ (49,341)	\$ (3,727,713)
Basic and diluted loss per share	\$ (0.11)	\$ (0.01)	\$ (0.27)
Weighted average shares outstanding - basic and diluted	31,525,497	5,232,641	13,816,910

The accompanying notes are an integral part of these financial statements.

RECOM MANAGED SYSTEMS, INC.

(A Development Stage Company)

STATEMENT OF STOCKHOLDERS' EQUITY

For The Nine Months Ended September 30, 2003 And From Inception
Of Development Stage (November 7, 2000) To September 30, 2003
(As Restated)

	Common Stock		Additional Paid-in Capital	Deferred Compensation	Deficit Accumulated During Development Stage	Total
	Shares	Amount				
Balance November 7, 2000 (as restated for 3:1 stock split)	4,139,784	\$4,139	\$(4,139)	\$-	-	\$-
Contributed capital	-	-	35,000	-	-	35,000
Net loss	-	-	-	-	(36,673)	(36,673)
Balance December 31, 2000	4,139,784	4,139	30,861	-	(36,673)	(1,673)
Contributed capital	-	-	45,000	-	-	45,000
Shares issued for services July 2001 - \$0.033	150,000	150	4,850	-	-	5,000
Net loss	-	-	-	-	(50,000)	(50,000)
Balance December 31, 2001	4,289,784	4,289	80,711	-	(86,673)	(1,673)
Capital contributed	-	-	56,400	-	-	56,400
Warrants issued for Cash	-	-	125,000	-	-	125,000
Issuance of common stock:						
Technology Sept. 2002 - \$0.006	23,400,000	23,400	4,623	-	-	78,023
Services rendered - Oct. 2002 - \$0.021	2,925,000	2,925	17,958	(19,678)	-	1,205
Cash Oct 2002 - \$0.03	564,810	565	17,221	-	-	17,786
Cash Nov 2002 - \$2.66	71,250	71	189,929	-	-	190,000
Contributed services - officer	-	-	20,000	-	-	20,000
Warrants issued for services	-	-	5,324	-	-	5,324

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

Net loss	-	-	-	-	-	(211,954)	(211,954)
Balance December 31, 2002	31,250,844	\$31,250	\$567,166	\$(19,678)	\$(298,627)		\$280,111

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
STATEMENT OF STOCKHOLDERS' EQUITY
For The Nine Months Ended September 30, 2003 And From Inception
Of Development Stage (November 7, 2000) To September 30, 2003
(As Restated)
(Continued)

	Common Stock		Additional Paid-in Capital	Deferred Compensation	Deficit Accumulated During Development Stage	Total
	Shares	Amount				
Issuance of common stock for cash and contributed property -						
April 2003- \$2.22	112,812	113	249,887			250,000
Issuance of common stock for cash:						
May 2003 - \$3	82,667	83	247,917	-	-	248,000
May 2003 - \$3.33	75,075	75	249,925	-	-	250,000
Issuance of common stock for services:						
April 2003 - \$2.80	147,192	147	411,653	-	-	411,800
April 2003 - \$3.14	11,045	11	34,780	-	-	34,791
Issuance of common stock for services:						
April 2003 - \$3.705	111,625	112	413,459	-	-	413,571
August 2003 - \$3.705	33,188	33	122,929	-	-	122,962
September 2003 - \$3.705	24,292	24	89,982	-	-	90,006
Cashless exercise of warrants	305,000	305	(305)	-	-	-
Contributed services - officer	-	-	56,203	-	-	56,203
Employee stock options issued at below market	-	-	38,400	-	-	38,400
Amortization of deferred compensation	-	-	-	6,356	-	6,356
Warrants issued for:						
Services	-	-	1,741,399	(432,170)	-	1,309,229
Financing cost	-	-	74,088	-	-	74,088
Net loss	-	-	-	-	(3,429,086)	(3,429,086)

Balance September 30, 2003 (unaudited)	32,153,740	\$32,153	\$4,297,484	\$(445,492)	\$(3,727,713)	\$156,432
---	------------	----------	-------------	-------------	---------------	-----------

The accompanying notes are an integral part of these financial statements.

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
STATEMENTS OF CASH FLOWS
For The Nine Months Ended September 30, 2003 And From Inception
Of Development Stage (November 7, 2000) To September 30, 2003
(Unaudited)
(As Restated)

	For Nine Months Ended September 30,		From Inception of Development Stage (November 7, 2000) to September 30, 2003
	2003	2002	
Cash flow from operating activities			
Net loss	\$ (3,429,086)	\$ (49,341)	\$ (3,727,713)
Adjustments to reconcile net loss to net cash used in operating activities			
Depreciation	21,522	-	22,215
Amortization of deferred compensation	6,356	-	6,356
Services as contributed capital	56,203	-	76,203
Common stock issued for services	1,141,071	5,000	1,147,276
Warrants issued for services	1,286,985	-	1,292,309
Change in assets & liabilities:			
Prepaid expenses	37,815	-	-
Accrued expenses	139,596	1,500	153,360
	<u>(739,538)</u>	<u>(42,841)</u>	<u>(1,029,994)</u>
Cash used in operating activities			
Cash flows from investing activities -			
Purchase of equipment	(41,466)	-	(70,507)
Capitalized technology cost	(62,706)	-	(62,706)
Cash used in investing activities	(104,172)	-	(133,213)
Cash flow from financing activities:			
Capital contributions	-	35,000	135,400
Sale of common stock for cash	598,000	125,000	905,786
Sale of warrants for cash	-	-	125,000
	<u>598,000</u>	<u>160,000</u>	<u>1,166,186</u>
Net cash provided by financing activities			
Net increase (decrease) in cash	(145,710)	117,159	2,979
Cash at beginning of period	148,689	8,262	-

Cash at end of period	\$	2,979	\$	125,421	\$	2,979
-----------------------	----	-------	----	---------	----	-------

The accompanying notes are an integral part of these financial statements.

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
STATEMENTS OF CASH FLOWS
For The Nine Months Ended September 30, 2003 And 2002 From Inception
Of Development Stage (November 7, 2000) To September 30, 2003
(Unaudited)
(As Restated)

(Continued)

Supplemental Cash Flow Information:

For the nine months ended September 30, 2003, and from inception of development stage (November 7, 2000), the Company paid no interest or income taxes.

Supplemental Investing and Financing Activities:

For the nine months ended September 30, 2003, the Company issued warrants to consultants to purchase the Company's common stock under consulting agreements. The value of the warrants based upon the fair value of the stock at the measurement dates using the Black-Scholes option model is \$ 1,815,407. The Company recorded compensation expense of \$1,383,317 for those agreements.

The Company recorded \$56,203 of compensation expense for the CEO of the Company. This compensation was recorded as additional paid in capital for the nine months ended September 30, 2003.

The accompanying notes are an integral part of these financial statements.

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
STATEMENTS OF CASH FLOWS
For The Nine Months Ended September 30, 2003 And 2002 From Inception
Of Development Stage (November 7, 2000) To September 30, 2003

1. BASIS OF PRESENTATION

The unaudited financial statements have been prepared by Recom Managed Systems, Inc. (the "Company"), pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments), which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited financial statements and footnotes for the year ended December 31, 2002 included elsewhere in the prospectus containing these unaudited financial statements. The results of the nine months ended September 30, 2003 are not necessarily indicative of the results to be expected for the full year ending December 31, 2003.

As reflected in the accompanying financial statements, the Company has losses from inception, negative cash flows from operations, limited working capital and no established source of revenue. These matters raise substantial doubt about the Company's ability to continue as a going concern.

In view of the matters described in the preceding paragraph, recoverability of a major portion of the recorded asset amounts shown in the accompanying consolidated balance sheet is dependent upon continued operations of the Company, which, in turn, is dependent upon the Company's ability to continue to raise capital and generate positive cash flows from operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classifications of liabilities that might be necessary should the Company be unable to continue its existence.

Management plans to, or has taken, the following steps that it believes will be sufficient to provide the Company with the ability to continue in existence. See Note 5 for further details.

- The Company has raised approximately \$4,806,000 through the sale of series 'A' convertible stock that will be used to fund any capital shortfalls. See Note 5 for further details.
 - Management will continue its business plan to develop its line of products, which will be ready for market approximately in late 2005. However, no assurance can be given that commercial products or services will ever result or that regulatory agencies, physicians, patients or insurance providers will accept those products or services.
-

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
STATEMENTS OF CASH FLOWS
For The Nine Months Ended September 30, 2003 And 2002 From Inception
Of Development Stage (November 7, 2000) To September 30, 2003

2. STOCK OPTIONS

Pro forma information regarding the effects on operations as required by SFAS No. 123 and SFAS No. 148, has been determined as if the Company had accounted for its employee stock options under the fair value method of those statements. Pro forma information using the Black-Scholes method at the date of grant based on the following assumptions: (i) risk free interest rate of 3.13%; (ii) dividend yield of 0%; (iii) volatility factor of the expected market price of the Company's common stock of 158.48%; and (iv) an expected life of the options of 1.5 years.

This option valuation model requires input of highly subjective assumptions. Because the Company's employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value of estimate, in management's opinion, the existing model does not necessarily provide a reliable single measure of fair value of its employee stock options.

The Company's pro forma information is as follows:

	Nine Month Period Ended September 30, 2003	Nine Month Period Ended September 30, 2002
Net loss, attributable to common shareholders as reported	\$ (3,429,086)	\$ (49,341)
Current period expense	242,550	-
Stock compensation calculated under APB 25	(459,241)	-
Pro forma net loss	\$ (3,645,777)	\$ (49,341)
Basic and diluted historical loss per share available to common shareholders	\$ (0.12)	\$ (0.01)
Pro forma basic and diluted loss per share available to common shareholders	\$ (0.12)	\$ (0.01)

3. EQUITY TRANSACTIONS

Dr. Lowell T. Harmison, one of the Company's Directors, provides consulting services to the Company under a three year agreement dated February 14, 2003. Under this agreement, Dr. Harmison provides advice to the Company in the areas of technological support and strategy, product development, medical and scientific advisory board development, and FDA regulation. The compensatory terms of the agreement are as follows:

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
STATEMENTS OF CASH FLOWS
For The Nine Months Ended September 30, 2003 And 2002 From Inception
Of Development Stage (November 7, 2000) To September 30, 2003

- The Company is obligated to pay Dr. Harmison \$36,000 per year over the term of the agreement, payable quarter. Dr. Harmison was entitled to receive upon execution of the agreement an initial grant of options entitling him to purchase 108,000 common shares (36,000 shares pre split) at \$0.97 per share, exercisable over five years. The fair value of warrants was \$153,352 estimated using the Black-Scholes option-pricing model computed as of the measurement date, which is the date that the service were performed, with thee following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 158.48%, (iii) weighed-average risk-free interest rate of approximately 3.13, and (iv) expected life of 1.5 years.
- On the date of Dr Harmison's execution of the agreement, as well as the commencement of the first and second years of service under the agreement, the Company is obligated to grant Dr. Harmison options entitling him to purchase 108,000 (36,000 pre-split) common shares at \$0.97 per share, exercisable over five years; except that these options will vest quarterly based upon his provision of services over the first year of the agreement.
- Dr. Harmison is entitled to receive common shares grants in tranches of 20,000 common shares per milestone for assisting the Company in attaining various milestones determined by the Company's Board of Directors, including the preparation and filing with the FDA of a 510(k) application for the Company's product, approval of that application by the FDA, and market launch of that product.
- A grant of 20,000 common shares in the event of a "change in control" as that term is defined in the agreement.

In the event the agreement is terminated by the Company for any reason other than negligence, misconduct, breach of its material terms by Dr. Harmison or the failure of Dr. Harmison to render services in a reasonable fashion, all compensation prospectively payable under the agreement will become due and payable in 90 days.

In March 2003, for services rendered, the Company recognized a total of \$14,000 in expense in connection with the issuance of warrants. The fair value of warrants was recorded using the Black-Scholes option-pricing model computed as of the date of grant using the following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 158.48%, (iii) weighed-average risk-free interest rate of approximately 3.13, and (iv) expected life of 1.5 years.

In March 2003, the Company entered into an agreement with its then CFO to issue him warrants to purchase 900,000 (300,000 pre-split) shares of the Company s common stock at \$0.95 per share. The warrants were issued as compensation for services. The warrants vest quarterly over a 3-year period. The warrants have been valued using the Black-Scholes value option method; with a measurement date as the date the services are rendered. The fair value of warrants was estimated at \$204,170 using the Black-Scholes option-pricing model computed as of the date of grant using the following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 158.48%, (iii) weighed-average risk-free interest rate of approximately 3.13, and (iv) expected life of 1.5 years.

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
STATEMENTS OF CASH FLOWS
For The Nine Months Ended September 30, 2003 And 2002 From Inception
Of Development Stage (November 7, 2000) To September 30, 2003

In March 2003, the Company's Board of Directors approved the issuance of five-year warrants to purchase 900,000 shares (300,000 pre-split) of the Company's common stock at \$.50 per share to a business advisory consulting firm retained to perform various services including: the introduction of the Company to investment banking firms; assistance in the structuring of the Company's private offerings; assistance in capital market transactions, mergers and acquisitions; advisory services; and assistance in developing strategic relationships. The fair value of warrants was estimated at \$657,779 using the Black-Scholes option-pricing model computed as of the date of grant using the following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 158.48%, (iii) weighed-average risk-free interest rate of approximately 1.65, and (iv) expected life of 1.5 years.

On April 1, 2003, the Company completed the private placement of 112,792 (37,604 pre-split) shares of its common stock for a total consideration of \$250,000. The consideration included \$100,000 in cash and the cancellation of \$150,000 of debt previously advanced for \$33,208 in expenses and \$116,792 of leasehold improvements.

On April 2, 2003, the Board of Directors declared a three-for-one stock split effective as of the close of business on Friday, April 11, 2003. All share amounts and earnings per share have been presented on a post split basis.

On April 15, 2003, the Company committed to issue to Brookstreet Securities Corporation warrants to purchase 200,000 shares of the Company's common stock pursuant to an investment banking agreement. The warrants are issuable in four tranches of 50,000 each, with the first tranche of 50,000 fully vested and exercisable at \$1.25 per share. The second tranche will vest in 90 days after the date of the agreement and will have an exercise price of \$2.25 per share. The third tranche will vest in 180 days and will have an exercise price of \$3.25 per share. The fourth tranche will vest in 270 days and will have an exercise price of \$4.25 per share. The fair value of warrants was estimated at \$338,261 using the Black-Scholes option-pricing model computed as of the measurement date, which is the date the at the services were performed, using the following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 114.24%, (iii) weighed-average risk-free interest rate of approximately 1.42, and (iv) expected life of 1.5 years.

In May 2003, the Company completed the first tranche of a private placement pursuant to which it sold 82,667 units to three accredited investors at \$3.00 per unit for cash amounting to \$248,000. Each unit consisted of one share of common stock and one warrant. Each warrant is exercisable at \$3.00 until May 14, 2004. Upon exercise of the warrants each investor will receive one share of common stock and an additional warrant to purchase one share of common stock at \$6.00 per share until November 15, 2004.

On June 20, 2003, Board of Directors' amended the Company's articles of incorporation to increase the number of authorized shares to 110,000,000 shares designating 100,000,000 to common stock and 10,000,000 to preferred stock. The Board of Directors is authorized to provide from time to time for the issuance of shares of preferred stock in series and to fix and determine from time to time, before issuance, the designation and relative rights and preferences of the shares of each series of preferred stock and the restrictions or qualifications.

On June 2, 2003, the Company committed to issue to a consultant warrants to purchase 108,000 shares of the Company's common stock at \$2.40 pursuant to a consulting agreement. The warrants are issuable on demand and vest quarterly over three years. The fair value of warrants was estimated at \$199,226 using the Black-Scholes option-pricing model computed as of the date of grant using the following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 114.24%, (iii) weighed-average risk-free interest rate of approximately 1.42, and (iv) expected life of 1.5 years.

On July 17, 2003 the Company retained Maxim Group, LLC ("Maxim") a New York based investment banking firm to act as its lead investment bank. Under that agreement Maxim provides, among other services, assistance with the Company's financing efforts as it attempts to secure additional capital for product development as well as to fund the process of gaining approval for the Company's cardiac monitoring device by the FDA. Maxim will also assist the Company with general business strategy and with seeking a listing on a national exchange. Maxim was paid \$50,000 at the inception of the agreement and will be paid \$7,500 per month through June 30, 2004. In addition, Maxim

received a total of 100,000 warrants to purchase shares of restricted common stock at \$4.92 per share. The fair value of warrants was estimated at \$133,349 using the Black-Scholes option-pricing model computed as of the date of grant using the following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 81.16%, (iii) weighed-average risk-free interest rate of approximately 1.68, and (iv) expected life of 1.5 years.

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
STATEMENTS OF CASH FLOWS
For The Nine Months Ended September 30, 2003 And 2002 From Inception
Of Development Stage (November 7, 2000) To September 30, 2003

In July 2003, the Company closed the second tranche of a private placement by selling 75,075 units to four accredited investors for total cash of \$250,000, under terms consistent with the first tranche.

In August 2003, the Company entered into voluntary trading restriction agreements with two shareholders in exchange for warrants to purchase a total of 23,501 shares of the Company's common stock at a price of \$3.29 per share. In September 2003, the Company entered into a voluntary trading restriction agreement with a shareholder in exchange for warrants to purchase 18,000 shares of the Company's common stock at 85% of the closing price of the common stock on the date of the agreement (\$5.29 at September 23, 2003). The fair value of the warrants was estimated at \$74,088 using the Black-Scholes option-pricing model computed as of the date of grant using the following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 81.16%, (iii) weighed-average risk-free interest rate of approximately 1.68, and (iv) expected life of 1.5 years.

In September 2003, the Company issued a consultant warrants to purchase 25,000 shares of the Company's common stock at an exercise price of \$3.29 per share. The fair value of warrants was estimated at \$41,202 using the Black-Scholes option-pricing model computed as of the measurement date, which is the date that the services were performed, using the following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 81.16%, (iii) weighed-average risk-free interest rate of approximately 1.68, and (iv) expected life of 1.5 years

In September 2003, the Company issued 305,000 shares of restricted common stock to three persons pursuant to the cashless exercise provisions of common stock purchase warrants held by such persons.

During the nine month period ended September 30, 2003, the Company issued 327,342 shares of common stock, for marketing and business services rendered during the period. These services were valued at \$1,073,131 based upon the market value of the shares at the date of issuance.

The Company has issues 1,359,000 options to employees under the 2002 Stock Plan.

4. STOCK-BASED COMPENSATION PLANS

The number and weighted average exercise prices of the options and warrants issued to employees are as follows:

	September 30, 2003		September 30, 2002	
	Number	Average Exercise Price	Number	Average Exercise Price
Outstanding at beginning of the period	-	-	-	-
Granted during the period	2,560,000	\$ 0.98	-	-
Exercised during the period	-	-	-	-
Terminated during the period	-	-	-	-
Outstanding at end of the period	2,560,000	0.98	-	-
Exercisable at end of the period	1,090,833	\$ 1.04	-	-

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
STATEMENTS OF CASH FLOWS
For The Nine Months Ended September 30, 2003 And 2002 From Inception
Of Development Stage (November 7, 2000) To September 30, 2003

The following table summarizes information on stock options and warrants outstanding and exercisable issued to employees at September 30, 2003:

Range of Exercise Prices	Remaining Number Outstanding	Weighted Average Contractual Life (Years)	Weighted Average Fair Value	Exercise Price
0 to 1	2,490,000	4.3	\$ 0.60	\$ 0.90
1 to 2	-	-	-	-
2 to 3	10,000	4.5	1.90	2.85
3 to 4	10,000	4.8	2.50	3.19
4 to 5	50,000	4.7	2.80	4.20

The number and weighted average exercise prices of the options and warrants issued to consultants are as follows:

	September 30, 2003		September 30, 2002	
	Number	Average Exercise Price	Number	Average Exercise Price
Outstanding at beginning of the period	1,025,000	\$ 1.25	-	\$ -
Granted during the period	1,426,501	1.12	575,000	0.71
Exercised during the period	-	-	-	-
Terminated during the period	-	-	-	-
Outstanding at end of the period	2,451,501	1.36	575,000	0.71
Exercisable at end of the period	1,207,250	\$ 1.39	575,000	\$ 0.71

The following table summarizes information on stock options and warrants outstanding and exercisable issued to consultants at September 30, 2003:

Range of Exercise Prices	Remaining Number Outstanding	Weighted Average Contractual Life (Years)	Weighted Average Fair Value	Exercise Price
0 to 1	971,000	3.6	\$ 0.90	\$ 0.53
1 to 2	131,000	2.9	2.24	1.14
2 to 3	158,000	5.6	2.10	2.35
3 to 4	48,501	4.9	1.60	3.24
4 to 5	118,000	4.9	1.47	4.98

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
STATEMENTS OF CASH FLOWS
For The Nine Months Ended September 30, 2003 And 2002 From Inception
Of Development Stage (November 7, 2000) To September 30, 2003

5. SUBSEQUENT EVENTS

Subsequent to September 30, 2003, the Company issued 15,385 shares of common stock to individuals for business services. These shares were valued at \$3.90 based on the market value of the stock at the date of issuance.

During October 2003, the Company sold 53.2875 units with each unit consisting of 33,334 shares of its series 'A' convertible preferred stock and 16,667 class 'C' common stock purchase warrants at a price of \$100,000 per unit. The proceeds to the Company, net of expenses, was approximately \$4,645,000. Each class 'C' warrant entitles the holder to purchase one share of common stock at an exercise price of \$3.75 per share. The class 'C' warrants are exercisable anytime during the four year period commencing on the final closing and do not contain provisions for cashless exercise.

The series 'A' convertible preferred stock will pay dividends of 8% annually, to be paid quarterly either in cash or in the form of convertible preferred stock at the Company's discretion. The series 'A' convertible preferred stock will be valued at \$3 per share when it is issued as a dividend. Each holder of the series 'A' convertible preferred stock will have the option at any time to convert all or any portion of the series 'A' convertible preferred stock held by such holder into shares of common stock. The series 'A' convertible preferred stock shall have a liquidation value equal to \$3 per share and shall be convertible into common stock on a one-for-one basis (the "Conversion Price"). The series 'A' convertible preferred stock shall be senior to all other shares of capital stock now existing or hereinafter created of the Company as to dividend and liquidation rights and shall have voting rights as if converted into common stock.

The Company can force conversion of the series 'A' convertible preferred stock into common stock upon 45 days written notice to the holders of the series 'A' convertible preferred stock, if (1) the common stock is listed on a qualified exchange (NASDAQ, AMEX or NYSE); (2) the closing price of the common stock is at least \$7.50 for 30 consecutive trading days; and (3) the common stock underlying the conversion is subject to an effective registration statement filed with the SEC pursuant to the Securities Act of 1933.

The Company will issue the Placement Agent a common stock purchase warrant exercisable for a number of units equal to 10% of the number of units sold in the offering. The Placement Agent's warrant will be exercisable at \$3.60 per share and will expire five years following the date of issuance.

As part of the unit offering, the Company entered into registration rights agreements which require the Company to use its best efforts to file a registration statement with the Securities and Exchange Commission statement as soon as reasonably practicable after the first closing for the offering (October 1, 2003), but in no event less than 90 days following the first closing, to register the shares of common stock issuable upon conversion of the series 'A' convertible preferred stock and upon exercise of the class 'C' warrants. If the Company fails to do so, the exercise price for the class 'C' warrants will be reduced to \$3 from \$3.75.

INDEPENDENT AUDITORS' REPORT

To The Board Of Directors And Stockholders Of Recom Managed Systems, Inc.
Studio City, California

We have audited the accompanying balance sheet of Recom Managed Systems, Inc. as of December 31, 2002, and the related statements of operations, stockholders' equity and cash flows for each of the two years in the period ended December 31, 2002 and from inception of development stage (November 7, 2000) to December 31, 2002. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that the Company plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Recom Managed Systems, Inc. as of December 31, 2002, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2002 and from inception of development stage (November 7, 2000) to December 31, 2002, in conformity with accounting principles generally accepted in the United States of America.

/s/ Stonefield Josephson, Inc.

Stonefield Josephson, Inc.
Certified Public Accountants

December 30, 2003

F-1

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
BALANCE SHEET
December 31, 2002
(As Restated)

December 31, 2002

ASSETS	
CURRENT ASSETS	
Cash	148,689
Prepaid expenses	37,815
Total Current Assets	186,504
Equipment, net of accumulated depreciation of \$ 693	28,348
Intangible - patents	105,023
TOTAL ASSETS	319,875
LIABILITIES AND STOCKHOLDERS'S EQUITY	
CURRENT LIABILITIES	
Accounts payable and accrued expenses	39,764
STOCKHOLDERS' EQUITY	
Common stock, \$.001 par value; 100,000,000 shares authorized; 31,250,844 shares issued and outstanding	31,250
Additional paid-in capital	567,166
Deferred compensation	(19,678)
Deficit accumulated during development stage	(298,627)
TOTAL STOCKHOLDERS' EQUITY	280,111
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	319,875

The accompanying notes are an integral part of these financial statements.

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
STATEMENT OF OPERATIONS
December 31, 2002
(As Restated)

	For the Years Ended December 31,		From Inception of Development Stage (Nov. 7, 2000) to Dec. 31, 2002) (As Restated)
	2002	2001	<u> </u>
Revenue	\$ --	\$ --	\$ --
Research and development	67,500		67,500
General and administrative expenses	<u>144,454</u>	<u>50,000</u>	<u>231,127</u>
Loss before income tax provisions	\$ (211,954)	\$ (50,000)	\$ (349,318)
Provision for income taxes	<u>--</u>	<u>--</u>	
Net Loss	<u>\$ (211,954)</u>	<u>\$ (50,000)</u>	<u>\$ (298,627)</u>
Basic and diluted loss per share	<u>\$ (0.02)</u>	<u>\$ (0.01)</u>	<u>\$ (.04)</u>
Weighted average shares outstanding - basic and diluted	<u>11,609,162</u>	<u>4,211,291</u>	<u>7,650,527</u>

The accompanying notes are an integral part of these financial statements.

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
STATEMENT OF STOCKHOLDERS EQUITY
For The Years Ended December 31, 2002 And 2001 And From Inception Of Development Stage
(November 7, 2000) To December 31, 2002
(As Restated)

	Common Stock		Additional Paid-in Capital	Deferred Compensation	Deficit Accumulated During Development Stage	Total
	Shares	Amount				
Balance November 7, 2000 (as restated for 3:1 split)	4,139,784	\$4,139	\$(4,139)	\$-	\$-	\$-
Contributed capital	-	-	35,000	-	-	35,000
Net loss	-	-	-	-	(36,673)	(36,673)
Balance December 31, 2000	4,139,784	4,139	30,861	-	(36,673)	(1,673)
Contributed capital	-	-	45,000	-	-	45,000
Shares issued for Jul 2001 - \$.033	150,000	150	4,850	-	-	5,000
Net loss	-	-	-	-	(50,000)	(50,000)
Balance at December 31, 2001	4,289,784	4,289	80,711	-	(86,673)	(1,673)
Capital contributed	-	-	56,400	-	-	56,400
Warrants issued for:						
Cash	-	-	125,000	-	-	125,000
Services	-	-	5,324	-	-	5,324
Issuance of common stock for:						
Technology 09/19/02 - \$.006	23,400,000	23,400	54,623	-	-	78,023
Services rendered - Oct. 2002 \$.021	2,925,000	2,925	17,958	(19,678)	-	1,205
Cash Oct 2002 \$.03	564,810	565	17,221	-	-	17,786
Cash Nov 2002 \$2.66	71,250	71	189,929	-	-	190,000
Contributed services - officer	-	-	20,000	-	-	20,000
Net loss	-	-	-	-	(211,954)	(211,954)
Balance at December 31, 2002	31,250,844	\$31,250	\$567,166	\$(19,678)	\$(298,627)	\$280,111

The accompanying notes are an integral part of these financial statements.

F-4

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
STATEMENT OF CASH FLOWS

For The Years Ended December 31, 2002 And 2001 And From Inception Of Development Stage
(November 7, 2000) To December 31, 2002
(As Restated)

	For the Year Ended December 31,		From Inception of Development Stage (Nov. 7, 2001 to Dec. 31, 2002) (As Restated)
	2002	2001	
Cash flow from operating activities			
Net loss	\$ (211,954)	\$ (50,000)	\$ (298,627)
Adjustments to reconcile net loss to net cash used in operating activities			
Depreciation	693	-	693
Services as contributed capital	20,000		20,000
Common stock issued for services	1,205	5,000	6,205
Warrants issued for services	5,324		5,324
Change in assets and liabilities:			
Prepaid expenses	(37,815)		(37,815)
Accrued expenses	2,829	(6,822)	12,944
	(219,718)	(51,822)	(299,276)
Net cash used in investing activities			
Net Cash Used In Investing Activities -			
Purchase of equipment	(29,041)	-	(29,041)
	(29,041)	-	(29,041)
Cash used in investing activities			
Cash flow from financing activities:			
Capital contributions	56,400	45,000	135,400
Sale of common stock for cash	207,786	-	207,786
Sale of warrants for cash	125,000	-	125,000
	389,186	45,000	469,186
Net cash provided by financing activities			
Net Increase (decrease) in cash	140,427	(6,822)	148,869
Cash at beginning of period	8,262	15,084	0

Supplemental Investing and Financing Activities:

Cash at end of period	\$	148,689	\$	8,262	\$	148,689
-----------------------	----	---------	----	-------	----	---------

The accompanying notes are an integral part of these financial statements.

F-5

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
STATEMENT OF CASH FLOWS

For The Years Ended December 31, 2002 And 2001 And From Inception Of Development Stage
(November 7, 2000) To December 31, 2002
(As Restated)

Supplemental Cash Flow Information:

For the years ended December 31, 2002 and 2001 and from inception of development stage (November 7, 2000) to December 31, 2002, the Company paid no interest or income taxes.

Supplement Investing and Financing Activities:

In September 2002, 23,400,000 shares of the Company's common stock was issued for a patent valued at \$78,023.

In October 2002, the Company issued 2,925,000 of the Company's common stock as compensation under employment agreements with multi-year terms. The shares were valued at \$20,883, the fair value of the stock at issuance date. The Company recognized \$ 1,205 of compensation expense for these agreements during the year.

In November 2002, the Company issued warrants to a consultant to purchase the Company's common stock under consulting contracts. The value of the warrants, based upon the fair value of the stock using the Black-Scholes option model, is \$5,324. The Company recorded compensation expense of \$5,324 for this agreement

The Company recorded compensation expense of \$20,000 for the CEO of the Company. This compensation was recorded as additional paid in capital for the year ended December 31, 2002.

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
For The Years Ended December 31, 2002 And 2001 And From Inception Of Development Stage
(November 7, 2000) To December 31, 2002

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization

On June 26, 2000, Recom Managed Systems, Inc. (the "Company") (a Development Stage Company) filed a Voluntary Petition for Reorganization Under Chapter 11 of the Federal Bankruptcy Code and substantially curtailed operations. The Plan of Reorganization was confirmed on November 7, 2000, at which date the Company became a development stage company under the provisions of Statement of Financial Accounting Standards ("SFAS") No. 7. This resulted in the post bankruptcy ownership group controlling approximately 87% of the common stock and the elimination of the outstanding liabilities and most assets.

On September 19, 2002, the Company issued 7,800,000 shares of common stock in exchange for intangible technology. The issuance of stock resulted in a change of control, with the new ownership group controlling approximately 85% of the outstanding stock. See Note 2.

Basis Of Presentation

As reflected in the accompanying financial statements, the Company has no established source of revenue, losses from inception, negative cash flows from operations and limited working capital. These matters raise substantial doubt about the Company's ability to continue as a going concern.

In view of the matters described in the preceding paragraph, recoverability of a major portion of the recorded asset amounts shown in the accompanying consolidated balance sheet is dependent upon continued operations of the Company, which, in turn, is dependent upon the Company's ability to continue to raise capital and generate positive cash flows from operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classifications of liabilities that might be necessary should the Company be unable to continue its existence.

Management plans to, or has taken, the following steps that it believes will be sufficient to provide the Company with the ability to continue in existence. See Note 7 for further details.

In October 2003, the Company has raised approximately \$4,806,000 through the sale of series 'A' convertible preferred stock. The funds will be used to fund any capital shortfalls. See Note 7 for further details.

Management will continue its business plan to develop its line of products, which management believes will be ready for market approximately in late 2005. However, no assurance can be given that commercial products or services will ever result or that regulatory agencies, physicians, patients or insurance providers will accept those products or services.

Management believes that the steps taken above will be sufficient to fund operations for the next twelve-months.

Summary Of Significant Accounting Policies

Use of Estimates - These financial statements have been prepared in accordance with accounting principles generally accepted in the United States and, accordingly, require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Fair Value of Financial Instruments - For certain of the Company's financial instruments, accounts payable and accrued expenses, the carrying amounts approximate fair value due to their relatively short maturities.

F-7

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
For The Years Ended December 31, 2002 And 2001 And From Inception Of Development Stage
(November 7, 2000) To December 31, 2002

Cash and Equivalents - Cash equivalents are comprised of certain highly liquid investments with maturity of three months or less when purchased. The Company maintains its cash in bank deposit accounts, which at times, may exceed federally insured limits. The Company has not experienced any losses in such account.

Equipment - Equipment is recorded at historical cost. Maintenance and repairs are expensed as incurred. Depreciation is provided by the straight-line method over three to five years.

Intangible and Long-Lived Assets - In October 2001, the FASB issued SFAS No. 144, "Accounting for Impairment of Disposal of Long-Lived Assets", which supercedes SFAS No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of", and the accounting and reporting provision of APB Opinion No. 30, "Reporting the Results of Operations-Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions", for the disposal of a segment of a business. This statement also amends ARB No. 51, "Consolidated Financial Statements", to eliminate the exception to consolidation for a subsidiary for which control is likely to be impaired. SFAS No. 144 requires that long-lived assets to be disposed of by sale, including those of discontinued operations, be measured at the lower of carrying amount or fair value less cost to sell, whether reported in continuing operations or in discontinued operations. SFAS No. 144 broadens the reporting of discontinued operations to include all components of an entity with operations that can be distinguished from the rest of the entity and that will be eliminated from the ongoing operations of the entity in a disposal transaction. SFAS No. 144 also establishes a "primary-asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. This statement is effective for fiscal years beginning after December 15, 2001. The Company's adoption did not have a material impact to the Company's financial position or results of operations.

Advertising Costs - The Company expenses advertising costs as incurred. The Company had no advertising costs for the years ended December 31, 2002 and 2001.

Research and Development Costs - Research and development costs consist of expenditures for the research and development of patents, which are not capitalizable.

Stock Based Compensation - SFAS No. 123, "Accounting for Stock-Based Compensation," establishes and encourages the use of the fair value based method of accounting for stock-based compensation arrangements under which compensation cost is determined using the fair value of stock-based compensation determined as of the date of grant and is recognized over the periods in which the related services are rendered. The statement also permits companies to elect to continue using the current intrinsic value accounting method specified in Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to Employees," to account for stock-based compensation to employees. The Company has elected to use the intrinsic value based method and has disclosed the pro forma effect of using the fair value based method to account for its stock-based compensation to employees. The Company uses the fair value method for equity instruments granted to non-employees.

Income Taxes - Deferred income taxes result primarily from temporary differences between financial and tax reporting. Deferred tax assets and liabilities are determined based on the difference between the financial statement bases and tax bases of assets and liabilities using enacted tax rates. A valuation allowance is recorded to reduce a deferred tax asset to that portion that is expected to more likely than not be realized.

Net Loss Per Share - The Company uses SFAS No. 128, "Earnings Per Share" for calculating the basic and diluted loss per share. Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. At December 31, 2002 and 2001, the Company had no potentially dilutive common shares.

Comprehensive Income - Comprehensive income is not presented in the Company's financial statements since the Company did not have any of the items of other comprehensive income in any period presented.

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
For The Years Ended December 31, 2002 And 2001 And From Inception Of Development Stage
(November 7, 2000) To December 31, 2002

New Accounting Pronouncements

In October 2001, the FASB issued SFAS No. 143, "Accounting for Asset Retirement Obligations," which requires companies to record the fair value of a liability for asset retirement obligations in the period in which they are incurred. The statement applies to a company's legal obligations associated with the retirement of a tangible long-lived asset that results from the acquisition, construction, and development or through the normal operation of a long-lived asset. When a liability is initially recorded, the company would capitalize the cost, thereby increasing the carrying amount of the related asset. The capitalized asset retirement cost is depreciated over the life of the respective asset while the liability is accreted to its present value. Upon settlement of the liability, the obligation is settled at its recorded amount or the company incurs a gain or loss. The statement is effective for fiscal years beginning after June 30, 2002. The adoption did not have a material impact on the Company's financial position or results of operations.

In October 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets". Statement 144 addresses the accounting and reporting for the impairment or disposal of long-lived assets. The statement provides a single accounting model for long-lived assets to be disposed of. New criteria must be met to classify the asset as an asset held-for-sale. This statement also focuses on reporting the effects of a disposal of a segment of a business. This statement is effective for fiscal years beginning after December 15, 2001. The adoption did not have a material impact on the Company's financial position or results of operations.

In April 2002, the FASB issued Statement No. 145, "Rescission of FASB Statements No. 4, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections." This Statement rescinds FASB Statement No. 4, "Reporting Gains and Losses from Extinguishment of Debt", and an amendment of that Statement, FASB Statement No. 64, "Extinguishments of Debt Made to Satisfy Sinking-Fund Requirements" and FASB Statement No. 44, "Accounting for Intangible Assets of Motor Carriers". This Statement amends FASB Statement No. 13, "Accounting for Leases", to eliminate an inconsistency between the required accounting for sale-leaseback transactions and the required accounting for certain lease modifications that have economic effects that are similar to sale-leaseback transactions. The adoption did not have a material impact on the Company's financial position or results of operations.

In July 2002, the FASB issued SFAS No. 146, "Accounting for Costs Associated with Exit or Disposal Activities", which addresses financial accounting and reporting for costs associated with exit or disposal activities and supersedes EITF Issue 94-3, "Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring)." SFAS No. 146 requires that a liability for a cost associated with an exit or disposal activity be recognized when the liability is incurred. Under Issue 94-3, a liability for an exit cost as defined in Issue 94-3 was recognized at the date of an entity's commitment to an exit plan. SFAS No. 146 also establishes that the liability should initially be measured and recorded at fair value. The adoption did not have a material impact on the Company's financial position or results of operations.

In October 2002, the FASB issued SFAS No. 147, "Acquisitions of Certain Financial Institutions" which provides guidance on the accounting for the acquisition of a financial institution. SFAS No. 147 removes acquisitions of financial institutions between one enterprise from the scope of both FASB Statement No. 72, "Accounting for Certain Acquisitions of Banking or Thrift Institutions, and FASB Interpretation No. 9, "Apply APB Opinion No. 16 and 17, "When a Savings and Loan Association or a Similar Institution is Acquired in a Business Combination Accounted for by the Purchase Method" and requires that those transactions be account for in accordance with FASB Statements No. 141 and 142. Additionally, SFAS No. 147 amends FASB Statement No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets, to include in its scope long-term customer-relationship intangible assets of financial institutions. The adoption of this pronouncement did not have a material impact on the Company's financial position

or results of operations.

In November 2002, the FASB issued Interpretation No. (FIN) 45, "Guarantor's Accounting and Disclosure requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others." Among other things, the Interpretation requires guarantors to recognize, at fair value, their obligations to stand ready to perform under certain guarantees. FIN 45 is effective for guarantees issued or modified on or after January 1, 2003. The Company does not expect the adoption of this pronouncement to have a material impact to the Company's financial position or results of operations.

F-9

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
For The Years Ended December 31, 2002 And 2001 And From Inception Of Development Stage
(November 7, 2000) To December 31, 2002

In December 2002, the FASB issued SFAS No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure", which amends SFAS No. 123, "Accounting for Stock-Based Compensation", to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. Additionally, SFAS No. 148 amends the disclosure requirements of SFAS No. 123, regardless of which method of accounting is chosen, to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results. The Company has adopted the disclosure requirements and has determined not to voluntarily change to the fair value based method of accounting for stock based employee compensation.

In January 2003, the FASB issued Interpretation No. 46, "Consolidation of Variable Interest Entities." Interpretation 46 changes the criteria by which one company includes another entity in its consolidated financial statements. Previously, the criteria were based on control through voting interest. Interpretation 46 requires a variable interest entity to be consolidated by a company if that company is subject to a majority of the risk of loss from the variable interest entity's activities or entitled to receive a majority of the entity's residual returns or both. A company that consolidates a variable interest entity is called the primary beneficiary of that entity.

In December 2003 the FASB concluded to revise certain elements of FIN 46, which will be issued shortly. The FASB also modified the effective date of FIN 46. For all entities that were previously considered special purpose entities, FIN 46 should be applied in periods ending after December 15, 2003. Otherwise, FIN 46 is to be applied for registrants who file under Regulation SX in periods ending after March 15, 2004, and for registrants who file under Regulation SB, in periods ending after December 15, 2003. The Company does not expect the adoption to have a material impact on the Company's financial position or results of operations.

During April 2003, the FASB issued SFAS 149 - "Amendment of Statement 133 on Derivative Instruments and Hedging Activities", effective for contracts entered into or modified after June 30, 2003, except as stated below and for hedging relationships designated after June 30, 2003. In addition, except as stated below, all provisions of this Statement should be applied prospectively. The provisions of this Statement that relate to Statement 133 Implementation Issues that have been effective for fiscal quarters that began prior to June 15, 2003, should continue to be applied in accordance with their respective effective dates. In addition, paragraphs 7(a) and 23(a), which relate to forward purchases or sales of when issued securities or other securities that do not yet exist, should be applied to both existing contracts and new contracts entered into after June 30, 2003. The Company does not participate in such transactions, however, is evaluating the effect of this new pronouncement, if any, and will adopt FASB 149 within the prescribed time.

During May 2003, the FASB issued SFAS 150 - "Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity", effective for financial instruments entered into or modified after May 31, 2003, and otherwise is effective at the beginning of the first interim period beginning after June 15, 2003. This Statement establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liabilities and equity. It requires that an issuer classify a freestanding financial instrument that is within its scope as a liability (or an asset in some circumstances). Many of those instruments were previously classified as equity. Some of the provisions of this Statement are consistent with the current definition of liabilities in FASB Concepts Statement No. 6, Elements of Financial Statements. The Company is evaluating the effect of this new pronouncement and will adopt FASB 150 within the prescribed time.

2. ASSET ACQUISITION

In September 2002, the Company acquired from ARC Finance Group LLC ("ARC"), technology, which consist of a patent, certain know how, trade secrets and other intellectual property in exchange for 7,800,000 shares of the Company's common stock. As a result of this transaction, ARC acquired approximately 84.5% of the Company's outstanding shares. The Company has valued the issuance of the common stock at \$78,023, which was ARC's historical cost basis for the patents.

F-10

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
For The Years Ended December 31, 2002 And 2001 And From Inception Of Development Stage
(November 7, 2000) To December 31, 2002

3. EQUITY TRANSACTIONS

During the years ended December 31, 2002 and 2001, the Company's former President and former majority shareholder contributed capital totaling \$56,400 and \$45,000, respectively. These contributions were made for working capital purposes.

At September 19, 2002, the former President purchased a warrant for \$125,000. The warrant is to purchase 600,000 (200,000 pre-split) shares of common stock at an exercise price of \$0.667 per share, which was above the current market price at the date of issuance. The warrant may not be exercised before September 1, 2003, expires in September 2006, and contains cashless exercise options and certain anti-dilution and other provisions.

On October 12, 2002, the Company agreed to issue a total of 2,100,000 (700,000 pre-split) shares of its common stock to Marvin H. Fink pursuant to a four-year employment agreement whereby Mr. Fink will serve as the Company's Chief Executive Officer and Chairman of the Board of Directors (see Note 6). The shares were valued at \$15,190 the current market value for the Company's common stock on the measurement date and vest at the rate of 8.33% or 174,999 (58,333 pre-split) shares per quarter with the first vesting on January 12, 2003. The value is being expensed over the life of the agreement of which \$906 was expensed during the year ended December 31, 2002 and the remainder is presented as deferred compensation in Stockholders' Equity. Also, per Mr. Fink's employment agreement, he is to be paid \$1.00 each year of his agreement. The Company has estimated that the values of his services are approximately \$80,000 per year. The Company has determined that an additional annual expense of \$80,000 should be recorded to fairly present the value of the services rendered. For the year ended December 31, 2002, the Company has recorded additional compensation expense of \$20,000, which will be classified as contributed capital and credited to additional paid-in capital.

On October 15, 2002, the Company agreed to issue a total of 600,000 (200,000 pre-split) shares of its common stock to B World Technologies, Inc. (a company owned by Budimir Drakulic) pursuant to a Loanout Agreement with Budimir Drakulic and B World Technologies, Inc. whereby Dr. Drakulic will work as an independent contractor for the Company and serve as Vice President and Chief Technology Officer for a term of ten years (see Note 6). The shares were valued at \$4,140, the current market value for the Company's common stock on the measurement date and vest at the rate of 5% or 30,000 (10,000 pre-split) shares per quarter with the first shares vesting on January 15, 2003. The value is being expensed over the life of the agreement of which \$153 was expensed during the year ended December 31, 2002 and the remainder is presented as deferred compensation in Stockholders' Equity.

Effective October 15, 2002, the Company agreed to issue a total of 150,000 (75,000 pre-split) shares of its common stock to Ellsworth Roston pursuant to a two-year consulting agreement whereby Mr. Roston will consult with the Company with respect to the engineering, development and refining of the Company's technologies (see Note 6). Mr. Roston also agreed to join the Company's Board of Directors. The shares were valued at \$1,553, the current market value for the Company's common stock on the measurement date and vest at the rate of 28,125 (9,375 pre-split) shares per quarter with the first shares vesting on February 1, 2003. The value is being expensed over the life of the agreement of, which \$146 was expensed during the year ended December 31, 2002 and the remainder is presented as deferred compensation in Stockholders' Equity.

October 30, 2002, Mr. Roston became a Director on the Company's Board and for \$190,000 purchased 71,250 (23,750 pre-split) shares of the Company's common stock and a five-year warrant to purchase 450,000 (150,000 pre-split) shares of the Company's common stock at an exercise price of \$1.667 per share.

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

In October 2002, the Company issued a total of 564,810 (188,270 pre-split) shares of common stock to eleven individuals for total cash consideration of \$17,786, and issued a five-year warrant to purchase 375,000 (125,000 pre-split) shares of common stock for \$0.007 per share to one of those individuals. These individuals alleged certain possible claims relating to Dr. Drakulic and/or his technology. The Company allowed the individuals to invest in the Company in order to protect the Company's rights in the technology. The Company further agreed that should it raise more than \$2 million in certain offerings, to pay 4% of the proceeds of those offerings to those individuals up to the amount of \$480,350. The effective date for the transaction, which was entered into in conjunction with the loanout agreement relating to Dr. Drakulic, was October 11, 2002. The fair value of warrants was estimated at \$5,324, which was expensed as of December 30, 2002, using the Black-Scholes option-pricing model computed as of the date of grant using the following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 120.25%, (iii) weighed-average risk-free interest rate of approximately 3.01, and (iv) expected life of 1.25 years.

F-11

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
For The Years Ended December 31, 2002 And 2001 And From Inception Of Development Stage
(November 7, 2000) To December 31, 2002

For the year ended December 31, 2002 and 2001 the Company issued warrants to purchase 1,425,000 and 0, respectively, shares of the Company's common stock. As of December 31, 2002 and 2001, the Company had warrants outstanding to purchase 1,425,000 and 0, respectively, shares of the Company's common stock. The weighted average remaining contractual life of warrants outstanding is 4.4 years at December 31, 2002. The exercise price for the warrants outstanding at December 31, 2002 ranged from \$.01 to \$.67. For warrants granted during the year ended December 31, 2002 the weighted-average fair value of such warrants was \$0.20 and the weighted-average exercise price of such options was \$.38.

4. INCOME TAXES

All prior net operating loss carryovers were eliminated due to change of ownership in September 2002. The cumulative losses since that time are of \$159,664, are available for carryover and, if not used, expire in 2022. A valuation allowance has been provided for the deferred tax benefit resulting from the net operating loss carryover. The Company has recorded a valuation allowance for the full amount of the deferred tax asset resulting from the net operating loss carryover due to the reorganized Company's limited operating history.

5. STOCK OPTIONS

In November 2002, the Company's Board of Directors approved the establishment of the 2002 Stock Plan (the "Plan"). The Company intends to submit the Plan to the shareholders for their approval at the next shareholders' meeting. The total number of shares of common stock available for grant and issuance under the Plan may not exceed 2,000,000, subject to adjustment in the event of certain recapitalizations, reorganizations and similar transactions. Options may be exercisable by the payment of cash or by other means as authorized by the committee or the Board of Directors. At December 31, 2002 no options had been granted, as the Plan, had not been approved by the shareholders.

6. COMMITMENTS AND CONTINGENCIES

The Company employs Mr. Marvin H. Fink as its Chief Executive Officer and Chairman of the Board currently under a four year employment agreement entered into effective as of October 12, 2002 (see Note 3). The essential terms of the employment agreement are as follows:

- Mr. Fink's initial base salary under the agreement is \$1 per year. Following the one year anniversary of the agreement, the Board of Directors may review and adjust the base salary in light of the Company's performance.
- Mr. Fink is entitled to a cash bonus for his second through fourth years of employment. The amount of the bonus is 10% of the after tax income exclusive of extraordinary expenses for the second year, and 15% of that amount for the third and fourth years.
- Mr. Fink is granted 2,100,000 "restricted" common shares (700,000 shares pre split), to be earned over three years of continuous employment. These shares, which are held in escrow by the company pursuant to the terms of a restricted stock agreement until they are earned, vest in tranches of 174,999 each at the end of the first eleven quarters of Mr. Fink's employment, with the balance vesting at the end of the twelfth quarter. Mr. Fink is entitled to all dividends, which may be declared with respect to these shares, even if not vested.

- The agreement contains a "gross up" provision obligating the Company to make a cash payment to Mr. Fink to cover any taxes he may incur by reason of receiving any payment or distribution that would constitute an excess golden parachute payment under the federal tax laws. The gross up provision also applies to the 2,100,000 restricted common shares described above, however, Mr. Fink exercised his section 83(b) election under the Internal Revenue Code subjecting him to immediate taxation upon the receipt of the shares notwithstanding their future forfeitability, so the Company's liability, if any, for any taxes imposed under that grant should be nominal.

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
For The Years Ended December 31, 2002 And 2001 And From Inception Of Development Stage
(November 7, 2000) To December 31, 2002

- Should The Company's common shares be listed on any of the NYSE, AMEX or Nasdaq national stock exchanges or markets, Mr. Fink would be entitled, if then still employed by the Company, to an additional grant of 600,000 common shares (200,000 shares pre split).
- In the event of a change in control (as that term is defined in the employment agreement), Mr. Fink would be entitled, if then still employed by the Company, to an additional grant of common shares having a market value of \$5,000,000, but not to exceed 600,000 common shares (200,000 shares pre split) in total.
- Mr. Fink is entitled to a number of employee benefits under the agreement, including a \$1,200 per month automobile allowance, individual medical plan reimbursement of up to \$2,000 per month until the Company adopts a group plan for the Company's employee's, and the right to participate in all benefit plans established for the Company's employees or executives, including medical, hospitalization, dental, long term care and life insurance programs.
- The employment agreement provides for early termination in the case of Mr. Fink's death or disability, Mr. Fink's termination by the Company for "cause" as that term is defined in the agreement; Mr. Fink's termination of employment for "good reason" as that term is defined in the agreement, a "change in ownership" as that term is defined in the agreement, or sixty days' prior notice by Mr. Fink. In the event of an early termination of the agreement for any reason, all compensation and benefits under the agreement will terminate and the unvested portion of the 2,100,000 restricted common share grant shall be deemed forfeit as of the effective termination date, with the following exceptions:
 - If the agreement is terminated during years two through four due to Mr. Fink's disability, termination by Mr. Fink for good reason; the Company's termination of Mr. Fink without cause, or a change in ownership, Mr. Fink will nevertheless be entitled to a pro rata portion (based upon the actual number of days of employment) of the cash bonus based on the Company's after tax income that he would have otherwise received for the year of termination had he remained employed until the end of that year;
 - If the agreement is terminated due to Mr. Fink's death, disability, termination by Mr. Fink for good reason; The Company's termination of Mr. Fink without cause, or a change in ownership, the unvested portion of the 2,100,000 restricted common share grant to Mr. Fink will become fully vested and the shares released from escrow; and
 - Mr. Fink and his family will be entitled to an additional three years' medical, hospitalization, dental, long term care and life insurance coverage if the agreement is terminated by Mr. Fink for good reason or terminated by The Company's termination without cause, and an additional one years' coverage if the agreement is terminated due to Mr. Fink's disability.

The Company has engaged Dr. Budimir Drakulic as Vice President and Chief Signal Technologies Officer on an independent contractor basis under a loan out agreement dated October 15, 2002 with two companies, B World Technologies, Inc. and B Technologies, Inc., and Dr. Drakulic individually. Dr. Drakulic is the president and owner of these companies. The essential terms of the agreement are as follows:

- The agreement provides for a ten year initial term. After the initial term, the agreement renews automatically for successive one-year terms, unless either party delivers 90 days' written notice to the other of their intent not to renew.

- Dr. Drakulic's services are provided on a mutually acceptable part time basis.
- The Company is obligated to pay B Technologies a \$10,000 bonus upon execution, and a monthly service fee of \$15,000 thereafter.

F-13

RECOM MANAGED SYSTEMS, INC.

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

For The Years Ended December 31, 2002 And 2001 And From Inception Of Development Stage

(November 7, 2000) To December 31, 2002

- B World Technologies was granted 600,000 "restricted" common shares (200,000 shares pre split), to be earned over five years of continuous provision of services by Dr. Drakulic. These shares, which will be held in escrow with the company pursuant to the terms of a restricted stock agreement until they are earned, vest at the rate of 30,000 shares per quarter with the first 30,000 shares vesting on January 15, 2003. B World Technologies is entitled to all dividends, which may be declared with respect to these shares, even if not vested.
- The loan out agreement provides for early termination should B World and B Technologies fail, neglect or refuse to provide Dr. Drakulic's services. In such an event, all compensation under the agreement will terminate and the unvested portion of the 600,000 restricted common share grants shall be deemed forfeit as of the effective termination date.

Since March 1, 2003, Dr. Drakulic has worked for the Company on a full time basis even though the loan out agreement only provides for the provision of part time services. The Company has agreed to characterize these additional services as being provided by Dr. Drakulic as an employee, and to pay him \$7,500 annually as compensation for their provision.

On March 10, 2003, as additional incentive for the performance of Dr. Drakulic, the Company granted to B World Technologies options entitling it to purchase 750,000 common shares at \$0.92 per share. These options vest quarterly over a four-year term, and lapse, if not exercised, on March 9, 2008 (unaudited).

Concurrent with entering into the loan out agreement, B World Technologies, B Technologies and Dr. Drakulic signed an employment, confidential information, invention assignment and arbitration agreement under which they agreed, among other things, to assign to the Company all of Dr. Drakulic's right, title and interest in and to any and all inventions, discoveries, etc. which he conceives or develops while engaged by the Company.

Mr. Ellsworth Roston, one of the Company's Directors, provides consulting services to the Company under a two year agreement dated November 1, 2002. Under this agreement, Mr. Roston provides advice to the Company relating to engineering, developing and refining the Company's products and technologies. Mr. Roston also agreed under the agreement to act as a member of the Company's Board of Directors during its term. Mr. Roston is a patent attorney who handles the Company's patent work. The agreement specifically provides that the consulting services provided by Mr. Roston will not include any legal work, for which the Company will compensate him separately. In compensation for his consulting services, the Company granted to Mr. Roston 225,000 "restricted" common shares (75,000 shares pre split).

7. SUBSEQUENT EVENT

Events Affecting Capitalization

On April 2, 2003, the Board of Directors declared a three-for-one stock split effective as of the close of business on Friday, April 11, 2003. All share amounts and earnings per share have been presented on a post split basis.

On June 20, 2003, the Company amended its Certificate of Incorporation to increase the number of authorized shares to 110,000,000 shares, designating 100,000,000 shares to common stock and 10,000,000 shares to preferred stock. The Board of Directors is authorized to provide from time to time for the issuance of shares of preferred stock in series and to fix and determine from time to time, before issuance, the designation and relative rights and preferences of the shares of each series of preferred stock and the restrictions or qualifications. On September 25, 2003, the Board of Directors designated 1,818,710 shares of the preferred stock as series A convertible preferred stock. The rights, preferences,

privileges and restrictions of the series A convertible preferred stock are described below.

F-14

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
For The Years Ended December 31, 2002 And 2001 And From Inception Of Development Stage
(November 7, 2000) To December 31, 2002

The total number of shares of common stock subject to options and grants of stock under the 2003 Plan may not exceed 500,000 shares, subject to adjustment in the event of certain capitalizations, reorganizations, and similar transactions. Options may be exercisable by the payment of cash or by other means as authorized by the Board of Directors.

The Board of Directors may amend the 2003 Plan at any time, provided that the Board of Directors may not amend the 2003 Plan to adversely effect the rights of participants under the 2003 Plan, without stockholder approval.

Issuance of Equity Instruments

Dr. Lowell T. Harmison, one of the Company's Directors, provides consulting services to the Company under a three year agreement dated February 14, 2003. Under this agreement, Dr. Harmison provides advice to the Company in the areas of technological support and strategy, product development, medical and scientific advisory board development, and FDA regulation. The compensatory terms of the agreement are as follows:

- The Company is obligated to pay Dr. Harmison \$36,000 per year over the term of the agreement, payable quarter. Dr. Harmison was entitled to receive upon execution of the agreement an initial grant of options entitling him to purchase 108,000 common shares (36,000 shares pre split) at \$0.97 per share, exercisable over five years. The fair value of warrants was \$153,352 estimated using the Black-Scholes option-pricing model computed as of the measurement date, which is the date that the service were performed, with thee following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 158.48%, (iii) weighed-average risk-free interest rate of approximately 3.13, and (iv) expected life of 1.5 years.
- On the date of Dr Harmison's execution of the agreement, as well as the commencement of the first and second years of service under the agreement, the Company is obligated to grant Dr. Harmison options entitling him to purchase 108,000 (36,000 pre-split) common shares at \$0.97 per share, exercisable over five years; except that these options will vest quarterly based upon his provision of services over the first year of the agreement.
- Dr. Harmison is entitled to receive common shares grants in tranches of 20,000 common shares per milestone for assisting the Company in attaining various milestones determined by the Company's Board of Directors, including the preparation and filing with the FDA of a 510(k) application for the Company's product, approval of that application by the FDA, and market launch of that product.
- A grant of 20,000 common shares in the event of a "change in control" as that term is defined in the agreement.

In the event the agreement is terminated by the Company for any reason other than negligence, misconduct, breach of its material terms by Dr. Harmison or the failure of Dr. Harmison to render services in a reasonable fashion, all compensation prospectively payable under the agreement will become due and payable in 90 days.

In March 2003, the Company recognized a total of \$14,000 in expense in connection with the issuance of warrants for services rendered. The fair value of warrants was recorded using the Black-Scholes option-pricing model computed as of the date of grant using the following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 158.48%, (iii) weighed-average risk-free interest rate of approximately 3.13, and

(iv) expected life of 1.5 years.

In March 2003, the Company entered into an agreement with its then CFO to issue him warrants to purchase 900,000 (300,000 pre-split) shares of the Company's common stock at \$0.76 per share. The warrants were issued as compensation for services. The warrants vest quarterly over a 3-year period. The warrants have been valued using the Black-Scholes value option method; with a measurement date as the date the services are rendered. The fair value of warrants was estimated at \$204,170 using the Black-Scholes option-pricing model computed as of the date of grant using the following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 158.48%, (iii) weighed-average risk-free interest rate of approximately 3.13, and (iv) expected life of 1.5 years.

F-15

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
For The Years Ended December 31, 2002 And 2001 And From Inception Of Development Stage
(November 7, 2000) To December 31, 2002

On April 2, 2003, the Board of Directors declared a three-for-one stock split effective as of the close of business on Friday, April 11, 2003. All share amounts and earnings per share have been presented on a post split basis.

In March 2003, the Company's Board of Directors approved the issuance of five-year warrants to purchase 900,000 shares (300,000 pre-split) of the Company's common stock at \$.95 per share to a firm which was retained to perform various services including: the introduction of the Company to investment banking firms; assistance in the structuring of the Company's private offerings; assistance in capital market transactions, mergers and acquisitions; advisory services; and assistance in developing strategic relationships. The fair value of warrants was estimated at \$657,779 using the Black-Scholes option-pricing model computed as of the date of grant using the following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 158.48%, (iii) weighed-average risk-free interest rate of approximately 1.65, and (iv) expected life of 1.5 years.

On April 1, 2003, the Company completed the private placement of 112,792 (37,604 pre-split) shares of its common stock for a total consideration of \$250,000. The consideration included \$100,000 in cash and the cancellation of \$150,000 of debt previously advanced for \$33,208 in expenses and \$116,792 of leasehold improvements.

On April 15, 2003, the Company committed to issue to Brookstreet Securities Corporation warrants to purchase 200,000 shares of the Company's common stock pursuant to an investment banking agreement. The warrants are issuable in four tranches of 50,000 each, with the first tranche of 50,000 fully vested and exercisable at \$1.25 per share. The second tranche will vest in 90 days after the date of the agreement and will have an exercise price of \$2.25 per share. The third tranche will vest in 180 days and will have an exercise price of \$3.25 per share. The fourth tranche will vest in 270 days and will have an exercise price of \$4.25 per share. The fair value of warrants was estimated at \$338,261 using the Black-Scholes option-pricing model computed as of the measurement date, which is the date the at the services were performed, using the following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 114.24%, (iii) weighed-average risk-free interest rate of approximately 1.42, and (iv) expected life of 1.5 years.

In May 2003, the Company completed the first tranche of a private placement pursuant to which it sold 82,667 units to three accredited investors at \$3.00 per unit for cash amounting to \$248,000. Each unit consisted of one share of common stock and one warrant. Each warrant is exercisable at \$3.00 until May 14, 2004. Upon exercise of the warrants each investor will receive one share of common stock and an additional warrant to purchase one share of common stock at \$6.00 per share until November 15, 2004.

On June 20, 2003, Board of Directors' amended the Company's articles of incorporation to increase the number of authorized shares to 110,000,000 shares designating 100,000,000 to common stock and 10,000,000 to preferred stock. The Board of Directors is authorized to provide from time to time for the issuance of shares of preferred stock in series and to fix and determine from time to time, before issuance, the designation and relative rights and preferences of the shares of each series of preferred stock and the restrictions or qualifications.

On June 2, 2003, the Company committed to issue to a consultant warrants to purchase 108,000 shares of the Company's common stock at \$2.40 pursuant to a consulting agreement. The warrants are issuable on demand and vest quarterly over three years. The fair value of warrants was estimated at \$199,226 using the Black-Scholes option-pricing model computed as of the date of grant using the following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 114.24%, (iii) weighed-average risk-free interest rate of approximately 1.42, and (iv) expected

life of 1.5 years.

F-16

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
For The Years Ended December 31, 2002 And 2001 And From Inception Of Development Stage
(November 7, 2000) To December 31, 2002

On July 17, 2003 the Company retained Maxim Group, LLC ("Maxim") a New York based investment banking firm to act as its lead investment bank. Under that agreement Maxim provides, among other services, assistance with the Company's financing efforts as it attempts to secure additional capital for product development as well as to fund the process of gaining approval for the Company's cardiac monitoring device by the FDA. Maxim will also assist the Company with general business strategy and with seeking a listing on a national exchange. Maxim was paid \$50,000 at the inception of the agreement and will be paid \$7,500 per month through June 30, 2004. In addition, Maxim received a total of 100,000 warrants to purchase shares of restricted common stock at \$4.92 per share. The fair value of warrants was estimated at \$133,349 using the Black-Scholes option-pricing model computed as of the date of grant using the following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 81.16%, (iii) weighed-average risk-free interest rate of approximately 1.68, and (iv) expected life of 1.5 years.

In July 2003, the Company closed the second tranche of a private placement by selling 75.075 units to four accredited investors for total cash of \$250,000, under terms consistent with the first tranche.

In August 2003, the Company entered into voluntary trading restriction agreements with two shareholders in exchange for warrants to purchase a total of 23,501 shares of the Company's common stock at a price of \$3.29 per share. In September 2003, the Company entered into a voluntary trading restriction agreement with a shareholder in exchange for warrants to purchase 18,000 shares of the Company's common stock at 85% of the closing price of the common stock on the date of the agreement (\$5.29 at September 23, 2003). The fair value of the warrants was estimated at \$74,088 using the Black-Scholes option-pricing model computed as of the date of grant using the following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 81.16%, (iii) weighed-average risk-free interest rate of approximately 1.68, and (iv) expected life of 1.5 years.

In September 2003, the Company issued a consultant warrants to purchase 25,000 shares of the Company's common stock at an exercise price of \$3.29 per share. The fair value of warrants was estimated at \$41,202 using the Black-Scholes option-pricing model computed as of the measurement date, which is the date that the services were performed, using the following assumptions: (i) dividend yield of 0%, (ii) expected volatility of 81.16%, (iii) weighed-average risk-free interest rate of approximately 1.68, and (iv) expected life of 1.5 years

In September 2003, the Company issued 305,000 shares of restricted common stock to three persons pursuant to the cashless exercise provisions of common stock purchase warrants held by such persons.

During the nine month period ended September 30, 2003, the Company issued 327,342 shares of common stock, for marketing and business services rendered during the period. These services were valued at \$1,073,131 based upon the market value of the shares at the date of issuance.

Subsequent to September 30, 2003, the Company issued 15,385 shares of common stock to individuals for business services. These shares were valued at \$3.90 based on the market value of the stock at the date of issuance.

During October 2003, the Company sold 53.2875 units with each unit consisting of 33,334 shares of its series 'A' convertible preferred stock and 16,667 class 'C' common stock purchase warrants at a price of \$100,000 per unit. The proceeds to the Company, net of expenses, was approximately \$4,645,000. Each class 'C' warrant entitles the holder to purchase one share of common stock at an exercise price of \$3.75 per share. The class 'C' warrants are exercisable anytime during the four year period commencing on the final closing and do not contain provisions for cashless exercise.

The series 'A' convertible preferred stock will pay dividends of 8% annually, to be paid quarterly either in cash or in the form of convertible preferred stock at the Company's discretion. The series 'A' convertible preferred stock will be valued at \$3 per share when it is issued as a dividend. Each holder of the series 'A' convertible preferred stock will have the option at any time to convert all or any portion of the series 'A' convertible preferred stock held by such holder into shares of common stock. The series 'A' convertible preferred stock shall have a liquidation value equal to \$3 per share and shall be convertible into common stock on a one-for-one basis (the "Conversion Price"). The series 'A' convertible preferred stock shall be senior to all other shares of capital stock now existing or hereinafter created of the Company as to dividend and liquidation rights and shall have voting rights as if converted into common stock.

F-17

RECOM MANAGED SYSTEMS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
For The Years Ended December 31, 2002 And 2001 And From Inception Of Development Stage
(November 7, 2000) To December 31, 2002

The Company can force conversion of the series 'A' convertible preferred stock into common stock upon 45 days written notice to the holders of the series 'A' convertible preferred stock, if (1) the common stock is listed on a qualified exchange (NASDAQ, AMEX or NYSE); (2) the closing price of the common stock is at least \$7.50 for 30 consecutive trading days; and (3) the common stock underlying the conversion is subject to an effective registration statement filed with the SEC pursuant to the Securities Act of 1933.

The Company will issue the Placement Agent a common stock purchase warrant exercisable for a number of units equal to 10% of the number of units sold in the offering. The Placement Agent's warrant will be exercisable at \$3.60 per share and will expire five years following the date of issuance.

As part of the unit offering, the Company entered into registration rights agreements which require the Company to use its best efforts to file a registration statement with the Securities and Exchange Commission statement as soon as reasonably practicable after the first closing for the offering (October 1, 2003), but in no event less than 90 days following the first closing, to register the shares of common stock issuable upon conversion of the series 'A' convertible preferred stock and upon exercise of the class 'C' warrants. If the Company fails to do so, the exercise price for the class 'C' warrants will be reduced to \$3 from \$3.75.

The Company has issued 2,560,000 options to employees under the 2002 Stock Plan.

8. RESTATEMENT OF FINANCIAL STATEMENTS

The Company has restated its 2000 and 2001 financial statements for correction of an error eliminating \$100,000 of goodwill and related amortization expense, which was inappropriately recorded upon exiting bankruptcy. The Company has restated its 2002 financial statements to properly account for the acquisition of its intangible property as an asset purchase rather than applying reorganization accounting.

The effects of the restatements are as follows:

	As Previously Reported	As Restated
	<hr/>	<hr/>
Total assets 12/31/00	\$111,751	\$15,084
Stockholders' equity 12/31/00	\$107,321	\$(1,673)
Net loss 2000	\$27,679	\$36,673
Net loss per share 2000	\$0.02	\$0.01
Total assets 12/31/01	\$84,929	\$8,262
Stockholders' equity 12/31/01	\$74,994	\$280,111
Net loss 2001	\$82,327	\$50,000
Net loss per share 2001	\$0.06	\$0.01
Total Assets 12/31/02	\$184,837	\$319,875
Stockholders; equity 12/31/02	\$182,073	\$280,111
Net loss 2002	\$214,195	\$211,954
Net loss per share 2002	\$0.02	\$0.02

PART II**INFORMATION NOT REQUIRED IN PROSPECTUS****Item 13 Other Expenses Of Issuance And Distribution**

The following table sets forth the estimated costs and expenses which we expect to incur with respect to the offering and sale or distribution of common shares under this registration statement. We have agreed to pay all of these expenses.

SEC Registration Fee	\$	800
Financial Printer Fees to EDGARize and Print Registration Statement		3,000
Transfer Agent Fees, including Printing and Engraving Stock Certificates		500
Legal Fees and Expenses		35,000
Accounting Fees and Expenses		25,000
Miscellaneous		1,000
		<hr/>
Total	\$	65,300
		<hr/>

* estimated

Item 14 Indemnification Of Directors And Officers

Our Articles of Incorporation, as amended, provide shall that we shall, to the maximum extent and in the manner under Delaware corporate law, indemnify each of our directors and officers against expenses (including attorneys' fees), judgments, fines, settlements, and other amounts actually and reasonably incurred in connection with any proceeding, arising by reason of the fact that such person is or was an agent of the corporation. The effect of this provision of our Articles of Incorporation, as amended, is to eliminate our right and our shareholders (through shareholders' derivative suits on behalf of our company) to recover damages against a director or officer for breach of the fiduciary duty of care as a director or officer (including breaches resulting from negligent or grossly negligent behavior), except under certain situations defined by statute. We believe that the indemnification provisions in our Articles of Incorporation are necessary to attract and retain qualified persons as directors and officers.

We have also entered into an indemnification agreement with Marvin Fink, our Chief Executive Officer and Chairman of the Board.

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and we will be governed by the final adjudication of such issue.

Item 15 Recent Sales Of Unregistered Securities

We have sold or issued the following securities not registered under the Securities Act during the three year period ending on the date of filing of this registration statement:

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

- On September 19, 2002, immediately prior to our acquisition of the Signal Technologies from ARC Finance Group, Mr. Sim Farar, our president and principal shareholder at that time, invested \$125,000 into the company as working capital in exchange for a warrant entitling him to purchase 200,000 common shares at \$0.65 per share (600,000 post-split shares at \$0.21 per share). The warrant may not be exercised before September 1, 2003, expires in September 2006, contains cashless exercise options and certain anti-dilution and other provisions. At the time, Vanguard West LLC, a company owned and controlled by Mr. Farar, held approximately 98% of our common shares. No underwriting discounts or placement agent commissions were payable with respect to this transaction. The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 506 insofar as (1) Mr. Farar is accredited by reason of being a director (2) the transfer of the securities were restricted by Recom in accordance with Regulation D; and (3) there were no more than 35 non-accredited investors, after taking into consideration all prior investors under Section 4(2) of the Securities Act within the twelve months before the start of and during the offering.
 - On September 19, 2002, we issued 7,800,000 common shares (23,400,000 shares post-split) to ARC Finance Group in connection with our acquisition of the Signal Technologies. The shares represented approximately 85% of our issued and outstanding common shares. We valued the Signal Technologies at \$78,023 for financial accounting purposes. No underwriting discounts or commissions were payable with respect to this transaction. For further information relating to this transaction see that section of this prospectus captioned Business Corporate History . The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 504 insofar as the aggregate offering price for this transaction did not exceed \$1,000,000, after taking into consideration the aggregate offering price for all securities sold by Recom under Section 3(b) of the Securities Act within the twelve months before the start of and during the offering of the shares.
 - On October 11, 2002, we reached an agreement-in-principle with Mr. Marvin H. Fink to become our Chief Executive Officer and President. Pursuant to that understanding, we entered into an employment agreement with Mr. Fink on October 12, 2002 and contemporaneously issued to him 700,000 restricted common shares (2,100,000 shares post-split) as an inducement for that employment. These shares vest over a period of four years based upon Mr. Fink's continuous provision of services. No underwriting discounts or commissions were payable with respect to this transaction. For further information relating to this transaction see that section of this prospectus captioned Management Employment And Consulting Agreements With Management . The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 504 insofar as the aggregate offering price for this transaction did not exceed \$1,000,000, after taking into consideration the aggregate offering price for all securities sold by Recom under Section 3(b) of the Securities Act within the twelve months before the start of and during the offering of the shares.
 - On October 11, 2002, we reached an agreement-in-principle with Dr. Budimir Drakulic to become our Vice President and Chief Technology Officer on a consulting basis through his consulting companies. Pursuant to that understanding, on October 15, 2002, we entered into a loan-out agreement with Dr. Drakulic's two consulting companies, B World Technologies, Inc. and B Technologies, Inc., relative to the provision of Dr. Drakulic's services, and contemporaneously issued to one of those companies, B World Technologies, 600,000 restricted common shares (200,000 shares post-split) as an inducement for the provision of those services. These shares vest over a period of five years. B World Technologies and B World are each owned and controlled by Dr. Drakulic. No underwriting discounts or commissions were payable with respect to this transaction. For further information relating to this transaction see that section of this prospectus captioned Management Employment And Consulting Agreements With Management . The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 504 insofar as the aggregate offering price for this transaction did not exceed \$1,000,000, after taking into consideration the aggregate offering price for all securities sold by Recom under Section 3(b) of the Securities Act within the twelve months before the start of and during the offering of the shares.
-

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

- As part of the October 11, 2002 agreement-in-principle with Dr. Budimir Drakulic described above, we also reached an agreement-in-principle to offer to sell our common shares to certain individuals in order to protect our rights in the Signal Technologies. Pursuant to this understanding, on October 22, 2002, we sold 564,810 common shares (188,270 shares pre-split) to eleven of those individuals, and issued a five-year warrant to purchase 375,000 common shares (125,000 shares pre-split) for \$0.007 per share to one of those individuals, in consideration of their cash investment of \$17,786. No underwriting discounts or commissions were payable with respect to this transaction. For further information relating to this transaction see that section of this prospectus captioned Transactions And Business Relationships With Management And Principal Shareholders . The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 504 insofar as the aggregate offering price for this transaction did not exceed \$1,000,000, after taking into consideration the aggregate offering price for all securities sold by Recom under Section 3(b) of the Securities Act within the twelve months before the start of and during the offering of the shares.
 - On October 11, 2003, we reached an agreement-in-principle with Mr. Ellsworth Roston to provide consulting advice to us relating to engineering, developing and refining our products and technologies; to become a director of the company, and to make an investment into the company. Pursuant to that understanding, on October 30, 2002 we sold Mr. Roston 23,750 common shares (71,250 shares post-split) for \$190,000 in cash, and on November 1, 2002 we entered into a two year consulting agreement with Mr. Mr. Roston documenting the provision of his consulting services and his appointment to our board of directors. Pursuant to that latter agreement we granted Mr. Roston 25,000 common shares (75,000 shares post-split), and five-year warrants to purchase an additional to purchase an additional 50,000 common shares at \$5 per share (150,000 shares post-split at \$1.67 per share). We consider the grant of common shares to Mr. Roston to be compensation for the provision of his consulting services, and the grant of the common share purchase warrants to be additional consideration for his cash investment pursuant to our original understanding. For further information relating to these transactions, see that section of this prospectus captioned Management Employment And Consulting Agreements With Management . No underwriting discounts or commissions were payable with respect to the transaction. The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 504 insofar as the aggregate offering price for this transaction did not exceed \$1,000,000, after taking into consideration the aggregate offering price for all securities sold by Recom under Section 3(b) of the Securities Act within the twelve months before the start of and during the offering of the shares.
 - On February 5, 2003, pursuant to a director s compensation plan adopted by our board of directors on that date, we issued to each of our five directors as of that date, including Messrs. Fink and Roston and Dr. Robert Koblin, options to purchase 50,000 common shares at \$2.65 per share (150,000 shares pre-split at \$0.88 per share) under our 2002 Stock Plan. The options are fully vested and lapse, if unexercised, on February 4, 2008. For further information relating to these transactions, see that section of this prospectus captioned Management Board Compensation . No underwriting discounts or commissions were payable with respect to the transactions. The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 506 insofar as (1) the directors are each accredited by reason of being a director; (2) the transfer of the securities were restricted by Recom in accordance with Regulation D; and (3) there were no more than 35 non-accredited investors, after taking into consideration all prior investors under Section 4(2) of the Securities Act within the twelve months before the start of and during the offering.
 - On February 14 2003 we issued to Dr. Lowell Harmison (1) fully vested options entitling him to purchase 36,000 common shares at \$1.08 per share (108,000 shares post-split at \$0.36 per share), and (2) options entitling him to purchase an additional 36,000 common shares at \$1.08 per share subject to vesting over one year. These options were issued as an inducement for Dr. Harmison to provide consulting services pursuant to a consulting agreement entered into on that same date. For further information relating to this transaction, see that section of this prospectus captioned Management Employment And Consulting Agreements With Management . No underwriting discounts or commissions were payable with respect to the transaction. The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 504 insofar as the aggregate offering price for this transaction did not exceed \$1,000,000, after taking into consideration the aggregate offering price for all securities sold by Recom under Section 3(b) of the Securities Act within the twelve months before the start of and during the offering of the shares.
-

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

- On March 10 2003 we issued to Mr. Charles McGill options to purchase 300,000 common shares at \$2.85 per share (900,000 shares post-split at \$0.95 per share). These options were issued as an inducement for Mr. McGill to become our Chief Financial Officer pursuant to an employment agreement entered into on that same date. The options vest over a period of three years, and lapse if unexercised on March 24, 2008. No underwriting discounts or commissions were payable with respect to the transaction. The issuance of these securities were exempt from the registration requirements of the Securities Act of 1933 under Rule 701 on the basis that (1) Recom is not subject to reporting under section 13 or 15(d) of the Exchange Act, (2) the transaction was evidenced by a written compensatory benefit plan, (3) Mr. McGill is a natural person providing bona fide services to the company, (4) Mr. McGill was not providing those services in connection with the offer or sale of securities in a capital-raising transaction, or to directly or indirectly promote or maintain a market for our securities; and (5) the aggregate sales price or amount of securities sold in reliance on Rule 701 for the past twelve months including this transaction did not exceed \$1,000,000 and/or 15% of our outstanding common shares as reported on our last annual balance sheet after taking into consideration all securities sold by Recom under Rule 701 over the past twelve months.
 - On March 10 2003, we issued to an employee options to purchase 80,000 common shares at \$2.76 per share (240,000 shares post-split at \$0.92 per share) under our 2002 Stock Plan. The options vest over a period of four years, and lapse if unexercised on March 9, 2008. No underwriting discounts or commissions were payable with respect to the transaction. The issuance of these securities were exempt from the registration requirements of the Securities Act of 1933 under Rule 701 on the basis that (1) Recom is not subject to reporting under section 13 or 15(d) of the Exchange Act, (2) the transaction was evidenced by a written compensatory benefit plan, (3) the employee is a natural person providing bona fide services to the company, (4) the employee was not providing those services in connection with the offer or sale of securities in a capital-raising transaction, or to directly or indirectly promote or maintain a market for our securities; and (5) the aggregate sales price or amount of securities sold in reliance on Rule 701 for the past twelve months including this transaction did not exceed \$1,000,000 and/or 15% of our outstanding common shares as reported on our last annual balance sheet after taking into consideration all securities sold by Recom under Rule 701 over the past twelve months.
 - On March 10 2003, we issued to Dr. Budimir S. Drakulic options to purchase 250,000 common shares at \$2.76 per share (750,000 shares post-split at \$0.92 per share) under our 2002 Stock Plan. The options vest over a period of four years, and lapse if unexercised on March 9, 2008. No underwriting discounts or commissions were payable with respect to the transaction. The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 506 insofar as (1) Dr. Drakulic is accredited by reason of being an executive officer; (2) the transfer of the securities were restricted by Recom in accordance with Regulation D; and (3) there were no more than 35 non-accredited investors, after taking into consideration all prior investors under Section 4(2) of the Securities Act within the twelve months before the start of and during the offering.
 - On March 10 2003, we issued to a consultant warrants to purchase 7,000 common shares at \$2.43 per share (21,000 shares post-split at \$0.81 per share). The warrants are fully vested, and lapse if unexercised on March 9, 2008. No underwriting discounts or commissions were payable with respect to the transaction. The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 504 insofar as the aggregate offering price for this transaction did not exceed \$1,000,000, after taking into consideration the aggregate offering price for all securities sold by Recom under Section 3(b) of the Securities Act within the twelve months before the start of and during the offering of the shares.
-

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

- On March 10 2003, we issued to a business advisory consultant warrants to purchase 300,000 common shares at \$1.50 per share (900,000 shares post-split at \$0.50 per share) in connection with their provision of consulting services. The warrants are fully vested, and lapse if unexercised on March 9, 2008. No underwriting discounts or commissions were payable with respect to the transaction. The consultant is an accredited investor as that term is defined in Rule 501. The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 506 insofar as (1) the investor is accredited; (2) the transfer of the securities were restricted by Recom in accordance with Regulation D; and (3) there were no more than 35 non-accredited investors, after taking into consideration all prior investors under Section 4(2) of the Securities Act within the twelve months before the start of and during the offering.
 - On April 8 2003, we sold to an investor 37,604 common shares (112,812 shares post-split) for \$100,000 in cash and \$150,000 in expenses and equipment. No underwriting discounts or commissions were payable with respect to the transaction. The investor is an accredited investor as that term is defined in Rule 501. The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 506 insofar as (1) the investor is accredited; (2) the transfer of the securities were restricted by Recom in accordance with Regulation D; and (3) there were no more than 35 non-accredited investors, after taking into consideration all prior investors under Section 4(2) of the Securities Act within the twelve months before the start of and during the offering.
 - On April 15 2003, we issued to Brookstreet Securities Corporation warrants to purchase 200,000 common pursuant to an investment banking agreement. The warrants are exercisable in four tranches of 50,000 common shares each. The first tranche was fully vested and exercisable at \$1.25 per share. The second tranche vests 90 days after issuance with an exercise price of \$2.25 per share. The third tranche vests 180 days after issuance with an exercise price of \$3.25 per share. The fourth tranche vests 270 days after issuance with an exercise price of \$4.25 per share. No underwriting discounts or commissions were payable with respect to the transaction. Brookstreet Securities Corporation is an accredited investor as that term is defined in Rule 501. The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 506 insofar as (1) the investor is accredited; (2) the transfer of the securities were restricted by Recom in accordance with Regulation D; and (3) there were no more than 35 non-accredited investors, after taking into consideration all prior investors under Section 4(2) of the Securities Act within the twelve months before the start of and during the offering.
 - On April 15 2003, we issued to an employee options to purchase 10,000 common shares at \$2.85 per share under our 2002 Stock Plan. The options vest over a period of four years, and lapse if unexercised on April 14, 2008. No underwriting discounts or commissions were payable with respect to the transaction. The issuance of these securities were exempt from the registration requirements of the Securities Act of 1933 under Rule 701 on the basis that (1) Recom is not subject to reporting under section 13 or 15(d) of the Exchange Act, (2) the transaction was evidenced by a written compensatory benefit plan, (3) the employee is a natural person providing bona fide services to the company, (4) the employee was not providing those services in connection with the offer or sale of securities in a capital-raising transaction, or to directly or indirectly promote or maintain a market for our securities; and (5) the aggregate sales price or amount of securities sold in reliance on Rule 701 for the past twelve months including this transaction did not exceed \$1,000,000 and/or 15% of our outstanding common shares as reported on our last annual balance sheet after taking into consideration all securities sold by Recom under Rule 701 over the past twelve months.
 - On May 15 2003, we completed the first tranche of a private placement pursuant to which we sold 82,667 units to three investors at \$3 per unit for cash amounting to \$248,000. Each unit consisted of one common share and one warrant. Each warrant is exercisable at \$3 until May 14, 2004. Upon exercise of the warrants each investor will receive one common share and an additional warrant to purchase one common share \$6 per share until November 15, 2004. Each of the investors are accredited as that term is defined in Rule 501. The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 506 insofar as (1) the investors are accredited; (2) the transfer of the securities were restricted by Recom in accordance with Regulation D; and (3) there were no more than 35 non-accredited investors, after taking into consideration all prior investors under Section 4(2) of the Securities Act within the twelve months before the start of and during the offering.
-

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

- On June 2 2003, we issued to a consultant options to purchase 108,000 common shares at \$2.40 per share under our 2002 Stock Plan. The options vest over a period of four years, and lapse if unexercised on June 4, 2008. No underwriting discounts or commissions were payable with respect to the transaction. The issuance of these securities were exempt from the registration requirements of the Securities Act of 1933 under Rule 701 on the basis that (1) Recom is not subject to reporting under section 13 or 15(d) of the Exchange Act, (2) the transaction was evidenced by a written compensatory benefit plan, (3) the consultant is a natural person providing bona fide services to the company, (4) the consultant was not providing those services in connection with the offer or sale of securities in a capital-raising transaction, or to directly or indirectly promote or maintain a market for our securities; and (5) the aggregate sales price or amount of securities sold in reliance on Rule 701 for the past twelve months including this transaction did not exceed \$1,000,000 and/or 15% of our outstanding common shares as reported on our last annual balance sheet after taking into consideration all securities sold by Recom under Rule 701 over the past twelve months.
 - On June 5 2003, we issued to Dr. Lowell T. Harmison, in his capacity as a director, options to purchase 50,000 common shares at \$4.20 per share under our 2002 Stock Plan. The options vest over a period of one year, and lapse if unexercised on June 4 2008. For further information relating to this transaction, see that section of this prospectus captioned Management Board Compensation . No underwriting discounts or commissions were payable with respect to the transaction. The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 506 insofar as (1) Dr. Harmison is accredited by reason of being a director; (2) the transfer of the securities were restricted by Recom in accordance with Regulation D; and (3) there were no more than 35 non-accredited investors, after taking into consideration all prior investors under Section 4(2) of the Securities Act within the twelve months before the start of and during the offering.
 - On July 17 2003, we issued to Maxim Group, LLC warrants to purchase 100,000 common shares at \$3.19 per share pursuant to an investment banking agreement. The warrants lapse if unexercised on July 16, 2008. No underwriting discounts or commissions were payable with respect to the transaction. Maxim Group is an accredited investor as that term is defined in Rule 501. The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 506 insofar as (1) the investor is accredited; (2) the transfer of the securities were restricted by Recom in accordance with Regulation D; and (3) there were no more than 35 non-accredited investors, after taking into consideration all prior investors under Section 4(2) of the Securities Act within the twelve months before the start of and during the offering.
 - On July 24 2003, we completed the second tranche of a private placement pursuant to which we sold 75,075 units to four investors at \$3.33 per unit for cash amounting to \$250,000. Each unit consisted of one common share and one warrant. Each warrant is exercisable at \$3.33 until July 14, 2004. Upon exercise of the warrants each investor will receive one common share and an additional warrant to purchase one common share at \$6.66 per share until November 15, 2004. Each of the investors are accredited as that term is defined in Rule 501. The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 506 insofar as (1) the investors are accredited; (2) the transfer of the securities were restricted by Recom in accordance with Regulation D; and (3) there were no more than 35 non-accredited investors, after taking into consideration all prior investors under Section 4(2) of the Securities Act within the twelve months before the start of and during the offering.
 - On July 29 2003, we issued to an employee options to purchase 10,000 common shares at \$3.19 per share under our 2002 Stock Plan. The options vest over a period of five years, and lapse if unexercised on July 28, 2008. No underwriting discounts or commissions were payable with respect to the transaction. The issuance of these securities were exempt from the registration requirements of the Securities Act of 1933 under Rule 701 on the basis that (1) Recom is not subject to reporting under section 13 or 15(d) of the Exchange Act, (2) the transaction was evidenced by a written compensatory benefit plan, (3) the employee is a natural person providing bona fide services to the company, (4) the employee was not providing those services in connection with the offer or sale of securities in a capital-raising transaction, or to directly or indirectly promote or maintain a market for our securities; and (5) the aggregate sales price or amount of securities sold in reliance on Rule 701 for the past twelve months including this transaction did not exceed \$1,000,000 and/or 15% of our outstanding common shares as reported on our last annual balance sheet after taking into consideration all securities sold by Recom under Rule 701 over the past twelve months.
-

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

- On August 5 2003, we issued to two shareholders warrants entitling them to purchase 23,501 common shares at \$3.29 per share pursuant to a voluntary partial trading restriction (lock-up) agreement entered into with each of those shareholders on that date. These warrants lapse on August 4, 2008 to the extent not exercised by the first shareholder, and February 4, 2005 to the extent not exercised by the second shareholder. No underwriting discounts or commissions were payable with respect to the transaction. The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 504 insofar as the aggregate offering price for this transaction did not exceed \$1,000,000, after taking into consideration the aggregate offering price for all securities sold by Recom under Section 3(b) of the Securities Act within the twelve months before the start of and during the offering of the shares.
 - On September 23 2003, we issued to a current shareholder warrants to purchase 18,000 common shares at \$5.29 per share pursuant to a voluntary partial trading restriction (lock-up) agreement with that shareholder entered into on that same date. These warrants lapse on March 22, 2005 to the extent not exercised. No underwriting discounts or commissions were payable with respect to the transaction. . The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 504 insofar as the aggregate offering price for this transaction did not exceed \$1,000,000, after taking into consideration the aggregate offering price for all securities sold by Recom under Section 3(b) of the Securities Act within the twelve months before the start of and during the offering of the shares.
 - On September 25 2003, we issued to a consultant warrants to purchase 25,000 common shares at \$3.19 per share under our 2002 Stock Plan. These warrants lapse on March 24, 2008 to the extent not exercised. No underwriting discounts or commissions were payable with respect to the transaction. The issuance of these securities were exempt from the registration requirements of the Securities Act of 1933 under Rule 701 on the basis that (1) Recom is not subject to reporting under section 13 or 15(d) of the Exchange Act, (2) the transaction was evidenced by a written compensatory benefit plan, (3) the consultant is a natural person providing bona fide services to the company, (4) the consultant was not providing those services in connection with the offer or sale of securities in a capital-raising transaction, or to directly or indirectly promote or maintain a market for our securities; and (5) the aggregate sales price or amount of securities sold in reliance on Rule 701 for the past twelve months including this transaction did not exceed \$1,000,000 and/or 15% of our outstanding common shares as reported on our last annual balance sheet after taking into consideration all securities sold by Recom under Rule 701 over the past twelve months.
 - On November 1, 2003 to October 2, 2003, we completed a private placement through Maxim Group LLC pursuant to which we sold 53,787 units to 100 investors at a price of \$100,000 per unit, for gross proceeds of \$5,378,750. The net proceeds of this offering, after expenses, was \$4,805,965. Each unit sold consisted of 33,334 series A preferred shares and 16,667 class C warrants. In total, we issued 1,792,921 series A preferred shares and 896,460 class C warrants. Each series A preferred share is convertible into one common share. Each warrant is exercisable at \$3.75 for a period of four years. For a more detailed description of the rights and preferences of the series A preferred shares, see that section of this prospectus captioned Description of Capital Stock-Series A Preferred Shares . Each of the investors are accredited as that term is defined in Rule 501. The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 506 insofar as (1) the investors are accredited; (2) the transfer of the securities were restricted by Recom in accordance with Regulation D; and (3) there were no more than 35 non-accredited investors, after taking into consideration all prior investors under Section 4(2) of the Securities Act within the twelve months before the start of and during the offering.
 - Under the terms of our agreement with Maxim Group, we were obligated to pay Maxim Group \$537,875, representing an 8% commission and a 2% non-accountable expense allowance. In addition, we are obligated to issue to Maxim an agent s warrant entitling it to purchase a number of units equal to 10% of the total units sold in this offering. Maxim has the right under the agent s warrant to purchase at total of 179,292 units at the price of \$3.60 per unit, each unit comprised on one series A preferred share and one-half of a class C warrant. The agent s warrant expires in five years to the extent unexercised. Maxim Group is an accredited investor as that term is defined in Rule 501. The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 506 insofar as (1) the investor is accredited; (2) the transfer of the securities were restricted by Recom in accordance with Regulation D; and (3) there were no more than 35 non-accredited investors, after taking into consideration all prior investors under Section 4(2) of the Securities Act within the twelve months before the start of and during the offering.
-

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

- On November 3 2003, we issued to Messrs. Fink and Roston, in their capacity as directors, options entitling each of them to purchase 28,000 common shares at \$4.40 per share pursuant to our director's compensation plan. The options vest over a period of one year, and lapse if unexercised on November 2, 2008. For further information relating to these transactions, see that section of this prospectus captioned "Management Board Compensation". No underwriting discounts or commissions were payable with respect to these transactions. The offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933 under Rule 506 insofar as (1) Messrs. Fink and Roston are accredited by reason of being a director; (2) the transfer of the securities were restricted by Recom in accordance with Regulation D; and (3) there were no more than 35 non-accredited investors, after taking into consideration all prior investors under Section 4(2) of the Securities Act within the twelve months before the start of and during the offering.

Item 16 Exhibits And Financial Statement Schedules

- 2.1 Plan of Reorganization **
- 3.1 Amended And Restated Certificate Of Incorporation Of Recom Managed System, Inc. filed by the Delaware Secretary of State on November 6, 2000 10(1)
- 3.2 Certificate Of Amendment Of Certificate Of Incorporation Of Recom Managed System, Inc. filed by the Delaware Secretary of State on June 20, 2003 *
- 3.3 Certificate Of Designation Of Rights, Preferences And Limitations Of Series 'A' Convertible Preferred Stock Of Recom Managed System, Inc. filed by the Delaware Secretary of State on September 9, 2003 *
- 3.4 Bylaws Of Recom Managed Systems, Inc. adopted March 31, 2003 10(7)
- 4 Legal opinion by Richardson & Patel LLP *
- 5.1 Specimen common stock certificate *
- 5.2 Specimen series 'A' preferred stock certificate *
- 5.3 Recom Managed Systems, Inc. 2002 Stock Plan adopted on November 1, 2002 10(6)
- 5.4 Form of option issued under Recom Managed Systems, Inc. 2002 Stock *
- 5.5 Recom Managed Systems, Inc. 2003 Nonqualified Stock Option And Stock Plan adopted on March 31, 2002 10(6)
- 5.7 Warrant To Purchase Common Stock dated September 19, 2002 issued to Sim Farrar 10(2)
- 5.9 Form of Standard Warrant *
- 5.10 Form of Class 'A' Warrant *
- 5.11 Form of Class 'C' Warrant *
- 5.12 Form of Agent's Warrant with Maxim Group LLC **
- 10.1 Stock Acquisition and Signal Technologies Transfer Agreement dated September 12, 2002 between Recom and ARC Finance Group, LLC 10(2)

- 10.2 Employment Agreement dated October 14, 2002 between Recom and Marvin H. Fink 10(3)
- 10.3 License Agreement dated December 9, 1993 between Dr. Budimir S. Drakulic and Teledyne Electronic Industries, Inc. *
- 10.4 Restricted Stock Agreement dated October 14, 2002 between Recom and Marvin H. Fink 10(3) 10(4)
- 10.5 Indemnification Agreement dated October 14, 2002 between Recom and Marvin H. Fink 10(3) 10(4)
- 10.6 Loan-out Agreement dated October 15, 2002 between Recom and Budimir Drakulic, B World and B Technologies 10(3)
- 10.7 Restricted Stock Agreement dated October 15, 2002 between Recom and Budimir Drakulic, B World and B Technologies 10(3) 10(5)
- 10.7 Consulting Agreement dated November 1, 2002 between Recom and Ellsworth Roston 10(3)
- 10.9 Employment, Confidential Information, Invention Assignment, And Arbitration Agreement dated October 15, 2002 between Recom and Budimir Drakulic, B World and B Technologies 10(3) 10(5) [
- 10.10 Consulting Agreement dated February 14, 2003 between Recom and Lowell T. Harmison *
- 10.11 Employment Agreement dated March 10, 2003 between Recom and Charles E. McGill 10(7)
- 10.12 Investment Banking Agreement dated April 15, 2003 between Recom and Brookstreet Securities Corporation 10(7)
- 10.13 Investment Banking Agreement dated July 17, 2003 between Recom and Maxim Group, LLC *
- 10.14 Form of Registration Rights Agreement for purchasers of Series 'A' Preferred Stock *
- 21 List of significant subsidiaries 10(8)
- 23.1 Consent of Stonefield Josephson, Inc. *
- 24 Powers of Attorney 10(9)

* Filed herewith

** To be filed at a future date

(1) Previously filed as an exhibit to our report on form 10-KSB for our fiscal year ended December 31, 2001 filed with the SEC on February 22, 2002.

(2) Previously filed as an exhibit to our report on form 8-K filed with the SEC on September 25, 2002.

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

- (3) Previously filed as an exhibit to our report on form 10-QSB for our fiscal quarter ended September 30, 2002 filed with the SEC on November 12, 2002.
- (4) Filed as part of the Employment Agreement for Mr. Fink noted in item 10.2.
- (5) Filed as part of the Loan-Out Agreement for with B World Technologies, B Technologies and Dr. Drakulic noted in item 10.5.
- (6) Previously filed as an exhibit to our report on form 10-KSB for our fiscal year ended December 31, 2002 filed with the SEC on March 26, 2003.
- (7) Previously filed as an exhibit to our report on form 10-QSB for our fiscal quarter ended March 30, 2003 filed with the SEC on May 7, 2003.
- (8) At present we have no significant subsidiaries
- (9) Included on signature page of registration statement

Item 17 Undertakings

We hereby undertake to:

1. File, during any period in which we offer or sell securities, a post-effective amendment to this registration statement to:
 - (i) Include any prospectus required by section 10(a)(3) of the Securities Act;
 - (ii) Reflect in the prospectus any facts or events which, individually or together, represent a fundamental change in the information in the registration statement; and notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospects filed with the SEC under Rule 424(b) if, in the aggregate, the changes in the volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the Calculation of Registration Fee table on the face page of the effective registration statement; or
 - (iii) Include any additional or changed material information on the plan of distribution.
-

Edgar Filing: RECOM MANAGED SYSTEMS INC DE/ - Form SB-2

2. For determining liability under the Securities Act, treat each post-effective amendment as a new registration statement of the securities offered, and the offering of the securities at that time to be the initial bona fide offering.
 3. File a post-effective amendment to remove from registration any of the securities that remain unsold at the end of the offering.
 4. For purposes of determining any liability under the Securities Act, treat the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act as part of this registration statement as of the time it was declared effective.
 5. For determining any liability under the Securities Act, treat each post-effective amendment that contains a form of prospectus as a new registration statement for the securities offered in the registration statement, and that offering of the securities at that time as the initial bona fide offering of those securities. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons under the foregoing provisions or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. If a claim for indemnification against such liabilities (other than our payment of expenses incurred or paid by any of our directors, officers or controlling persons in the successful defense of any action, suit, or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by a controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
-

SIGNATURES

In accordance with the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements of filing on Form SB-2 and authorizes this registration statement to be signed on its behalf by the undersigned, in the City of Studio City, State of California, on December 29, 2003.

RECOM MANAGED SYSTEMS, INC.

By: */s/ Marvin H. Fink*

Marvin H. Fink, Chief Executive Officer
(principal executive officer)

RECOM MANAGED SYSTEMS, INC.

By: */s/ Charles Dargan*

Charles Dargan Temporary Chief Financial Officer
(principal accounting and financial officer)

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below followed by an asterisk hereby constitutes and appoints Marvin H. Fink and Charles Dargan, and each of them, as the undersigned's true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution for such person and in such person's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto, and other documents in connection therewith to this registration statement and any later registration statement filed by the registrant under Rule 462(b) of the Securities Act of 1933, which relates to this registration statement) and to file the same with exhibits thereto and other documents in connection therewith with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents, or any of them, or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

By: */s/ Marvin H. Fink* Chief Executive Officer (principal executive officer) and Chairman December 29, 2003

Marvin H. Fink

By: */s/ Charles Dargan* Chief Financial Officer (principal accounting and financial officer) December 29, 2003

Charles Dargan

By: */s/ Ellsworth Roston ** Director December 29, 2003

Ellsworth Roston

By: */s/ Robert Koblin ** Director December 29, 2003

Robert Koblin

By: */s/ Lowell T. Harmison ** Director December 29, 2003

Lowell T. Harmison

